
<html lang="en"     class="pb-page"  data-request-id="aaba60a0-cfb8-4c52-b563-2654e35497d9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm500827t;issue:issue:10.1021/jmcmar.2014.57.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2" /></meta><meta name="dc.Creator" content="Dean Y.  Maeda" /></meta><meta name="dc.Creator" content="Angela M.  Peck" /></meta><meta name="dc.Creator" content="Aaron D.  Schuler" /></meta><meta name="dc.Creator" content="Mark T.  Quinn" /></meta><meta name="dc.Creator" content="Liliya N.  Kirpotina" /></meta><meta name="dc.Creator" content="Winston N.  Wicomb" /></meta><meta name="dc.Creator" content="Guo-Huang  Fan" /></meta><meta name="dc.Creator" content="John A.  Zebala" /></meta><meta name="dc.Description" content="The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) throu..." /></meta><meta name="Description" content="The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) throu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 8, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500827t" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500827t" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500827t" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500827t" /></link>
        
    
    

<title>Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500827t" /></meta><meta property="og:title" content="Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0020.jpeg" /></meta><meta property="og:description" content="The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure–activity studies that examined the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [35S]GTPγS binding (IC50 = 60 nM) and ERK1/2 phosphorylation. Inhibition was noncompetitive, with SX-517 unable to compete the binding of [125I]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model. SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500827t"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500827t">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500827t&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500827t&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500827t&amp;href=/doi/10.1021/jm500827t" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8378-8397</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5008209" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm500853v" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+Y.++Maeda">Dean Y. Maeda</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela+M.++Peck">Angela M. Peck</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aaron+D.++Schuler">Aaron D. Schuler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+T.++Quinn">Mark T. Quinn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liliya+N.++Kirpotina">Liliya N. Kirpotina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Winston+N.++Wicomb">Winston N. Wicomb</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guo-Huang++Fan">Guo-Huang Fan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+A.++Zebala">John A. Zebala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Syntrix Biosystems, 215 Clay Street, Auburn, Washington 98001, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Microbiology and Immunology, Montana State University, 960 Technology Boulevard, Bozeman, Montana 59717, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Pharmacology, Meharry Medical College, 1005 Dr. DB Todd Boulevard, Nashville, Tennessee 37208, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#3551585450515475464c5b41475c4d575c5a1b565a58"><span class="__cf_email__" data-cfemail="6c08010d09080d2c1f1502181e05140e0503420f0301">[email protected]</span></a>. Tel: (253) 833-8009. Fax: (253) 833-8127.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500827t&amp;href=/doi/10.1021%2Fjm500827t" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8378–8397</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 25, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 June 2014</li><li><span class="item_label"><b>Published</b> online</span>8 October 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 October 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500827t" title="DOI URL">https://doi.org/10.1021/jm500827t</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500827t"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2212</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500827t" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;Y. Maeda&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;M. Peck&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;D. Schuler&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;T. Quinn&quot;},{&quot;first_name&quot;:&quot;Liliya&quot;,&quot;last_name&quot;:&quot;N. Kirpotina&quot;},{&quot;first_name&quot;:&quot;Winston&quot;,&quot;last_name&quot;:&quot;N. Wicomb&quot;},{&quot;first_name&quot;:&quot;Guo-Huang&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;A. Zebala&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;8378-8397&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500827t&quot;},&quot;abstract&quot;:&quot;The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure–activity studies that examined the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [35S]GTPγS binding (IC50 = 60 nM) and ERK1/2 phosphorylation. Inhibition was noncompetitive, with SX-517 unable to compete the binding of [125I]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv)&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500827t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500827t" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500827t&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500827t" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500827t&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500827t" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500827t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500827t&amp;href=/doi/10.1021/jm500827t" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500827t" /></input><a href="/doi/pdf/10.1021/jm500827t" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500827t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500827t%26sid%3Dliteratum%253Aachs%26pmid%3D25254640%26genre%3Darticle%26aulast%3DMaeda%26date%3D2014%26atitle%3DDiscovery%2Bof%2B2-%255B5-%25284-Fluorophenylcarbamoyl%2529pyridin-2-ylsulfanylmethyl%255Dphenylboronic%2BAcid%2B%2528SX-517%2529%253A%2BNoncompetitive%2BBoronic%2BAcid%2BAntagonist%2Bof%2BCXCR1%2Band%2BCXCR2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D20%26spage%3D8378%26epage%3D8397%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jmcmar.2014.57.issue-20/20141023/jmcmar.2014.57.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure–activity studies that examined the effect of a novel series of S-substituted 6-mercapto-<i>N</i>-phenyl-nicotinamides on CXCL1-stimulated Ca<sup>2+</sup> flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca<sup>2+</sup> flux (IC<sub>50</sub> = 38 nM) in human PMNs but had no effect on the Ca<sup>2+</sup> flux induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [<sup>35</sup>S]GTPγS binding (IC<sub>50</sub> = 60 nM) and ERK1/2 phosphorylation. Inhibition was noncompetitive, with SX-517 unable to compete the binding of [<sup>125</sup>I]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model. SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The chemokine receptors CXCR1 and CXCR2 are closely related members of the class A (rhodopsin-like) family of seven transmembrane G-protein-coupled receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The chemokine CXCL8 (Interleukin-8, IL8) activates the receptors CXCR1 and CXCR2, whereas the chemokine CXCL1 (growth related oncogene α, GROα) is a selective agonist for CXCR2.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> CXCR1/2 signaling is sensitive to the pertussis toxin, indicating involvement of the Gαi subunit in the heterotrimeric G-protein.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Agonist-induced changes in receptor conformation uncouple the Gβγ subunit from the heterotrimeric G-protein complex, activating signaling pathways that include phospholipase Cβ, phosphatidylinositol-3-kinase, and mitogen-activated protein kinases. Phospholipase Cβ in turn generates inositol-1,4,5-triphosphate, which binds to the endoplasmic reticulum and leads to a release of Ca<sup>2+</sup> into the cytoplasm.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> CXCR1/2 signaling is involved in inflammation, wound healing, and angiogenesis, and their dysregulation has been implicated in a myriad of diseases involving acute and chronic inflammation,<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14">(6-14)</a> as well as tumorigenesis.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20">(15-20)</a> In particular, CXCR1/2 signaling mediates agonist-induced neutrophil activation and recruitment to sites of inflammation (i.e., chemotaxis) and is therefore thought to play an important role in inflammatory diseases characterized by a significant neutrophil component.</div><div class="NLM_p">Due to the involvement of these receptors in a wide range of inflammatory diseases and carcinogenesis, CXCR1 and CXCR2 have attracted attention as targets for small-molecule drug discovery (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Reparixin <b>1</b> is a ketoprofen derivative being investigated in trials for the prevention and treatment of delayed graft function and pancreatic islet transplantation.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Diarylureas exemplified by <b>2</b> (SB225002) have been disclosed  as either selective CXCR2 antagonists<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> or dual CXCR1/2 antagonists.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The central urea motif in the diarylureas was later replaced with the cyclic urea bioisostere 3,4-diaminocyclobut-3-ene-1,2-dione to provide potent CXCR2-selective analogues as represented by SCH527123 (<b>3</b>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The diarylurea SB656933 has advanced into clinical trials for chronic obstructive pulmonary disease (COPD)<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> and cystic fibrosis,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and SCH527123 inhibited ozone inhalation-induced sputum neutrophil recruitment in healthy subjects.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> AZD-8309 (<b>4</b>) is representative of the bicyclic thiazolopyrimidine class of CXCR2 antagonists,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and this antagonist effectively inhibited the increase of LPS-mediated neutrophil recruitment in the nasal lavage of healthy subjects.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. CXCR1 and CXCR2 receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As disclosed by Cutshall and co-workers, nicotinamide glycolate esters exemplified by the methyl ester <b>5</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) are antagonists of CXCR2-mediated human neutrophil chemotaxis and are distinct from the diarylurea and related cyclobutane classes.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> We have previously shown that CXCR2 antagonism by nicotinamide glycolate esters proceeded through a novel intracellular mechanism that required hydrolytic cleavage of the ester within the neutrophil for activity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, the unique pharmacology of this class also led to rapid degradation in plasma, making it untenable as a therapeutic. The mechanistic insights gleaned from these studies inspired us to search for new nicotinamide templates that would directly antagonize CXCR2 without requiring intracellular hydrolytic activation for their activity. Herein, we report the discovery, structure–activity relationship (SAR), in vitro pharmacology, and in vivo biologic activity of <b>7</b> (SX-517). Compound <b>7</b> is a potent noncompetitive CXCR1/2 antagonist resulting from a novel series of S-substituted 6-mercapto-<i>N</i>-phenyl-nicotinamides active in their native form, and is the first reported boronic acid chemokine antagonist.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The compounds described in this study are shown in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, and their synthetic methods are outlined in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch4" aria-label="4">4</a>.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Synthetic Strategies and Focused Parallel Combinatorial Synthesis</h3><div class="NLM_p">The synthesis of S-substituted <i>N</i>-(4-fluorophenyl)-6-mercapto-nicotinamides (<b>7</b>–<b>53</b>) was carried out as described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> by first condensing 6-thio-nicotinic acid with 4-fluoroaniline using the coupling reagent 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ). The resulting <i>N</i>-(4-fluorophenyl)-6-mercapto-nicotinamide <b>64</b> was then S-alkylated with a commercially available alkyl halide, typically an alkyl bromide, using one of three methods that differed primarily in their solvent and base. Method A utilized the thio-nicotinamide intermediate <b>64</b> and bromomethyl building blocks (Maybridge Chemical Co., Cornwall, U.K.) dissolved in anhydrous DMF in the presence of resin-bound tertiary amine (4-methylmorpholino polystyrene resin, NovaBiochem, La Jolla, CA). The reaction mixture was heated at 60 °C for 1 h, followed by thiol scavenger resin (mercaptomethyl polystyrene resin, NovaBiochem, La Jolla, CA) addition. The suspension was heated to 60 °C for 2 h, and then the reaction mixture was filtered and the filtrate diluted with water. The resulting precipitate was collected by centrifugation. Purity of the synthesized compounds was assessed by HPLC, and the identification of compounds was done by electrospray ionization mass spectroscopy (ESI-MS). In all cases, the major reaction product was the derivatized thionicotinamide. Method A was used to initially synthesize compounds <b>13</b>–<b>43</b> in moderate to excellent purity by facile filtration. The synthesized compounds were screened at initial test concentrations of 5 and 10 μM for antagonism of CXCL1-mediated intracellular Ca<sup>2+</sup> release in isolated human neutrophils (hPMNs). Compounds that exhibited greater than 50% inhibition at 5 μM were then resynthesized by either methods B or C and re-evaluated in the assay to obtain IC<sub>50</sub> values of these selected compounds at a higher tested purity. Method B utilized an alkyl halide and a tertiary amine [typically triethylamine (TEA), diisopropylethylamine (DIPEA), or <i>N</i>-methylmorpholine (NMM)] to give the final compounds <b>8</b>–<b>13</b>, <b>15</b>, <b>17</b>, <b>22</b>, <b>43</b>, <b>46</b>, <b>48</b>, and <b>50</b>. Method C utilized an alkyl halide and aqueous NaOH in EtOH at reflux to give the final compounds <b>7</b>, <b>30</b>, and <b>53</b> in good yield.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of S-Substituted <i>N</i>-(4-Fluoro-phenyl)-6-mercapto-nicotinamides <b>9</b>–<b>45</b>, <b>47</b>–<b>48</b>, <b>52</b>, and <b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 4-fluoroaniline, EEDQ, DMF, rt; (ii) method A: Br-CH<sub>2</sub>–R, solid-phase base (<i>N</i>-methylmorpholino-substituted resin), DMF, 60 °C; method B: Br-CH<sub>2</sub>–R or Cl-CH<sub>2</sub>–R, DMF, base (TEA, DIPEA, or), rt; method C: Br-CH<sub>2</sub>–R, EtOH, 1 N NaOH, reflux.</p></p></figure><div class="NLM_p">Further chemical modification of intermediates to final test compounds is shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Treatment of <b>7</b> by potassium peroxymonosulfate (Oxone), according to the procedure of Webb and Levy for the hydroxylation of aryl boronic acids,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> afforded compound <b>44</b>. Saponification of the methyl esters <b>46</b>, <b>48</b>, and <b>50</b> with NaOH afforded carboxylic acids <b>47</b>, <b>49</b>, and <b>51</b>, respectively. The tetrazoles <b>8</b> and <b>52</b> were prepared via the cycloaddition of the cyano intermediates with trimethylsilyl azide and dibutyltin oxide<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> in toluene under reflux.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>S</i>-Substituted <i>N</i>-(4-Fluoro-phenyl)-6-mercapto-nicotinamides <b>8, 44, 47, 49, 51–52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) TMS-N<sub>3</sub>, Bu<sub>2</sub>SnO, toluene, reflux; (ii) 1 N NaOH, MeOH, rt; and (iii) oxone, aq NaHCO<sub>3</sub>, acetone, 4 °C</p></p></figure><div class="NLM_p">The synthesis of <i>N</i>-substituted 6-(thiobenzyl-2-borono)-nicotinamides <b>54</b>–<b>59</b> was performed as in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. 6-Thio-nicotinic acid was coupled to 2-bromomethyl-phenylboronic acid using a modified method B employing TEA, DMF, and elevated temperature (60 °C) to give intermediate <b>67</b>. Intermediate <b>67</b> was treated with neopentyl glycol in toluene under reflux to afford the protected neopentyl boronate ester. After cooling to 0 °C, pivaloyl chloride was added with triethylamine (TEA), and the reaction proceeded for an hour and then with gradual warming to room temperature for another hour to give the pivaloyl mixed anhydride intermediate <b>68</b>, which was used without purification. Intermediate <b>68</b> was then coupled immediately to either 4-trifluoromethoxyaniline, 4-aminobenzoic acid, 5-(4-aminophenyl)-1H-tetrazole, 4-amino-pyridine, 4-hydroxy-aniline, or 2-amino-5-fluoropyridine under heating to give the corresponding 6-(thiobenzyl-2-neopentyl boronate ester)-nicotinamides. Exposure to water liberated the boronic acid moiety from the neopentyl boronate ester, which after purification by preparative HPLC afforded <b>54</b>–<b>59</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Anilide Derivatives of 6-(Thiobenzyl-2-borono)-nicotinamides <b>54–59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 2-bromomethyl-phenylboronic acid, DMF, TEA, 60 °C; (ii) neopentyl glycol, toluene, reflux; (iii) pivaloyl chloride, TEA, toluene, 0 °C to rt; and (iv) aniline derivative, TEA, DMF, 60 °C.</p></p></figure><div class="NLM_p">The synthesis of <i>N,N</i>-disubstituted 6-(thiobenzyl-2-borono)-nicotinamides <b>60</b>–<b>63</b> was performed through two alternative routes as described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. In one route, 6-chloronicotinoyl chloride was amidated with the secondary amines <b>70a</b> and <b>70b</b>, using DBU as the base to give the <i>N,N</i>-disubstituted 6-chloronicotinamides <b>71a</b> and <b>71b</b>, respectively. The secondary amine <b>70a</b> was derived from reductive amination of <i>N</i>-Boc-2-piperidinecarbaldehyde (Chem-Impex, Wood Dale, IL) with 4-fluoroaniline and sodium triacetoxyborohydride. The secondary amine <b>70b</b> was derived from the coupling of 4-fluoroaniline with <i>tert</i>-butyl bromoacetate in DMF with DIPEA as base. In the alternate route, 6-chloronicotinoyl chloride was amidated with 4-fluoroaniline in THF in the presence of potassium carbonate to form intermediate <b>69</b>. Compounds <b>72a</b>–<b>72</b><b>b</b> were synthesized from intermediate <b>69</b> under phase transfer catalyzed conditions, utilizing either 2-bromomethylpyridine or 4-bromomethylpyridine, respectively. The tertiary amides <b>71a</b>–<b>71b</b> and <b>72a</b>–<b>72b</b> were then subjected to the same treatment with sodium hydrogen sulfide (NaHS) in DMF to displace the pyridinyl chloride and form the corresponding thio-nicotinamide intermediates <b>73a</b>–<b>73d</b>, respectively. The resultant thio-nicotinamide intermediates <b>73a</b> and <b>73b</b> were alkylated with 2-bromomethyl-phenylboronic acid using method C to afford <b>60</b> and <b>61</b>, respectively. Method C applied to <b>73c</b> followed by treatment with 4 M HCl in dioxane deprotected the Boc-piperidyl moiety to yield <b>62</b>. Method B applied to <b>73d</b> followed by acid hydrolysis of the <i>tert</i>-butyl protected carboxyl group with 90% TFA yielded <b>63</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Substituted 6-(Thiobenzyl-2-borono)-nicotinamides <b>60–63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 4-fluoroaniline, K<sub>2</sub>CO<sub>3</sub>, THF, rt; (ii) <i>N</i>-Boc-2-piperidinecarbaldehyde, NaBH(OAc)<sub>3</sub>, DCE, glacial AcOH, rt; (iii) <i>tert</i>-butyl bromoacetate, DIPEA, DMF, 80 °C; (iv) phase-transfer reaction: bromomethylpyridine, toluene, 50% aq NaOH, TBAH, rt; (v) 6-chloronicotinoyl chloride, DBU, DMF, heat; (vi) NaHS, DMF, heat; (vii) 2-bromomethyl-phenylboronic acid, EtOH, 1 N aq NaOH, reflux; (viii) 2-bromomethyl-phenylboronic acid, DMF, TEA; (ix) 4 M HCl, dioxane, rt; and (x) 90% aq TFA, rt.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> CXCL1-Stimulated Ca<sup>2+</sup> Flux in Human Neutrophils</h3><div class="NLM_p last">An increased flux of intracellular Ca<sup>2+</sup> represents a key signaling event in CXCL1-induced neutrophil activation through CXCR2.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Since nicotinamide-based chemokine antagonists act intracellularly,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the activity of a compound will depend not only on its target affinity but also on its ability to transit into the intracellular compartment. To simultaneously capture both properties in initial SAR evaluations, all compounds prepared were evaluated for their ability to inhibit CXCL1-stimulated Ca<sup>2+</sup> flux in whole hPMNs. Full dose–response curves were determined for select compounds using at least seven concentrations, and the resulting IC<sub>50</sub> values listed in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> as part of these SAR studies are the mean of at least three determinations.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Studies</h3><div class="NLM_p">The nicotinamide glycolate methyl ester <b>5</b> antagonized CXCL1-stimulated Ca<sup>2+</sup> flux by an intracellular mechanism that required hydrolytic cleavage of the ester within the hPMN to liberate the active species.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The required hydrolytic cleavage of the ester led to instability in plasma that was inseparable from the intrinsic activation mechanism of this pharmacophore class. Since in vivo stability of a potential therapeutic is essential, novel CXCR2 antagonists were sought that would directly antagonize the receptor without the need for hydrolytic activation and, thus, resist in vivo esterase activity. To this end and based on the above activation mechanism involving the glycolate ester moiety, new S-substituted nicotinamides and related congeners were evaluated for antagonism of CXCL1-stimulated Ca<sup>2+</sup> flux in whole hPMNs, as summarized in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. CXCL1-Inhibitory Activity of Carboxylate and Carboxylate Isostere Substituted Thionicotinamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Each IC<sub>50</sub> determination was performed in triplicate with ≥6 concentrations, and reported as the mean ± standard error.</p></div></div><div></div></div><div class="NLM_p">Our SAR efforts first involved the bioisosteric replacement of the ester/acid moiety of lead nicotinamides <b>5</b> and <b>6</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Replacement of the carboxylate moiety with either a cyclic ester (<b>9</b>), a sulfone (<b>10</b>), a nitro (<b>11</b>), or a phosphite (<b>12</b>) resulted in loss of activity in our assay. We previously demonstrated that the negatively charged nicotinamide carboxylate <b>6</b> could not enter hPMNs, and its activity was only observed after hPMNs were electropermeabilized.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> On the basis of this observation, we hypothesized that the <i>S</i>-methyl-tetrazole <b>8</b> might serve as a more lipophilic bioisostere of the thioglycolate moiety that could passively enter hPMNs. Its activity (IC<sub>50</sub> = 3900 nM) supported this hypothesis, but its potency was relatively weak in this capacity.</div><div class="NLM_p">In order to widen our SAR efforts, a focused combinatorial library screen was implemented. As we discussed above, this successful parallel synthetic effort was made possible through the use of excess alkyl bromide reagent and heat to drive the alkylation to completion, as well as the use of solid phase scavenging resins to aid in product isolation. The compounds (<b>13</b>–<b>43</b>) were first screened for activity versus CXCL1-mediated calcium flux in hPMNs at test concentrations of 5 and 10 μM. In our initial screen, compounds <b>13</b>, <b>15</b>, <b>17</b>, <b>20</b>, <b>22</b>, <b>30</b>, and <b>43</b> exhibited greater than 50% inhibition of CXCL1-mediated intracellular Ca<sup>2+</sup> release at a test concentration of 5 μM and were therefore identified as potential hits. These compounds were then resynthesized and retested, and the results are shown in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Upon resynthesis and retesting, compounds <b>13</b>, <b>15</b>, <b>17</b>, and <b>22</b> exhibited IC<sub>50</sub> values greater than 5 μM. Inhibitory activity was confirmed for the tetrahydrofuran derivative <b>20</b> (IC<sub>50</sub> = 540 nM), the <i>S</i>-benzyl derivative <b>30</b> (IC<sub>50</sub> = 390 nM), and the <i>S</i>-dichlorobenzyl derivative <b>43</b> (IC<sub>50</sub> = 1610 nM). The activity of <i>S</i>-benzyl derivative <b>30</b> was similar to the intrinsic activity of the de-esterified carboxylate species (IC<sub>50</sub> = 100–500 nM) of nicotinamide methyl ester <b>5</b> reported previously in electropermeabilized hPMNs.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Removal of the methylene between the sulfur and the aryl ring resulted in loss of activity (<b>45</b>). The results from this focused combinatorial chemistry effort indicated that the <i>S</i>-benzyl nicotinamide nucleus held potential as a new CXCR2 inhibitor template.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. CXCL1-Inhibitory Activity of Heterocyclyl- and Heteroalkyl-Substituted Thionicotinamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Select IC<sub>50</sub> determinations were performed in triplicate with ≥6 concentrations, and reported as the mean ± standard error.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. CXCL1-Inhibitory Activity of Aryl-Substituted Thionicotinamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0017.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Select IC<sub>50</sub> determinations were performed in triplicate with ≥6 concentrations and reported as the mean ± standard error.</p></div></div><div></div></div><div class="NLM_p">Elaboration of the benzyl ring with a carboxyl group resulted in activity, with the 2-position (<b>51</b>, IC<sub>50</sub> = 1480 nM) favored over both the 3-position (<b>49</b>, IC<sub>50</sub> = 2120 nM) and the 4-position (<b>47</b>, IC<sub>50</sub> > 10000 nM). We hypothesized that the reduced activity of <b>51</b> was the result of poor accumulation in the hPMN as a result of the negatively charged carboxylate adversely affecting uptake, efflux, or both. To examine this hypothesis further and because we have shown previously that the nicotinamide methyl ester <b>5</b> can be de-esterified within hPMNs to liberate high concentrations of the corresponding acid,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> we examined the uncharged <i>S</i>-methyl-benzoyl methyl esters <b>46</b>, <b>48</b>, and <b>50</b> as potential intracellular precursors to the corresponding acids. There was a 2-fold improvement in potency in the 2-methyl ester <b>50</b> relative to the corresponding free acid <b>51</b>, but the 3- and 4-methyl esters <b>48</b> and <b>46</b> were inactive. It is possible that the limited improvement in potency arose because benzoyl methyl esters are poorer substrates for intracellular esterase activity than the thioglycolate methyl ester <b>5</b>.</div><div class="NLM_p">To explore bioisosteric replacements for the carboxylate in our intermediate lead compound, the tetrazole derivative was synthesized and evaluated for activity. Compound <b>52</b> (IC<sub>50</sub> = 170 nM) exhibited an almost 10-fold increase in activity as compared to the 2-carboxylate derivative <b>51</b>. Our SAR efforts then turned to carboxyl replacements at the 2-position. An important functionality being explored in recent pharmaceutical development is the boronic acid moiety.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> Inclusion of a boronic acid at the 2-postion of the <i>S</i>-benzyl nicotinamide scaffold resulted in compound <b>7</b> exhibiting potent inhibition of CXCR2 activation with an IC<sub>50</sub> of 38 nM. Phenylboronic acid has a p<i>K</i><sub>a</sub> of 8.9,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and at neutral pH, compound <b>7</b> is expected to be mostly uncharged and readily transit into the cell interior. However, to test the possibility that greater lipophilicity would further increase potency, we prepared the corresponding pinacol ester <b>53</b>. Although acyclic and unhindered cyclic esters of boronic acids are rapidly hydrolyzed in water, hydrolysis is slowed considerably for hindered cyclic aliphatic esters such as the pinacol ester.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Remarkably, the pinacol ester derivative <b>53</b> retained the same order of activity as the parent boronic acid, with its activity modestly reduced by approximately 7-fold (IC<sub>50</sub> = 275 nM). Whether the pinacol ester was active at the target or served to liberate the boronic acid inside the cell is unknown, but importantly the enhanced lipophilicity of the boronyl ester offered no advantage in potency over the underivatived boronyl group.</div><div class="NLM_p">Concluding that the <i>S</i>-benzyl-2-borono scaffold in <i>N</i>-(4-fluorophenyl)-6-(thiobenzyl-2-borono)-nicotinamide <b>7</b> provided optimal nanomolar potency against CXCL1-induced Ca<sup>2+</sup> flux, we undertook separate focused SAR studies of the apical 4-fluorophenyl-carboxamido domain (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The 4-fluoroanilide moiety was previously investigated and optimized for a related class of CXCR2 antagonists,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> but our focus was to introduce polar and/or ionizable substitutions that could potentially increase aqueous solubility while retaining potent chemokine antagonism. To accomplish this, the SAR of the apical 4-fluorophenyl-carboxamido- moiety in <b>7</b> was explored in compounds <b>54</b>–<b>59</b>, a series of R2 N-monosubstituted 6-(thiobenzyl-2-borono)-nicotinamides (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The results clearly revealed the importance of the 4-fluoroanilide. Its replacement with carboxyl (<b>55</b>) or tetrazolyl (<b>56</b>) abrogated all activity. Its replacement with trifluoromethoxy (<b>54</b>), a pyridinyl nitrogen (<b>57</b>), hydroxyl (<b>58</b>), or inclusion of a ring nitrogen (<b>59</b>) resulted in a 7-, 14-, 3-, and 8-fold reduction in activity, respectively. The <i>N,N</i>-disubstituted 6-(thiobenzyl-2-borono)-nicotinamides <b>60</b>–<b>63</b> were explored by leaving the <i>N</i>-4-fluorophenyl R2 moiety constant and elaborating the R1 <i>N</i>-substitution. The <i>N</i>-methyl-2-pyridyl (<b>60</b>) was found to be well-tolerated (IC<sub>50</sub> = 78 nM), yielding an activity nearly equivalent to <b>7</b> and providing evidence that the pyridyl group, which would be expected to be uncharged at neutral pH, does not preclude entry of the molecule into the cell. Surprisingly, the potency of the closely related congener <b>61</b> employing <i>N</i>-methyl-4-pyridyl was 11-fold lower than <b>60</b>, suggesting a model where the pyridyl moieties are engaged in a highly structured and restricted environment. <i>N</i>-methyl-2-piperidyl <b>62</b> was explored as a nonplanar and nonaromatic analog of <b>60</b>. It was completely devoid of activity, possibly because it was not accommodated at the target or because its positive charge prevented passive diffusion into the cell. A similar finding was obtained for the <i>N</i>-2-acetic acid analog <b>63</b>. None of the compounds <b>60</b>–<b>63</b> exhibited significantly improved aqueous solubility relative to <b>7</b>, despite attempts to prepare conjugate salts (data not shown).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effect of <i>N</i>-Substituted 6-(Thiobenzyl-2-borono)-nicotinamides on CXCL1-Induced Ca<sup>2+</sup> Flux in Human Neutrophils</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0018.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0019.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Each IC<sub>50</sub> determination was performed in triplicate with ≥6 concentrations and reported as the mean ± standard error.</p></div></div><div></div></div><div class="NLM_p last">On the basis of its optimal in vitro potency in inhibiting CXCL1-stimulated Ca<sup>2+</sup> release in the above SAR studies, compound <b>7</b> was further evaluated with respect to its in vitro signaling pharmacology and in vivo biologic activity as described below.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> G-Protein Coupling to CXCR2</h3><div class="NLM_p">CXC receptors transduce signals to the interior of the cell through activation of a coupled heterotrimeric G-protein, the most proximal signaling event after agonist binding to the receptor.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> CXCR2 is bound and activated by both CXCL1 and CXCL8.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The effect of compound <b>7</b> on G-protein coupling to CXCR2 was evaluated by [<sup>35</sup>S]GTPγS binding in CXCR2 membranes prepared from HEK293 cells that stably expressed the human receptor (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Compound <b>7</b> potently inhibited [<sup>35</sup>S]GTPγS binding in response to 10 nM CXCL8 with an IC<sub>50</sub> of 60 ± 7 nM (mean + S.E.).</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of chemokine-stimulated [<sup>35</sup>S]GTPγS binding by compound <b>7</b>. HEK293 cells stably expressing CXCR2 were incubated with different concentrations of compound (from 10<sup>–10</sup> to 10<sup>–4</sup> M) at 37 °C for 60 min, and then the membranes were prepared by lysis and centrifugation. The membranes were then incubated in buffer containing 50 μM GDP, 8 nM [<sup>35</sup>S]GTPγS, and 10 nM CXCL8 at 30 °C for another 60 min. Membranes were harvested by rapid filtration and membrane-bound [<sup>35</sup>S]GTPγS quantitated. Data, expressed as a percentage of basal [<sup>35</sup>S]GTPγS bound in the absence of CXCL8, are the mean ± SE from three independent experiments, each done in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> CXCL8 Binding at CXCR2</h3><div class="NLM_p">We have shown that nicotinamide glycolates act away from the orthosteric chemokine binding site to antagonize CXCR2 through an intracellular mechanism.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Maximal inhibition of radioligand binding by an allosteric antagonist can be observed in displacement experiments with radioligand concentrations much lower than the <i>K</i><sub>d</sub> value.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> We examined the ability of compound <b>7</b> to displace binding of [<sup>125</sup>I]-CXCL8 from CXCR2 membranes using a radioligand concentration (25 pM) that was >10-fold below the <i>K</i><sub>d</sub> for CXCL8 binding to CXCR2.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Although compound <b>7</b> potently inhibited functional CXCR2 signaling by CXCL1 (IC<sub>50</sub> = 38 nM, CXCL1-stimulated Ca<sup>2+</sup> flux) and CXCL8 (IC<sub>50</sub> = 60 nM, CXCL8-stimulated [<sup>35</sup>S]GTPγS binding), up to 10 μM failed to compete the binding of [<sup>125</sup>I]-CXCL8 to CXCR2 membranes (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). In parallel controls, unlabeled CXCL8 isopotently displaced its homologous radioligand (IC<sub>50</sub> = 28 pM). Collectively, these data support a model where compound <b>7</b> acts as a noncompetitive, intracellular allosteric inhibitor of CXCR2. These findings mirrored those of the noncompetitive allosteric inhibitor reparixin <b>1</b>, which inhibited CXCR1 responses with no effect on CXCL8 binding to CXCR1.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a></div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Competition binding assay with <b>7</b> and CXCL8 at human CXCR2. Membranes from recombinant HEK293-CXCR2 cells were incubated with the compound at the indicated concentrations and 25 pM [<sup>125</sup>I]-CXCL8. Radioligand binding to the membranes was measured by scintillation. Data show the mean ± SD (<i>n</i> = 3) radioligand binding, expressed as the percent of control specific radioligand binding with vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cell Surface Expression of CXCR2</h3><div class="NLM_p">CXCR2 activation by chemokines is followed by receptor phosphorylation and subsequent down-regulation; events that are accompanied by receptor internalization.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> We considered the possibility that compound <b>7</b> may antagonize CXCR2 in whole cells at least partially through a similar mechanism of sequestering receptor away from the cell membrane signaling machinery. We therefore evaluated the effect of compound <b>7</b> on the CXCR2 surface expression in stably transfected HEK293 cells using a fluorescently labeled antibody to the receptor and fluorescence-activated cell sorting. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, 60 min exposure to 10 μM compound <b>7</b> did not significantly alter the cell surface expression of CXCR2. These data together with the data showing inhibition of CXCL8-stimulated [<sup>35</sup>S]GTPγS binding are most consistent with a mechanism of antagonism involving direct blockade of receptor activation.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>7</b> on the cell surface expression of CXCR2. HEK293 cells stably expressing CXCR2 were pretreated with 1% DMSO (vehicle) or 10 μM compound (cpd. <b>7</b>) for 60 min. HEK293 cells not expressing CXCR2 served as a negative isotype control (isotype). All cells were then incubated with <i>R</i>-phycoerythrin (<i>PE</i>)-conjugated antihuman CXCR2 mouse monoclonal antibody at 4 °C for 60 min. Cells were washed, fixed in 2% formaldehyde in PBS, and subjected to flow cytometric fluorescence-activated cell sorting (FACS) analysis of the PE signal. Results are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> CXCR2 MAPK Signaling</h3><div class="NLM_p">CXCR1 and CXCR2 mediate downstream signaling in part through MAPK activation.<a onclick="showRef(event, 'ref4 ref45'); return false;" href="javascript:void(0);" class="ref ref4 ref45">(4, 45)</a> To assess the ability of compound <b>7</b> to inhibit MAPK in HEK293 cells that stably expressed CXCR2, we measured ERK1/2 phosphorylation in response to CXCL8 in the presence of vehicle or 10 μM compound <b>7</b>. As shown in the vehicle arm in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, CXCR2 induced a time-dependent phosphorylation of ERK1/2 upon activation by CXCL8. Maximum response was obtained at 15 min. In contrast, compound <b>7</b> completely blocked CXCR2-mediated phosphorylation of ERK1/2 by 30 min. There was no effect on the amount of ERK1/2 present in the lysates (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, lower panel) as assessed by an anti-ERK1/2 antibody recognizing ERK1/2 irrespective of its phosphorylation state. These data are consistent with receptor blockade by compound <b>7</b> as the common event that abrogates signaling pathways downstream of CXCR2 involving G-proteins, MAP kinases, and intracellular Ca<sup>2+</sup>.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of Compound <b>7</b> on CXCR2-induced ERK1/2 phosphorylation. HEK293 cells stably expressing CXCR2 were stimulated with CXCL8 (100 ng/mL) for 0–30 min in the presence of vehicle or 10 μM compound <b>7</b>. Phosphorylated ERK1/2 and total ERK were determined by Western blotting using antiphospho-ERK1/2 (<i>P-ERK1/2</i>) and antitotal ERK1/2 (<i>T-ERK1/2</i>) antibodies, respectively. Data are representative of three independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Selectivity of Antagonism</h3><div class="NLM_p">CXCR1 and CXCR2 are expressed in equal numbers on the surface of hPMNs.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Whereas CXCL8 activates both CXCR1 and CXCR2, CXCL1 is a selective agonist for CXCR2.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Compound <b>7</b> inhibited both CXCL1- and CXCL8-stimulated Ca<sup>2+</sup> flux in hPMNs with IC<sub>50</sub> values of 38 and 36 nM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effect of <b>7</b> on Agonist-Induced Ca<sup>2+</sup> Flux</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">hPMN</th><th class="colsep0 rowsep0" align="center">HEK293-CXCR1</th><th class="colsep0 rowsep0" align="center">HEK293-CXCR2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCL1</td><td class="colsep0 rowsep0" align="left">38 ± 3</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCL8</td><td class="colsep0 rowsep0" align="left">36 ± 11</td><td class="colsep0 rowsep0" align="left">880 ± 90</td><td class="colsep0 rowsep0" align="left">210 ± 40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C5a</td><td class="colsep0 rowsep0" align="left">>5000</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAF<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>5000</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fMLF<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>5000</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Each IC<sub>50</sub> determination was performed in triplicate with ≥6 concentrations and reported as the mean ± standard error.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">ND = not determined.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Platelet activating factor.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Formyl-Met-Leu-Phe.</p></div></div></div><div class="NLM_p">This inhibition was not partial, since a concentration of 1 μM compound <b>7</b> was sufficient to completely eliminate CXCL8-stimulated Ca<sup>2+</sup> flux in hPMNs. The total antagonism of CXCL8-induced Ca<sup>2+</sup> flux by compound <b>7</b> presumably reflected a dual blockade of both CXCR1 and CXCR2 signaling. The antagonism of CXCR1 and CXCR2 by compound <b>7</b> in hPMNs was found to be selective; however, as concentrations up to 5 μM failed to inhibit Ca<sup>2+</sup> flux induced by optimal concentrations of the chemokines C5a, PAF, and fMLF (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_p last">Although the inhibition of CXCL8-induced Ca<sup>2+</sup> flux in hPMNs indicated dual antagonism of CXCR1 and CXCR2, the coexpression of these receptors in hPMNs precluded evaluating the relative inhibitory potency at each receptor. Additional experiments were therefore performed to separately evaluate the potency of compound <b>7</b> at CXCR1 and CXCR2. For these determinations, CXCL8-induced Ca<sup>2+</sup> flux was measured in recombinant HEK293 cells that stably expressed CXCR1 (HEK293-CXCR1) or CXCR2 (HEK293-CXCR2) in the presence of vehicle and different concentrations of compound <b>7</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). For CXCL8-induced Ca<sup>2+</sup> flux, the data showed that compound <b>7</b> exhibited a 4-fold selectivity in inhibition for CXCR2 (IC<sub>50</sub> = 210 nM) over CXCR1 (IC<sub>50</sub> = 880 nM) in these recombinant systems. As a positive control, the CXCR2-selective antagonist SB225002 inhibited CXCL8-induced Ca<sup>2+</sup> flux in the HEK293-CXCR2 cells with an IC<sub>50</sub> of 40 nM, a value consistent with its previously reported IC<sub>50</sub> value of 30 nM for CXCL1-induced Ca<sup>2+</sup> flux in hPMNs.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The observed discrepancy in the potency of <b>7</b> when evaluated in isolated hPMNs versus HEK cells is not fully understood but may be attributed to intracellular differences between the native (hPMN) and artificially engineered (HEK) systems.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Effect on Inflammation in Vivo</h3><div class="NLM_p">To confirm the in vitro effects on the neutrophil function in vivo, compound <b>7</b> was evaluated in the murine air-pouch model of inflammation (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). An air-pouch was induced on the backs of male CD1 Swiss mice as described.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Cohorts of five animals each were given vehicle (negative and positive control cohorts) or compound <b>7</b> dissolved in vehicle (0.02 mg/kg and 0.20 mg/kg test cohorts) by intravenous injection. Three hours afterward, the pouches in the negative control cohort were injected with sterile phosphate-buffered saline. Inflammation was induced in the pouches of the remaining three cohorts by injection with 2% carrageenan, which causes an inflammatory infiltrate consisting predominantly of neutrophils. The total cell count in the inflammatory infiltrate from each pouch was quantitated. At a dose of 0.2 mg/kg of compound <b>7</b>, there was a significant reduction in cell count in the pouches of treated animals compared to the positive control cohort (**<i>p</i> < 0.01, Student’s <i>t</i>-test).</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. An air-pouch was formed on the backs of 10–15 week old, male CD1 Swiss mice in four cohorts (<i>n</i> = 5 animals per cohort). Compound dissolved in vehicle (0.02 mg/kg and 0.20 mg/kg cohorts) or vehicle alone (positive and negative cohorts) was administered intravenously. After 3 h, each air pouch was injected with 1 mL of PBS (negative cohort) or 2% carrageenan in PBS (positive, 0.02 mg/kg and 0.20 mg/kg cohorts). After 4 h, the pouch fluid was collected and combined with an additional 2 mL PBS wash of the pouch. The cells in the combined fluid were stained with trypan blue and manually counted on a hemocytometer. Data show the mean ± SE of the absolute pouch cell count per cohort. Student’s <i>t-</i>test: **<i>p</i> < 0.01 vs positive cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The results reported here describe SAR studies that examined the effect of a novel series of S-substituted 6-mercapto-<i>N</i>-phenyl-nicotinamides on CXCL1-stimulated Ca<sup>2+</sup> flux in whole hPMNs. The SAR data established that an ortho-modified <i>S</i>-benzyl substituent played a critical role in determining activity, with an ortho-boronyl group being optimal. The fluorine in the 4-fluorophenyl-carboxamido- moiety was also an important requirement for optimal inhibitory activity. Among the derivatives exhibiting the most potent antagonism of CXCL1 described here, <b>7</b> was selected for further evaluation of its in vitro pharmacology and in vivo biologic activity.</div><div class="NLM_p">Compound <b>7</b> was found to be a dual CXCR2/1 antagonist with a modest preference for CXCR2. It inhibited CXCL1- and CXCL8-induced Ca<sup>2+</sup> flux (IC<sub>50</sub> = 38 and 36 nM, respectively) in hPMNs. In response to CXCL8 stimulation, compound <b>7</b> directly antagonized [<sup>35</sup>S]GTPγS binding (IC<sub>50</sub> = 60 nM) and ERK1/2 phosphorylation in HEK293 cells that stably expressed CXCR2. In an in vivo murine model of inflammation characterized by an inflammatory infiltrate predominated by neutrophils, compound <b>7</b> significantly reduced total cell count at an intravenous dose of 0.2 mg/kg.</div><div class="NLM_p">Early work by others to develop small-molecule chemokine inhibitors focused on evolving compounds that were highly specific for either CXCR1<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> or CXCR2.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> These efforts were later followed by compounds with dual-activity at CXCR1 and CXCR2<a onclick="showRef(event, 'ref26 ref48'); return false;" href="javascript:void(0);" class="ref ref26 ref48">(26, 48)</a> in recognition that these homologous receptors mediate inflammation through unique and overlapping pathways. For example, whereas both CXCR1 and CXCR2 mediate CXCL8-induced chemotaxis,<a onclick="showRef(event, 'ref23 ref49'); return false;" href="javascript:void(0);" class="ref ref23 ref49">(23, 49)</a> myeloperoxidase release from hPMNs occurs mainly through CXCR1 activation.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a> CXCL8-mediated neutrophil chemotaxis is most effectively inhibited by dual CXCR1 and CXCR2 blockade.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Compared to specific antagonists, dual CXCR2/1 inhibition by compound <b>7</b> may therefore offer a more complete therapeutic strategy in a number of inflammatory diseases where the CXCR2 pathway is involved specifically or in conjunction with CXCR1 signaling.</div><div class="NLM_p">G-protein coupled receptors (GPCRs) are thought to exist in multiple conformational states, and activation by an agonist mediates signaling to the cell interior through poorly understood conformational changes in the receptor. It has been proposed that allosteric sites in the transmembrane domain of GPCRs may represent high-value targets for noncompetitive inhibitors that block agonist-induced G-protein activation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Indeed, studies have found that the antagonist reparixin (<b>1</b>),<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> and the CXCR2-specific antagonists SB265610, SB332235, and SCH527123 (<b>3</b>), act as allosteric inhibitors.<a onclick="showRef(event, 'ref43 ref49 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref43 ref49 ref54 ref55 ref56">(43, 49, 54-56)</a> These inhibitors achieve receptor selectivity by exploiting amino acid differences between these homologous receptors, with reparixin (<b>1</b>) differentially binding the extracellular half of the seven-transmembrane core<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and SB332235 differentially binding an intracellular pocket made up of several transmembrane helices.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> We previously demonstrated that the nicotinamide glycolate methyl ester <b>5</b> inhibited CXCL1-induced effects in hPMNs through an intracellular mechanism.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In the studies herein, potent antagonism of CXCL8-stimulated [<sup>35</sup>S]GTPγS binding by compound <b>7</b> localized inhibition to a proximal signaling event involving the CXCR2 receptor and its G-protein. Further data demonstrated compound <b>7</b> was CXCR2/1 specific, with no inhibition of fMLF-, C5a-, or PAF-induced Ca<sup>2+</sup> flux through their corresponding GPCRs. We therefore speculate that compound <b>7</b> acts at an intracellular pocket, involving at least the CXCR2/1 receptor to lock the receptor in a conformation unable to activate downstream signaling. Studies to explore this postulated mechanism are underway in our group.</div><div class="NLM_p">Consistent with being a noncompetitive inhibitor, compound <b>7</b> potently inhibited functional CXCR2 signaling by CXCL1 and CXCL8 but failed to compete with the binding of [<sup>125</sup>I]-CXCL8 to CXCR2 at concentrations ∼100-fold larger than its IC<sub>50</sub> for inhibiting CXCR2 ligand-triggered Ca<sup>2+</sup> flux. Others have earlier recognized the possibility of identifying allosteric small-molecule chemokine inhibitors that disrupt receptor function without displacing the chemokine from its orthosteric binding site.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The SAR studies herein demonstrate that our whole-cell functional assay for CXCL1-induced Ca<sup>2+</sup> flux in hPMNs beneficially allowed for the selection of a novel class of potent noncompetitive inhibitors that would have otherwise been missed by a competitive displacement screen. Our findings mirror those of the noncompetitive allosteric inhibitor reparixin, which likewise inhibited CXCR1 responses with no effect on CXCL8 binding to CXCR1.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a></div><div class="NLM_p">Compound <b>7</b> is notable for being the first reported boronic acid chemokine antagonist. Due to the unique chemical similarities and differences between boron and carbon, boronic acid based inhibitors have been the subject of considerable recent interest as a new source of small-molecule therapeutics.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The clinical utility of the boronyl moiety has been validated with the U.S. and European approval of bortezomib (Velcade), and other boronic acids have been previously disclosed as inhibitors of serine proteases, proteasomes, arginase, nitric oxide synthase, and transpeptidases.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The effectiveness of boronic acids as inhibitors of proteosomes<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> and serine proteases<a onclick="showRef(event, 'ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62 ref63">(60-63)</a> has been ascribed to the ability of the boronyl group to form a reversible tetrahedral adduct with an active-site nucleophile that has most often been serine but has also included histidine.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> On the basis of crystallographic and NMR studies of boronic acid inhibitors in complex with their target enzymes, this adduct closely mimics the putative tetrahedral intermediate or transition-state formed between the enzyme and its substrates. Although CXCR1 and CXCR2 are not thought to possess intracellular enzymatic activity, we speculate that the marked increase in potency observed upon incorporation of the boronyl group at the 2-position of the <i>S</i>-benzyl scaffold in compound <b>7</b> may be due to an analogous reversible boronyl-mediated adduct with a receptor-based nucleophile in the putative intracellular binding pocket. The potential benefit of such a postulated adduct in prolonging pharmacodynamic effects in subjects remains to be investigated. However, like other CXCR2/1 inhibitors with a low off-rate (e.g., SCH527123),<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> the benefit will likely be limited by the kinetics of new receptor biosynthesis and the 1–2 day tissue lifespan of the neutrophil itself.</div><div class="NLM_p last">Current efforts are underway in our laboratory to increase the oral bioavailability of compound <b>7</b> and to further investigate the interaction of this class of compounds with CXCR1 and CXCR2 receptors. Compound <b>7</b> (SX-517) represents a novel boronic acid containing pharmacophore for the antagonism of CXCR1/2 chemokine receptors and may prove useful in the treatment of inflammatory diseases with a significant neutrophil component.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">A Pharmacology and Biology</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Materials and Reagents</h4><div class="NLM_p last">Chemicals and carrageenan were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). Chemokines were from PeproTech (Rocky Hill, NJ) or from R&D Systems (Minneapolis, MN). Control CXCR2 antagonists (SB265610 and SB225002) were from Tocris Biosciences (Ellisville, MO). The HEK293 cell line was from ATCC (Manassas, VA). Erk1/2 and phospho-Erk (p-Erk) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Cellulose nitrate membrane filters were from Whatman Inc. (Piscataway, NJ). [<sup>35</sup>S]GTPγS (1250 Ci/mmol), <sup>125</sup>I-CXCL8 (2200 Ci/mmol), and Unifilter GF/C 96-well filter plates were from PerkinElmer Life and Analytical Sciences (Waltham, MA).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> HEK293 Cell Stably Expressing Human CXCR1 and CXCR2</h4><div class="NLM_p last">HEK293 cells were cultured in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 50 units/mL penicillin, 50 μg/mL streptomycin, 3 mM glutamine, 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) at 37 °C, 5% CO<sub>2</sub>. Transfection with a human CXCR1<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> or CXCR2 plasmid<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> was performed with Lipofectamine (Invitrogen Life Technology) based on the manufacturer’s protocol. For selection of stable polyclonal cell lines, 800 μg/mL G418 (Sigma, St Louis, MO) were added 24 h after transfection and cells were maintained in DMEM medium containing 800 μg/mL G418 through subculture procedures until a pooled, stable cell line was established. Surface expression of CXCR1 and CXCR2 was confirmed using <i>R</i>-phycoerythrin (PE)-conjugated antihuman CXCR1 or CXCR2 mouse monoclonal antibody (BD Pharmingen, San Diego, CA) and fluorescence-activated cell sorting as described below.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Isolation of Human Neutrophils</h4><div class="NLM_p last">Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Human polymorphonuclear leukocytes (hPMNs) were purified from the blood using dextran sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as described previously.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> hPMN preparations were routinely >95% pure, as determined by light microscopy, and >98% viable, as determined by trypan blue exclusion. Isolated hPMNs were washed twice and resuspended in RPMI containing 10% fetal bovine serum (FBS).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Animals</h4><div class="NLM_p last">Male CD1 mice were obtained from Charles River Laboratories (Wilmington, MA). Animals were housed and acclimatized for 1 week under controlled temperature (20 ± 2 °C), humidity (55 ± 10%), and lighting (7 a.m. to 7 p.m.). Standard sterilized food and water were supplied <i>ad libitum</i> during acclimatization and experiments. All procedures and protocols were approved by the Institutional Animal Care and Use Committee and were carried out in accordance with NIH guidelines for the handling and use of laboratory animals.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Calcium Flux Assay</h4><div class="NLM_p last">hPMNs (or cells expressing either CXCR1 or CXCR2) were suspended in HBSS<sup>–</sup> (Hank’s balanced salt solution without Ca<sup>2+</sup> and Mg<sup>2+</sup>) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1 × 10<sup>7</sup> cells in total volume 1.7 mL). Cells were aliquoted (200 μL of the cell suspension per tube, 8 tubes total), and 2 μL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 μL of DMSO (1% final concentration) were added to two other tubes. Cells were incubated at 37 °C for 30 min. After dye loading, tubes were centrifuged at 6000 rpm for 1 min, supernatant was removed, and the cell pellet was resuspended in 200 μL of HBSS<sup>+</sup> (with Ca<sup>2+</sup> and Mg<sup>2+</sup>), containing 10 mM HEPES. The test compound or DMSO (control) were added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 μL (105 cells/well). The Compound Plate contained agonist in HBSS<sup>–</sup>) or HBSS<sup>–</sup> (control). After 15 s of reading the basal level of fluorescence by FlexStation II, 10 μL of agonist or HBSS<sup>–</sup> were automatically transferred from the compound plate into the reading plate. The agonists used and their final concentrations were 25 nM CXCL1, 1 nM CXCL8, 10 nM <i>N</i>-formyl-<span class="smallcaps smallerCapital">l</span>-methionyl-<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-phenylalanine (fMLF), and 50 nM C5a. Changes in fluorescence were monitored (λ<sub>ex</sub> = 485 nm, λ<sub>em</sub> = 525 nm) every 5 s for 240 to 500 s at room temperature. The maximum change in fluorescence, expressed in arbitrary units over baseline (max–min), was used to determine the agonist response. The effect of each compound on the agonist response was normalized and expressed as a percent of the DMSO control, which was designated as “100% response.” Curve fitting and calculation of the compound inhibitory concentration that reduced the level of the agonist response by 50% (IC<sub>50</sub>) was determined by nonlinear regression analysis of the dose–response curves generated using Prism 4 (GraphPad Software, Inc., San Diego, CA).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> [<sup>35</sup>S]GTPγS Assay</h4><div class="NLM_p last">[<sup>35</sup>S]GTPγS assays were performed as previously described<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> with the following modifications: HEK293 cells stably expressing hCXCR2, pretreated with different concentrations of compound, were lysed in buffer containing 5 mM Tris-HCl, pH 7.5, 5 mM EDTA, and 5 mM EGTA, and the cell lysate was centrifuged at 30000<i>g</i> for 10 min. Protein concentration in membrane preparations was determined using the BioRad Protein Determination assay 18 from Bio-Rad (Hercules, CA). Membranes containing 50 μg of protein were incubated in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl<sub>2</sub>, 1 mM EGTA, 100 mM NaCl, 50 μM GDP, 8 nM [<sup>35</sup>S]GTPγS, 10 nM CXCL8 in a total volume of 0.1 mL at 30 °C for 1 h. The reaction was terminated by dilution into phosphate-buffered saline and rapid filtration through Unifilter GF/C 96-well filter plates pretreated with 0.3% polyethylenimine and washed three times with ice-cold wash buffer (50 mM Na<sub>2</sub>HPO<sub>4</sub> and 50 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4). Bound radioactivity was determined using a MicroBeta counter (PerkinElmer Life and Analytical Sciences). Basal binding was assessed in the absence of CXCL8, and nonspecific binding was determined in the presence of 10 μM GTPγS. The percentage of CXCL8-stimulated [<sup>35</sup>S]GTPγS binding was calculated as [cpm<sub>CXCL8</sub> – cpm<sub>nonspecific</sub>]/[cpm<sub>basal</sub> – cpm<sub>nonspecific</sub>]. Curve fitting and calculation of the compound inhibitory concentration that reduced the percentage of CXCL8-stimulated [<sup>35</sup>S]GTPγS binding by 50% (IC<sub>50</sub>) was determined by nonlinear regression analysis of the dose–response curves generated using Prism 4 (GraphPad Software, Inc., San Diego, CA).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Competition <sup>125</sup>I-CXCL8 Binding Assay</h4><div class="NLM_p last">This was performed according to White et al. using HEK293-hCXCR2 membranes.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Briefly, assays were performed in 96-well microtiter plates where the reaction mixture contained 1.0 μg/mL membrane protein in 20 mM Bis-trispropane, pH 8.0, with 1.2 mM MgSO<sub>4</sub>, 0.1 mM EDTA, 25 mM NaCl, and 0.03% CHAPS and compound (100 μM stock in DMSO) added at the indicated concentrations, the final DMSO concentration was <0.5% under standard binding conditions. Binding was initiated with 25 pM [<sup>125</sup>I]-CXCL8. Nonspecific binding was determined with 30 nM CXCL8. After 1 h incubation at room temperature, membranes were harvested by rapid filtration. The filter was dried and counted with a liquid scintillation counter. Specific CXCL8 binding to the receptors was defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabeled CXCL8. The results were expressed as a percent of control specific binding: (specific binding with compound)/(control specific binding) × 100. IC<sub>50</sub> for unlabeled CXCL8 was determined by nonlinear regression analysis of the concentration–response curve generated with mean replicate values fitted to the Hill equation.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> CXCR2 Cell Surface Expression by Flow Cytometry</h4><div class="NLM_p last">HEK293 cells stably expressing CXCR2 were pretreated with 1% DMSO (vehicle) or compound (10 μM) for 60 min. HEK293 cells not expressing CXCR2 served as a negative isotype control. All cells were then incubated with a 1:100 dilution of <i>R</i>-phycoerythrin (PE)-conjugated antihuman CXCR2 mouse monoclonal antibody (BD Pharmingen, San Diego, CA) at 4 °C for 60 min. Cells were washed, fixed in 2% formaldehyde in phosphate-buffered saline, and quantitated by fluorescence-activated cell sorting (FACS) using a FACScan flow cytometer equipped with CellQuest software (BD Biosciences, Mountain View, CA).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> ERK1/2 Phosphorylation</h4><div class="NLM_p last">HEK293 cells expressing CXCR2 were harvested and plated in equal number to 60 mm plates (5 × 10<sup>6</sup> cells/plate). The cells were then incubated with PBS containing 1% DMSO (vehicle) or 10 μM compound for 60 min at 37 °C, followed by the addition of 100 ng/mL CXCL8. All cells in a plate were then lysed at 0, 5, 15, and 30 min after agonist-treatment by adding lysis buffer: 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, and 10 μg/mL leupeptin. Lysates containing equal amounts of protein (∼50 μg) were resolved by 10% SDS–polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, and probed with antibody against phospho-ERK1/2 or ERK1/2. Visualization was carried out with a horseradish peroxidase-conjugated secondary antibody.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Murine Air-Pouch Model of Inflammation</h4><div class="NLM_p last">An air-pouch was induced on the backs of 10–15 week old, male CD1 Swiss mice by subcutaneous injection (2 mL) of air as described.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> An additional subcutaneous injection of air (1.5 mL) was given to reinflate the pouch the following day. The compound was solubilized in vehicle consisting of a 20:20:80 mixture of PEG400:DMF:saline. Compound dissolved in vehicle, or vehicle alone was administered via iv tail vein injection at different doses according to body weight. After 3 h, either sterile phosphate-buffered saline (PBS, 1 mL) or 2% carrageenan in sterile PBS (1 mL) was injected into the air pouch. After 4 h, the mice were sedated with ketamine and sacrificed by cervical dislocation. The pouch fluid was then collected by syringe and combined with an additional 2 mL PBS wash of the pouch. The cells in the combined fluid were stained with trypan blue and manually counted on a hemocytometer under 20× magnification.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">B Chemistry</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Materials and Reagents</h4><div class="NLM_p last">General chemicals and reagents for synthesis were purchased from Sigma-Aldrich (Milwaukee, WI), and solvents were purchased from VWR International (West Chester, PA) and used without further purification. Commercial synthetic precursors and intermediates were from Acros Organics (Pittsburgh, PA), Sigma-Adrich Chemical (Milwaukee, WI), Avocado Research (Lancashire, U.K.), Bionet (Cornwall, U.K.), Boron Molecular (Research Triangle Park, NC), Combi-Blocks (San Diego, CA), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. (Cornwall, U.K.), Pierce Chemical Co. (Rockford, IL), Riedel de Haen (Hannover, Germany), Santa Cruz Biotechnology (Dallas, TX), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), and Wako Chemicals USA, Inc. (Richmond, VA). Solid phase scavenger resins were from NovaBiochem (La Jolla, CA).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Analytical Procedures</h4><div class="NLM_p">Synthetic reaction progression was monitored by thin-layer chromatography (TLC) using precoated aluminum-backed plates with silica gel with fluorescent indicator (precoated F254 Macherey-Nagel plates, EMD Chemicals); the spots were examined with UV light. Chromatographic purification was performed with 230–400 mesh (32–63 μm) flash silica gel (Dynamic Adsorbents, Norcross, GA) or by preparative high-performance liquid chromatography (HPLC) using a Waters Delta Prep 4000 HPLC fitted with a Phenomenex Gemini 250 × 21 mm, 10 μm, C<sub>18</sub> column and monitored at 254 nm. Retention time (RT) is reported in minutes (min), and purity as measured by UV absorbance is reported as a percentage of all peak areas. HPLC analyses were performed using the following gradients and systems:</div><div id="sec4_2_2a" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Gradient A</h5><div class="NLM_p last">Water:acetonitrile:formic acid (95:5:0.1) to water:acetonitrile:formic acid (5:95:0.1) at 35 °C over 12 min, on a Shimadzu HPLC system, with a Phenomenex Gemini 50 × 2 mm, 5 μm, C<sub>18</sub> column, monitored at 254 nm.</div></div><div id="sec4_2_2b" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Gradient B</h5><div class="NLM_p last">Water:acetonitrile:formic acid (95:5:0.1) to water:acetonitrile:formic acid (5:95:0.1) at 30 °C over 30 min, on an Agilent 1100 Series HPLC system, with a Phenomenex Gemini 50 × 2 mm, 5 μm, C<sub>18</sub> column, monitored at 254 nm.</div></div><div id="sec4_2_2c" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Gradient C</h5><div class="NLM_p last">Water:acetonitrile:trifluoroacetic acid (95:5:0.1) to water:acetonitrile:trifluoroacetic acid (5:95:0.1) at 35 °C over 0.5 min, held at 5:95:0.1 for 6.5 min, on an Agilent 1100 Series HPLC system, with Phenomenex Gemini 50 × 2 mm, 5 μm, C<sub>18</sub> column, monitored at 254 nm.</div></div><div id="sec4_2_2d" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Gradient D</h5><div class="NLM_p">Water:acetonitrile:formic acid (95:5:0.1) to water:acetonitrile:formic acid (5:95:0.1) at 35 °C over 4 min, held at 5:95:0.1 for 5 min, on a Shimadzu HPLC system, with Phenomenex Gemini 50 × 2 mm, 5 μm, C<sub>18</sub> column, monitored at 254 nm.</div><div class="NLM_p last">Electrospray ionization mass spectrometric analysis (ESI-MS) was performed using a Micromass Quattro II mass spectrometer with MassLynx 4.0. <sup>1</sup>H NMR spectra were obtained on a Bruker AVance (300 or 500 MHz, <sup>1</sup>H) and are reported as parts per million downfield from tetramethylsilane with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Elemental analyses were performed by Atlantic Microlab (Norcross, GA).</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> General Procedures for the Synthesis of <i>S</i>-Substituted <i>N</i>-(4-Fluoro-phenyl)-6-mercapto-nicotinamides (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>)</h4><div class="NLM_p">Accomplished by one of the following three methods. If required, the crude was purified by either flash silica gel chromatography or preparative HPLC. Final product was characterized by HPLC, ESI-MS, and <sup>1</sup>H NMR where indicated.</div><div id="sec4_2_3a" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Method A</h5><div class="NLM_p last">A solution of the bromomethyl derivative (2.5 equiv) in anhydrous DMF (5 mL/mmol) was added to thionicotinamide <b>64</b> (1 equiv) and <i>N</i>-methylmorpholino-substituted polystyrene resin (5 equiv) and heated at 60 °C for 2 h in a screw cap glass vial. Sulfhydryl-bearing scavenger resin (5 equiv) was then added to the reaction mixture and heated at 60 °C for a further 4 h. After cooling, the organic reaction solution was filtered, and then diluted into water (100 mL/mmol) to precipitate the product. The resulting suspension was then centrifuged at 5000 rpm for 15 min, the aqueous supernatant was decanted, and the product dried in a vacuum oven overnight at 50 °C. Compounds prepared by this method were used without further purification.</div></div><div id="sec4_2_3b" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Method B</h5><div class="NLM_p last">Thionicotinamide <b>64</b> (1 equiv) and the corresponding bromomethyl or chloromethyl derivative (1 equiv) was dissolved in anhydrous DMF (2 mL/mmol). To the solution, a tertiary amine base (diisopropylethylamine, triethylamine, or <i>N</i>-methylmorpholine, 1 equiv) was added. The reaction was allowed to proceed at room temperature and monitored by either TLC or LC–MS until complete (1–18 h). The crude product was then precipitated out of solution by the addition of water (5–50 mL/mmol).</div></div><div id="sec4_2_3c" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Method C</h5><div class="NLM_p last">Thionicotinamide <b>64</b> (1 equiv) and the corresponding bromomethyl derivative (1 equiv) were suspended in EtOH (5 mL/mmol). To the suspension, 1 N NaOH (1 equiv) was added, and the reaction mixture was brought to gentle reflux and monitored by either TLC or LC–MS until complete (0.5–2 h). The crude product was then precipitated out of solution by the addition of water (5–20 mL/mmol).</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>7</b>, SX-517)</h4><div class="NLM_p last">Prepared via method C using thionicotinamide <b>64</b> (1.27 g, 5.10 mmol) and 2-bromomethyl-phenylboronic acid (1.09 g, 5.10 mmol) suspended in EtOH (50 mL). To the suspension, 1 N NaOH (5.1 mL, 5.10 mmol) was added and the reaction mixture heated to gentle reflux for 2 h. Then water (50 mL) was added to the reaction mixture while still hot. Upon cooling, a white precipitate formed and this was filtered, washed with 50% aqueous EtOH, and then water and dried in an oven to yield 1.53 g (78%) of <b>7</b> (SX-517) as an off-white solid. ESI-MS <i>m</i>/<i>z</i> = 383.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 8.99 (s, 1H), 8.23 (s, 2H), 8.13–8.11 (m, 1H), 7.80–7.77 (m, 2H), 7.55 (d, <i>J</i> = 7.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.30 (t, <i>J</i> = 7.0 Hz, 1H), 7.22 (t, <i>J</i> = 8.8 Hz, 3H), 4.69 (s, 2H). <sup>13</sup>C NMR (100.6 MHz, DMSO-<i>d</i><sub>6</sub>): d 163.6, 162.7, 159.6, 157.2, 148.6, 141.5, 136.2, 135.5, 135.3, 134.0, 129.3, 129.0, 126.2, 122.2, 122.1, 120.7, 115.4, 115.1. Anal. Calcd for C<sub>19</sub>H<sub>16</sub>BFN<sub>2</sub>O<sub>3</sub>S: C, 59.71%; H, 4.22%; N, 7.33%; S, 8.39%. Found: C, 59.54%; H, 4.38%; N, 7.48%; S, 8.49%. HPLC (gradient B): RT = 18.45 min, purity 96.1%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-((<i>2H</i>-Tetrazol-5-yl)methylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>8</b>)</h4><div class="NLM_p last">The cyano intermediate was prepared via method B using thionicotinamide <b>64</b> and chloroacetonitrile. This intermediate was used without further purification. The cyano-intermediate (190 mg, 0.66 mmol), dibutyltin oxide (33 mg, 0.14 mmol) and trimethylsilyl azide (174 μL, 1.32 mmol) were suspended in toluene (50 mL) and refluxed for 24 h. The mixture was allowed to cool to room temperature, and the resulting precipitate was filtered and washed with toluene to yield 160 mg (73%) of <b>8</b> as a light yellow solid. TLC (1% AcOH/ethyl acetate): <i>R</i><sub><i>f</i></sub> = 0.32. ESI-MS <i>m</i>/<i>z</i> = 331.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.41 (s, 1H), 8.97 (s, 1H), 8.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (t, <i>J</i> = 6.0 Hz, 6.6 Hz, 2H), 7.58 (d, <i>J</i> = 8.2 Hz, 1H), 7.21 (t, <i>J</i> = 8.2 Hz, 2 H), 4.81 (s, 2H). HPLC (gradient B): RT = 14.52 min, purity 96.4%.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(4-Fluorophenyl)-6-(2-oxotetrahydrofuran-3-ylthio)nicotinamide (<b>9</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and α-bromo-γ-butyrolactone and purified by flash silica gel chromatography (2:3 ethyl acetate:hexanes) to yield 135 mg (41%) of <b>9</b> as a white waxy solid. ESI-MS: <i>m</i>/<i>z</i> = 333.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.43 (s, 1H), 8.96 (s, 1H), 8.19 (dd, <i>J</i> = 8.3 Hz, 2.3 Hz, 1H), 7.80–7.77 (m, 2H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.22 (t, <i>J</i> = 8.8 Hz, 2H), 4.77 (t, <i>J</i> = 9.7 Hz, 1H), 4.50–4.46 (m, 1H), 4.40–4.35 (m, 1H), 2.79–2.74 (m, 1H), 2.47–2.39 (m, 1H). Anal. Calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>S: C, 57.82%; H, 3.94%; N, 8.43%. Found: C, 57.61%; H, 4.04%; N, 8.14%. HPLC (gradient B): RT = 16.23 min, purity 99.8%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-(4-Fluorophenyl)-6-(phenylsulfonylmethylthio)nicotinamide (<b>10</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and bromomethyl phenyl sulfone and purified by flash silica gel chromatography (step gradient of 1:2 to 2:3 ethyl acetate:hexanes) to yield 159 mg (40%) of <b>10</b> as a white waxy solid. ESI-MS: <i>m</i>/<i>z</i> = 403.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.41 (s, 1H), 8.86 (s, 1H), 8.15 (dd, <i>J</i> = 8.2 Hz, 2.0 Hz, 1H), 7.92 (s, 1H), 7.90 (d, <i>J</i> = 1.1 Hz, 1H), 7.80–7.77 (m, 2H), 7.69 (t, <i>J</i> = 7.3 Hz, 1H), 7.60 (t, <i>J</i> = 7.6 Hz, 2H), 7.57 (d, <i>J</i> = 8.6 Hz, 1H), 7.22 (t, <i>J</i> = 8.8 Hz, 2H), 5.33 (s, 2H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>S<sub>2</sub>: C, 56.70%; H, 3.76%; N, 6.96%. Found: C, 56.20%; H, 3.97%; N, 6.51%. HPLC (gradient B): RT = 19.06 min, purity 97.9%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(4-Fluorophenyl)-6-(nitromethylthio)nicotinamide (<b>11</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and bromonitromethane to yield 197 mg (51%) of <b>11</b> as an off-white solid. ESI-MS: <i>m</i>/<i>z</i> = 308.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.44 (s, 1H), 8.97 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 7.78 (t, <i>J</i> = 7.1 Hz, 5.3 Hz, 2H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.22 (t, <i>J</i> = 8.0 Hz, 8.4 Hz, 2H), 6.32 (s, 2H). Purity determined by HPLC (gradient B): RT = 17.78 min, purity 88.4%.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Diethyl (5-(4-fluorophenylcarbamoyl)pyridin-2-ylthio)methylphosphonate (<b>12</b>)</h4><div class="NLM_p last">The screened compound was prepared via method B using thionicotinamide <b>64</b> and diethyl-(bromomethyl)-phosphonate and purified by flash silica gel chromatography (step gradient of 1:1, 2:1, and 1:0 ethyl acetate:hexanes) to yield 138 mg (34.7%) of <b>12</b> as a white waxy solid. ESI-MS: <i>m</i>/<i>z</i> = 399.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.42 (s, 1H), 9.00 (s, 1H), 8.20 (dd, <i>J</i> = 8.4 Hz, 2.0 Hz, 1H), 7.80–7.77 (m, 2H), 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (t, <i>J</i> = 8.8 Hz, 2H), 4.08–4.03 (m, 4H), 3.78 (d, <i>J</i> = 13.1 Hz, 2H), 1.21 (t, <i>J</i> = 6.7 Hz, 7.2 Hz, 6H). Anal. Calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>PS: C, 51.25%; H, 5.06%; N, 7.03%. Found: C, 51.52%; H, 5.09%; N, 7.19%. HPLC (gradient B): RT = 17.56 min, purity 98.5%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(4-Fluorophenyl)-6-((tetrahydro-<i>2H</i>-pyran-2-yl)methylthio)nicotinamide (<b>13</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and 2-(bromomethyl)-tetrahydropyran to yield 143 mg (41%) of <b>13</b> as an off-white solid. ESI-MS: <i>m</i>/<i>z</i> = 346.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.37 (s, 1H), 8.97 (s, 1H), 8.13 (d, <i>J</i> = 8.2 Hz, 1H), 7.80–7.77 (m, 2H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 7.21 (t, <i>J</i> = 7.8 Hz, 8.4 Hz, 2H), 3.90 (d, <i>J</i> = 11.1 Hz, 1H), 3.49–3.46 (m, 1H), 3.40–3.35 (m, 2H), 3.28–3.24 (m, 1H), 1.78–1.72 (m, 2H), 1.45 (broad m, 3H), 1.33–1.27 (m, 1H). Anal. Calcd for C<sub>18</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>2</sub>S: C, 62.41%; H, 5.53%; N, 8.09%. Found: C, 62.37%; H, 5.49%; N, 8.20%. HPLC (gradient B): RT = 19.80 min, purity 95.5%.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-Fluorophenyl)-6-(4-(2-methylthiazol-4-yl)benzylthio)nicotinamide (<b>14</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-[4-(bromomethyl)phenyl]-2-methyl-1,3-thiazole. ESI-MS: <i>m</i>/<i>z</i> = 436.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.66 min, purity 71.1%.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-Fluorophenyl)-6-(pyridin-4-ylmethylthio)nicotinamide (<b>15</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and 4-(bromomethyl)pyridine to yield 146 mg (43%) of <b>15</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 340.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 8.98 (s, 1H), 8.53 (d, <i>J</i> = 3.9 Hz, 1H), 8.16 (d, <i>J</i> = 8.3 Hz, 1H), 7.79–7.75 (m, 3H), 7.54–7.53 (m, 2H), 7.29 (t, <i>J</i> = 2.9 Hz, 5.5 Hz, 1H), 7.21 (t, <i>J</i> = 8.2 Hz, 8.8 Hz, 2H), 4.61 (s, 2H). Anal. Calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>3</sub>OS: C, 63.70%; H, 4.16%; N, 12.38%. Found: C, 63.28%; H, 3.90%; N, 12.11%. HPLC (gradient B): RT = 12.63 min, purity 93.7%.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Benzyl 4-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)piperidine-1-carboxylate (<b>16</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and benzyl 4-(bromomethyl)tetrahydro-1-(<i>2H</i>)-pyridinecarboxylate. ESI-MS: <i>m</i>/<i>z</i> = 495.0 [M + H]<sup>+</sup>. HPLC (gradient D): RT = 5.90 min, purity 89.1%.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(4-Fluorophenyl)-6-((tetrahydro-<i>2H</i>-pyran-4-yl)methylthio)nicotinamide (<b>17</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and 4-(bromomethyl)-tetrahydropyran to yield 286 mg (83%) of <b>16</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 347.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.38 (s, 1H), 8.98 (s, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.80–7.77 (m, 2H), 7.48 (d, <i>J</i> = 8.3 Hz, 1H), 7.21 (t, <i>J</i> = 8.7 Hz, 9.1 Hz, 2H), 3.86–3.84 (m, 2H), 3.26 (t, <i>J</i> = 11.4 Hz, 2H), 3.20 (d, <i>J</i> = 6.7 Hz, 2H), 1.83–1.80 (m, 1H), 1.73 (d, <i>J</i> = 12.3 Hz, 2H), 1.33–1.23 (m, 2H). HPLC (gradient B): RT = 18.64 min, purity 89.1%.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(4-Fluorophenyl)-6-(4-(5-methyl-1,2,4-oxadiazol-3-yl)benzylthio)nicotinamide (<b>18</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 3-[3-(bromomethyl)phenyl]-5-methyl-1,2,4-oxadiazole. ESI-MS: <i>m</i>/<i>z</i> = 421.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.63 min, purity 80.7%.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-Fluorophenyl)-6-((5-(trifluoromethyl)furan-2-yl)methylthio)nicotinamide (<b>19</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 2-(bromomethyl)-5-(trifluoromethyl)furan. ESI-MS: <i>m</i>/<i>z</i> = 397.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.82 min, purity 82.0%.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(4-Fluorophenyl)-6-((tetrahydrofuran-2-yl)methylthio)nicotinamide (<b>20</b>)</h4><div class="NLM_p last">Prepared via method C using thionicotinamide <b>64</b> and 2-(bromomethyl)tetrahydrofuran to yield 140 mg (41%) of <b>20</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 333.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.38 (s, 1H), 8.97 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.78 (t, <i>J</i> = 6.1 Hz, 6.8 Hz, 2H), 7.49 (d, <i>J</i> = 8.3 Hz, 1H), 7.21 (t, <i>J</i> = 8.3 Hz, 8.6 Hz, 2H), 4.08–4.04 (m, 1H), 3.81 (q, <i>J</i> = 7.0 Hz, 1H), 3.66 (q, <i>J</i> = 7.0 Hz, 1H), 3.43–3.35 (m, 2H), 2.04–1.97 (m, 1H), 1.94–1.78 (m, 2H), 1.67–1.60 (m, 1H). Anal. Calcd for C<sub>17</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub>S: C, 61.43%; H, 5.16%; 8.43%. Found: C, 61.34%; H, 5.07%; N, 8.47%. HPLC (gradient B): RT = 18.14 min, purity 95.6%.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 6-(2-(3,5-Dimethyl-<i>1H</i>-pyrazol-4-yl)ethylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>21</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-(2-bromoethyl)-3,5-dimethyl-<i>1H</i>-pyrazole. ESI-MS: <i>m</i>/<i>z</i> = 371.1 [M + H]<sup>+</sup>. HPLC (gradient D): RT = 5.47 min, purity 81.0%.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(4-Fluorophenyl)-6-((5-nitrofuran-2-yl)methylthio)nicotinamide (<b>22</b>)</h4><div class="NLM_p last">The screened compound was prepared via method B using thionicotinamide <b>64</b> and 2-(bromomethyl)-5-(nitro)furan and purified by flash silica gel chromatography (1:2 ethyl acetate:hexanes) to yield 91 mg (24%) of <b>22</b> as an orange solid. ESI-MS: <i>m</i>/<i>z</i> = 374.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.42 (s, 1H), 9.02 (d, <i>J</i> = 2.0 Hz, 1H), 8.20 (dd, <i>J</i> = 8.3 Hz, 2.2 Hz, 1H), 7.80–7.77 (m, 2H), 7.64 (d, <i>J</i> = 3.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.23–7.20 (m, 2H), 6.79 (d, <i>J</i> = 3.8 Hz, 1H), 4.71 (s, 2H). Anal. Calcd for C<sub>17</sub>H<sub>12</sub>FN<sub>3</sub>O<sub>4</sub>S: C, 54.69%; H, 3.24%; N, 11.25%. Found: C, 55.20%; H, 3.24%; N, 11.01%. HPLC (gradient B): RT = 20.13 min, purity 91.1%.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(4-Fluorophenyl)-6-((5-methylisoxazol-3-yl)methylthio)nicotinamide (<b>23</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 3-(bromomethyl)-5-methylisoxazole. ESI-MS: <i>m</i>/<i>z</i> = 344.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.21 min, purity 92.9%.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(4-Fluorophenyl)-6-((5-methyl-2-phenyl-<i>2H</i>-1,2,3-triazol-4-yl)methylthio)nicotinamide (<b>24</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-(bromomethyl)-5-methyl-2-phenyl-<i>2H</i>-1,2,3-triazole. ESI-MS: <i>m</i>/<i>z</i> = 420.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 7.03 min, purity 91.7%.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(4-Fluorophenyl)-6-((3-methyl-5-phenylisoxazol-4-yl)methylthio)nicotinamide (<b>25</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-(bromomethyl)-3-methyl-5-phenylisoxazole. ESI-MS: <i>m</i>/<i>z</i> = 420.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.81 min, purity 85.8%.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(4-Fluorophenyl)-6-((5-methyl-3-phenylisoxazol-4-yl)methylthio)nicotinamide (<b>26</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-(bromomethyl)-5-methyl-3-phenylisoxazole. ESI-MS: <i>m</i>/<i>z</i> = 420.1 [M + H]<sup>+</sup>. HPLC (gradient B): RT = 24.01 min, purity 72.0%.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(4-fluorophenyl)-6-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)nicotinamide (<b>27</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 5-(bromomethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole. ESI-MS: <i>m</i>/<i>z</i> = 504.1 [M + H]<sup>+</sup>. HPLC (gradient D): RT = 6.41 min, purity 86.9%.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(4-Fluorophenyl)-6-((4-methyl-2-phenylthiazol-5-yl)methylthio)nicotinamide (<b>28</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 5-(bromomethyl)-4-methyl-2-[4-phenyl]-1,3-thiazole. ESI-MS: <i>m</i>/<i>z</i> = 436.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.85 min, purity 70.7%.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 6-(2-(3,5-Dimethyl-<i>1H</i>-pyrazol-4-yl)ethylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>29</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-(2-bromoethyl)-3,5-dimethyl-<i>1H</i>-pyrazole. ESI-MS: <i>m</i>/<i>z</i> = 371.1 [M + H]<sup>+</sup>. HPLC (gradient D): RT = 5.47 min, purity 81.0%.</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(Benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>30</b>)</h4><div class="NLM_p last">Prepared via method C using thionicotinamide <b>64</b> and benzyl bromide to yield 108 mg (64%) of <b>30</b> as an off-white powder. ESI-MS: <i>m</i>/<i>z</i> = 338.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 9.00 (s, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.80–7.77 (m, 2H), 7.49–7.45 (m, 3 H), 7.34 (t, <i>J</i> = 7.7 Hz, 6.9 Hz, 2H), 7.27–7.20 (m, 3H), 4.51 (s, 2H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>FN<sub>2</sub>OS: C, 67.44%; H, 4.47%; N, 8.28%. Found: C, 67.17%; H, 4.37%; N, 8.13%. HPLC (gradient B): RT = 21.66 min, purity 96.5%.</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(4-Fluorophenyl)-6-(4-nitrobenzylthio)nicotinamide (<b>31</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-(bromomethyl)-4-nitrobenzene. ESI-MS: <i>m</i>/<i>z</i> = 384.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.63 min, purity 66.3%.</div></div><div id="sec4_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(4-Fluorophenyl)-6-(4-(trifluoromethoxy)benzylthio)nicotinamide (<b>32</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-(bromomethyl)-4-(trifluoromethoxy)benzene. ESI-MS: <i>m</i>/<i>z</i> = 423.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 7.12 min, purity 83.6%.</div></div><div id="sec4_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(4-Fluorophenyl)-6-(3-(trifluoromethoxy)benzylthio)nicotinamide (<b>33</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-(bromomethyl)-3-(trifluoromethoxy)benzene. ESI-MS: <i>m</i>/<i>z</i> = 423.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 7.12 min, purity 86.3%.</div></div><div id="sec4_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(4-Fluorophenyl)-6-(2-(thiophen-2-yl)benzylthio)nicotinamide (<b>34</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 2-[2-(bromomethyl)phenyl]thiophene and screened without purification. ESI-MS: <i>m</i>/<i>z</i> = 421.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 7.31 min, purity 73.7%.</div></div><div id="sec4_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-(4-Fluorophenyl)-6-(4-(2-methylthiazol-4-yl)benzylthio)nicotinamide (<b>35</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-[4-(bromomethyl)phenyl]-2-methyl-1,3-thiazole. ESI-MS: <i>m</i>/<i>z</i> = 436.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.66 min, purity 71.1%.</div></div><div id="sec4_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 6-(4-(<i>1H</i>-1,2,4-Triazol-1-yl)benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>36</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-[4-(bromomethyl)phenyl]-<i>1H</i>-1,2,4-triazole. ESI-MS: <i>m</i>/<i>z</i> = 406.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.06 min, purity 85.3%.</div></div><div id="sec4_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(4-Fluorophenyl)-6-(3-(5-methyl-1,2,4-oxadiazol-3-yl)benzylthio)nicotinamide (<b>37</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 3-[3-(bromomethyl)phenyl]-5-methyl-1,2,4-oxadiazole. ESI-MS: <i>m</i>/<i>z</i> = 421.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.63 min, purity 80.7%.</div></div><div id="sec4_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 6-(4-(<i>1H</i>-Pyrazol-1-yl)benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>38</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-[4-(bromomethyl)phenyl]-1H-pyrazole. ESI-MS: <i>m</i>/<i>z</i> = 405.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.54 min, purity 92.6%.</div></div><div id="sec4_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-(4-Fluorophenyl)-6-(3-(2-methylthiazol-4-yl)benzylthio)nicotinamide (<b>39</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 4-[3-(bromomethyl)phenyl]-2-methyl-1,3-thiazole. ESI-MS: <i>m</i>/<i>z</i> = 436.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.68 min, purity 69.2%.</div></div><div id="sec4_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 6-(4-(<i>1H</i>-Pyrrol-1-yl)benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>40</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-[4-(bromomethyl)phenyl]-1H-pyrrole. ESI-MS: <i>m</i>/<i>z</i> = 404.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 7.03 min, purity 70.7%.</div></div><div id="sec4_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 6-(3-(<i>1H</i>-pyrrol-1-yl)benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>41</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-[3-(bromomethyl)phenyl]-1H-pyrrole. ESI-MS: <i>m</i>/<i>z</i> = 404.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.98 min, purity 91.8%.</div></div><div id="sec4_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 6-(2-Fluoro-3-methylbenzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>42</b>)</h4><div class="NLM_p last">Prepared via method A using thionicotinamide <b>64</b> and 1-(bromomethyl)-2-fluoro-3-methylbenzene. ESI-MS: <i>m</i>/<i>z</i> = 371.1 [M + H]<sup>+</sup>. HPLC (gradient C): RT = 6.97 min, purity 83.5%.</div></div><div id="sec4_2_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 6-(3,4-Dichlorobenzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>43</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and 1-(bromomethyl)-3,4-dichlorobenzene. The crude material was purified by flash chromatography using a gradient elution of 10% ethyl acetate/hexanes to 95% ethyl acetate/hexanes over 30 min to yield 355 mg (83%) of compound <b>43</b> as a white solid. TLC (ethyl acetate/hexane, 1:4): <i>R</i><sub><i>f</i></sub> = 0.27. ESI-MS: <i>m</i>/<i>z</i> = 407.0, 409.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.35 (s, 1H), 8.96 (s, 1H), 8.12–8.10 (m, 1H), 7.75–7.72 (m, 2H), 7.69 (s, 1H), 7.55 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (d, <i>J</i> = 12.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 1H), 7.17 (t, <i>J</i> = 8.9 Hz, 2H), 4.47 (s, 2H). Purity determined by HPLC (gradient B): RT = 26.18 min, purity 71.2%.</div></div><div id="sec4_2_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(4-Fluorophenyl)-6-(2-hydroxybenzylthio)nicotinamide (<b>44</b>)</h4><div class="NLM_p last">The boronic acid <b>6</b> (200 mg) was dissolved in 18 mL of THF/acetone/0.1 N NaOH (1:1:1) and cooled to −3 °C. OXONE (1.0 eq, 311 mg) dissolved in 0.4 mM EDTA (2.1 mL) was added, according to the procedure of Webb and Levy for the hydroxylation of aryl boronic esters or boronic acids.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The reaction was then stirred for 1 h and quenched with sodium bisulfite (3 mL, 5 M aqueous), while being stirred for 10 min. The solvent was removed by reduced pressure rotary evaporation, leaving an aqueous suspension. The suspension was extracted 3× with ethyl acetate, and the combined ethyl acetate layers were washed with 0.01 N HCl, water, 0.01 N NaOH, and brine. They were dried over MgSO<sub>4</sub>, filtered, and dried under vacuum. The residue was dissolved in THF/MeOH and adhered to 2 g of silica gel. The adhered silica was loaded onto 20 g of silica gel, eluting the product with 3:1 hexanes:ethyl acetate, which was dried under vacuum to provide 67 mg of compound <b>44</b> (36% yield). ESI-MS: <i>m</i>/<i>z</i> = 355.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.75 (s, 1H), 9.01 (d, <i>J</i> = 2.1 Hz, 1H), 8.14 (dd, <i>J</i> = 8.7 Hz, 2.6 Hz, 1H), 7.80–7.77 (m, 3H), 7.48 (d, <i>J</i> = 8.3 Hz, 1H), 7.33 (dd, <i>J</i> = 7.4 Hz, 1.3 Hz, 1H), 7.23–7.20 (m, 2H), 7.11–7.07 (m, 1H), 6.85 (dd, <i>J</i> = 8.1 Hz, 0.8 Hz, 1H), 6.75–6.72 (m, 1H), 4.42 (s, 2H). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub>S: C, 64.39%; H, 4.27%; N, 7.90%. Found: C, 64.50%; H, 4.47%; N, 7.72%. HRMS: calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>2</sub>S [M + 1]<sup>+</sup> 355.0911, found 355.0901; calcd for C<sub>19</sub>H<sub>15</sub>FN<sub>2</sub>NaO<sub>2</sub>S [M + Na]<sup>+</sup> 377.0730, found 377.0718. HPLC (gradient B): RT = 20.18 min, purity 97.4%.</div></div><div id="sec4_2_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-(4-Fluorophenyl)-6-(phenylthio)nicotinamide (<b>45</b>)</h4><div class="NLM_p last">Chloronicotinamide <b>69</b> (200 mg, 0.75 mmol), thiophenol (77 μL, 0.75 mmol), potassium <i>tert</i>-butoxide (112 mg, 1.5 mmol) and 18-crown-6 (10 mg), was dissolved in NMP (3 mL) and heated to 160 °C for 3 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and purified using flash chromatography (7:3 hexanes/ethyl acetate) to yield 99 mg (31%) of <b>45</b> as an off-white powder. TLC (ethyl acetate/hexane, 1:1): <i>R</i><sub><i>f</i></sub> = 0.47. ESI-MS: <i>m</i>/<i>z</i> = 325.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.35 (s, 1H), 8.88 (d, J = 2.3 Hz, 1H), 8.08 (dd, J = 8.4 Hz, 2.3 Hz, 1H), 7.74–7.71 (m, 2H), 7.62–7.60 (m, 2H), 7.53–7.50 (m, 3H), 7.18 (t, J = 2.3 Hz, 2H), 7.02 (d, J = 8.5 Hz, 1H).</div></div><div id="sec4_2_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Methyl 4-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate (<b>46</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and methyl 4-bromomethylbenzoate to yield 343 mg (87%) of <b>46</b> as an off-white solid. ESI-MS: <i>m</i>/<i>z</i> = 397.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.38 (s, 1H), 9.00 (d, <i>J</i> = 1.6 Hz, 1H), 8.15 (dd, <i>J</i> = 8.6 Hz, 2.5 Hz, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.79–7.76 (m, 2H), 7.61 (d, <i>J</i> = 8.3 Hz, 2H), 7.50 (d, <i>J</i> = 8.2 Hz, 1H), 7.21 (t, <i>J</i> = 9.0 Hz, 2H), 4.59 (s, 2H), 3.84 (s, 3H). Anal. Calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>3</sub>S: C, 63.63%; H, 4.32%; N, 7.07%. Found: C, 63.38%; H, 4.22%; N, 7.23%. Purity determined by HPLC (gradient B): RT = 21.59 min, purity 97.5%.</div></div><div id="sec4_2_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoic acid (<b>47</b>)</h4><div class="NLM_p last">The thionicotinamide methyl ester <b>46</b> (140 mg, 0.35 mmol) was saponified using 1 N NaOH (1.1 equiv) in MeOH (5 mL) at reflux for 1 h. The mixture was acidified using 1 N HCl and extracted into ethyl acetate. The organic layer was washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to yield 81 mg (83%) of compound <b>47</b> as a white solid. TLC (ethyl acetate/hexane 1:1): <i>R</i><sub><i>f</i></sub> = 0.23. ESI-MS: <i>m</i>/<i>z</i> = 383.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.55 (s, 1H), 9.01 (d, <i>J</i> = 1.6 Hz, 1H), 8.15 (dd, <i>J</i> = 8.6 Hz, 2.5 Hz, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.79–7.76 (m, 2H), 7.61 (d, <i>J</i> = 8.3 Hz, 2H), 7.50 (d, <i>J</i> = 8.2 Hz, 1H), 7.21 (t, <i>J</i> = 9.0 Hz, 2H), 4.59 (s, 2H), 3.84 (s, 3H).</div></div><div id="sec4_2_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Methyl 3-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate (<b>48</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and methyl 3-bromomethylbenzoate to yield 180 mg (45%) of <b>48</b> as a crystalline material. An analytical sample was recrystallized from hot ethyl acetate. ESI-MS: <i>m</i>/<i>z</i> = 397.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.40 (s, 1H), 8.99 (d, <i>J</i> = 1.4 Hz, 1H), 8.15 (dd, <i>J</i> = 8.6 Hz, 2.2 Hz, 1H), 8.07 (s, 1H), 7.85 (d, <i>J</i> = 8.2 Hz, 1H), 7.79–7.74 (m, 3H), 7.51–7.47 (m, 2H), 7.21 (t, <i>J</i> = 8.8 Hz, 2H), 4.59 (s, 2H), 3.85 (s, 3H). Anal. Calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>3</sub>S: C, 63.63%; H, 4.32%; N, 7.07%. Found: C, 63.53%; H, 4.18%; N, 7.13%. Purity determined by HPLC (gradient B): RT = 21.57 min, purity 82.8%.</div></div><div id="sec4_2_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 3-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoic acid (<b>49</b>)</h4><div class="NLM_p last">The thionicotinamide methyl ester <b>48</b> (100 mg, 0.25 mmol) was saponified using 1 N NaOH (1.1 equiv) in MeOH at room temperature for 1 h. The mixture was acidified using 1 N HCl and extracted into ethyl acetate. The organic layer was washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to yield 81 mg (83%) of compound <b>49</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 382.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.00 (br s, 1H), 10.39 (s, 1H), 9.00 (s, 1H), 8.16 (d, <i>J</i> = 8.6 Hz, 1H), 8.05 (s, 1H), 7.84 (d, <i>J</i> = 7.9 Hz, 1H), 7.78 (t, <i>J</i> = 7.3 Hz, 4.8 Hz, 2H), 7.71 (d, <i>J</i> = 7.5 Hz, 1H), 7.51 (d, <i>J</i> = 8.5 Hz, 1 H), 7.46 (t, <i>J</i> = 7.7 Hz, 7.5 Hz, 1H), 7.21 (t, <i>J</i> = 7.5 Hz, 8.8 Hz, 2H), 4.59 (s, 2H). Anal. Calcd for C<sub>20</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>3</sub>S: C, 62.82%; H, 3.95%; N, 7.33%. Found: C, 62.53%; H, 3.82%; N, 7.28%. Purity determined by HPLC (gradient B): RT = 19.11 min, purity 97.6%.</div></div><div id="sec4_2_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Methyl 2-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoate (<b>50</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> and methyl 2-bromomethylbenzoate to yield 300 mg (76%) of <b>50</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 397.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.40 (s, 1H), 9.00 (s, 1H), 8.13 (dd, <i>J</i> = 8.5 Hz, 1.8 Hz, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 1H), 7.80–7.77 (m, 2H), 7.66 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (t, <i>J</i> = 7.5 Hz, 1H), 7.46 (d, <i>J</i> = 8.6 Hz, 1H), 7.41 (t, <i>J</i> = 7.6 Hz, 7.1 Hz, 1H), 7.22 (t, <i>J</i> = 8.7 Hz, 9.0 Hz, 2H), 4.84 (s, 2H), 3.87 (s, 3H). HRMS: calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>3</sub>S [M + 1]+ 397.1017, found 397.1006; calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>NaO<sub>3</sub>S [M + Na]+ 419.0836, found 419.0822. Purity determined by HPLC (gradient A): RT = 10.86 min, purity 95.2%.</div></div><div id="sec4_2_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 2-((5-(4-Fluorophenylcarbamoyl)pyridin-2-ylthio)methyl)benzoic acid (<b>51</b>)</h4><div class="NLM_p last">The thionicotinamide methyl ester <b>50</b> (100 mg, 0.25 mmol) was saponified using 1 N NaOH (1.55 mmol, 6.2 equiv) in MeOH at room temperature for 1 h. The mixture was acidified using 1 N HCl and extracted into ethyl acetate. The organic layer was washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to yield 37.7 mg (40%) of compound <b>51</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 382.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.14 (s, 1H), 10.40 (s, 1H), 9.01 (s, 1H), 8.13 (dd, <i>J</i> = 8.7 Hz, 2.1 Hz, 1H), 7.90 (d, <i>J</i> = 7.5 Hz, 1H), 7.80–7.77 (m, 2H), 7.64 (d, <i>J</i> = 7.5 Hz, 1H), 7.50 (t, <i>J</i> = 6.9 Hz, 7.3 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 1H), 7.38 (t, <i>J</i> = 7.3 Hz, 1H), 7.22 (t, <i>J</i> = 8.8 Hz, 2H), 4.87 (s, 2H). HRMS: calcd for C<sub>20</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>3</sub>S [M + 1]+ 383.0860, found 383.0852; calcd for C<sub>20</sub>H<sub>15</sub>FN<sub>2</sub>NaO<sub>3</sub>S [M + Na]+ 405.0680, found 405.0667. Purity determined by HPLC (gradient B): RT = 19.28 min, purity 98.3%.</div></div><div id="sec4_2_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 6-(2-(<i>2H</i>-Tetrazol-5-yl)benzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>52</b>)</h4><div class="NLM_p last">The cyanobenzyl intermediate <b>66</b> (363 mg, 1 mmol) was suspended in anhydrous toluene (25 mL). Dibutyltin oxide (25 mg, 0.1 mmol) was added, followed by trimethylsilyl azide (131 μL, 1 mmol). The mixture was then heated to reflux for 18 h. The dark yellow brown solution was allowed to cool to room temperature, at which time a brown precipitate was seen to form. The precipitate was filtered and washed with toluene to yield 190 mg (47%) of compound <b>52</b>. ESI-MS: <i>m</i>/<i>z</i> = 407.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 8.93 (s, 1H), 8.11 (dd, <i>J</i> = 8.6 Hz, 1.6 Hz, 1H), 7.80–7.75 (m, 4H), 7.55–7.49 (m, 2H), 7.42 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (t, <i>J</i> = 8.6 Hz, 2H), 4.90 (s, 2H). HRMS: calcd for C<sub>20</sub>H<sub>16</sub>FN<sub>6</sub>OS [M + 1]+ 407.1085, found 407.1078; calcd for C<sub>20</sub>H<sub>15</sub>FN<sub>6</sub>NaOS [M + Na]<sup>+</sup> 429.0904, found 429.0896. Purity determined by HPLC (gradient B): RT = 18.81 min, purity 94.6%.</div></div><div id="sec4_2_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>-(4-Fluorophenyl)-6-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylthio)nicotinamide (<b>53</b>)</h4><div class="NLM_p last">Prepared via method C using thionicotinamide <b>64</b> and 2-bromomethyl-phenylboronic acid pinacol ester, and purified by flash silica gel chromatography (step gradient of 1:6 and 1:3 ethyl acetate:hexanes) to yield 197 mg (42%) of <b>53</b> as an off-white hygroscopic solid. ESI-MS: <i>m</i>/<i>z</i> = 465.4 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 9.01 (s, 1H), 8.14 (d, <i>J</i> = 8.7 Hz, 1H), 7.80–7.77 (m, 2H), 7.68 (d, <i>J</i> = 7.2 Hz, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.40 (t, <i>J</i> = 7.5 Hz, 1H), 7.26 (t, <i>J</i> = 7.1 Hz, 7.5 Hz, 1H), 7.21 (t, <i>J</i> = 8.8 Hz, 2H), 4.73 (s, 2H), 1.29 (s, 12H). Anal. Calcd for C<sub>25</sub>H<sub>26</sub>BFN<sub>2</sub>O<sub>3</sub>S: C, 64.66%; H, 5.64%; N, 6.03%. Found: C, 64.45%; H, 5.60%; N, 5.83%. Purity determined by HPLC (gradient B): RT = 24.93 min, purity 95.7%.</div></div><div id="sec4_2_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 2-((5-(4-(Trifluoromethoxy)phenylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>54</b>)</h4><div class="NLM_p last">Intermediate <b>68</b> (0.5 mmol) was reacted with 4-trifluoromethoxy aniline (177 mg, 0.5 mmol, 1 equiv) and TEA (70 mL, 0.5 mmol, 1 equiv) in anhydrous DMF. The reaction mixture was heated to 60 °C for 16 h. The crude material was diluted with ethyl acetate and the organic layer washed with water and saturated NaHCO<sub>3</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude was purified using flash silica gel chromatography (ethyl acetate/hexanes 1:2 as eluent) to provide 53 mg (12%) of <b>54</b>. ESI-MS: <i>m</i>/<i>z</i> = 449.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.52 (s, 1H), 9.00 (s, 1H), 8.23 (s, 2H), 8.14 (dd, <i>J</i> = 8.6 Hz, 1.8 Hz, 1H), 7.90–7.86 (m, 2H), 7.55 (d, <i>J</i> = 7.1 Hz, 1H), 7.46 (d, <i>J</i> = 3.8 Hz, 1H), 7.45 (d, <i>J</i> = 2.4 Hz, 1H), 7.40–7.37 (m, 2H), 7.30 (t, <i>J</i> = 7.1 Hz, 1H), 7.22 (t, <i>J</i> = 7.0 Hz, 1H), 4.69 (s, 2H). HRMS: calcd for C<sub>20</sub>H<sub>17</sub>BF<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S [M + 1]<sup>+</sup> 449.0949, found 449.0960. Purity determined by HPLC (gradient B): RT = 21.19 min, purity 98.3%.</div></div><div id="sec4_2_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 4-(6-(2-Boronobenzylthio)nicotinamido)benzoic acid (<b>55</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>54</b> and starting from intermediate <b>68</b> (0.5 mmol) and 4-aminobenzoic acid (70 mg, 0.5 mmol, 1 equiv), and purified using preparative HPLC (60:40:0.1 water:acetonitrile:formic acid isocratic) to yield 23 mg (11%) of compound <b>55</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 409.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.79 (s, 1H), 10.61 (s, 1H), 9.00 (s, 1H), 8.23 (s, 2H), 8.15 (dd, <i>J</i> = 8.2 Hz, 1.7 Hz, 1H), 7.97–7.90 (m, 4H), 7.54 (d, <i>J</i> = 6.8 Hz, 1H), 7.47–7.44 (m, 2H), 7.30 (t, <i>J</i> = 6.9 Hz, 7.2 Hz, 1H), 7.22 (t, <i>J</i> = 8.3 Hz, 7.1 Hz, 1H), 4.69 (s, 2H). HRMS: calcd for C<sub>20</sub>H<sub>18</sub>BN<sub>2</sub>O<sub>5</sub>S [M + 1]+ 409.1024, found 409.1018; calcd for C<sub>20</sub>H<sub>17</sub>BN<sub>2</sub>NaO<sub>5</sub>S [M + Na]+ 431.0843, found 431.0837. Purity determined by HPLC (gradient B): RT = 16.61 min, purity 98.4%.</div></div><div id="sec4_2_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-((5-(4-(<i>2H</i>-Tetrazol-5-yl)phenylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>56</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>54</b> and starting from intermediate <b>68</b> (0.5 mmol) and the 4-tetrazole-aniline (80 mg, 0.5 mmol, Santa Cruz Biotechnology, Dallas, TX), the crude material after workup was further purified using preparative HPLC (60:40:0.1 water:acetonitrile:formic acid isocratic) to yield 38 mg (18%) of compound <b>56</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 433.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 10.63 (s, 1H), 9.02 (s, 1H), 8.23 (s, 1H), 8.16 (dd, <i>J</i> = 8.6 Hz, 1.8 Hz, 1H), 8.06–8.00 (m, 4H), 7.55 (d, <i>J</i> = 6.9 Hz, 1H), 7.46 (t, <i>J</i> = 8.5 Hz, 7.7 Hz, 2H), 7.31 (t, <i>J</i> = 7.3 Hz, 1H), 7.22 (t, <i>J</i> = 7.2 Hz, 1H), 4.70 (s, 2H). HRMS: calcd for C<sub>20</sub>H<sub>18</sub>BN<sub>6</sub>O<sub>3</sub>S [M + 1]<sup>+</sup> 433.1249, found 433.1239. HPLC (gradient B): RT = 16.29 min, purity 100.0%.</div></div><div id="sec4_2_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 2-((5-(Pyridin-4-ylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>57</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>54</b> and starting from intermediate <b>68</b> (0.33 mmol) and 4-amino-pyridine (31 mg, 0.33 mmol), and purified by preparative HPLC (95:5:0.1 water:acetonitrile:formic acid to 5:95:0.1 water:acetonitrile:formic acid over 30 min) to yield 18 mg (21%) of compound <b>57</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 366.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.68 (s, 1H), 9.01 (d, <i>J</i> = 1.7 Hz, 1H), 8.51 (d, <i>J</i> = 5.9 Hz, 2H), 8.24 (s, 2H), 8.15 (dd, <i>J</i> = 8.4 Hz, 2.4 Hz, 1H), 8.01–7.95 (m, 1H), 7.79 (dd, <i>J</i> = 5.0 Hz, 1.3 Hz, 2H), 7.48–7.43 (m, 2H), 7.32–7.23 (m, 2H), 4.70 (s, 2H). HPLC (gradient B): RT = 10.79 min, purity 95.7%.</div></div><div id="sec4_2_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 2-((5-(4-Hydroxyphenylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>58</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>54</b> and starting from intermediate <b>68</b> (0.33 mmol) and 4-hydroxy-aniline (36 mg, 0.33 mmol), the crude material after workup was further purified using preparative HPLC (60:40:0.1 water:acetonitrile:formic acid isocratic) to yield 21 mg (17%) of compound <b>58</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 381.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.11 (s, 1H), 9.30 (s, 1H), 8.96 (s, 1H), 8.23 (s, 1H), 8.11 (dd, <i>J</i> = 8.2 Hz, 1.6 Hz, 1H), 7.54–7.52 (m, 3H), 7.45–7.39 (m, 2H), 7.30 (t, <i>J</i> = 6.0 Hz, 7.5 Hz, 1H), 7.22 (t, <i>J</i> = 7.2 Hz, 1H), 6.76 (d, <i>J</i> = 8.9 Hz, 2H), 4.68 (s, 2H). HRMS: calcd for C<sub>19</sub>H<sub>18</sub>BN<sub>2</sub>O<sub>4</sub>S [M + 1]<sup>+</sup> 381.1075, found 381.1093; calcd for C<sub>19</sub>H<sub>17</sub>BN<sub>2</sub>NaO<sub>4</sub>S [M + Na]<sup>+</sup> 403.0894, found 403.0910. HPLC (gradient B): RT = 15.40 min, purity 98.8%.</div></div><div id="sec4_2_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 2-((5-(5-Fluoropyridin-2-ylcarbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>59</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>54</b> and starting from intermediate <b>68</b> (0.22 mmol) and 2-amino-5-fluoropyridine (25 mg, 0.22 mmol), the crude material after workup was further purified using preparative HPLC (60:40:0.1 water:acetonitrile:formic acid isocratic) to yield 17 mg (20%) of compound <b>59</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 383.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.08 (s, 1H), 9.02 (s, 1H), 8.42 (s, 1H), 8.23–8.16 (m, 4H), 7.82 (t, <i>J</i> = 8.8 Hz, 8.6 Hz, 1H), 7.54 (d, <i>J</i> = 7.3 Hz, 1H), 7.43 (t, <i>J</i> = 9.3 Hz, 10.5 Hz, 2H), 7.30 (t, <i>J</i> = 7.0 Hz, 7.8 Hz, 1H), 7.22 (t, <i>J</i> = 7.4 Hz, 7.2 Hz, 1H), 4.68 (s, 2H). HPLC (gradient B): RT = 17.24 min, purity 97.8%.</div></div><div id="sec4_2_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 2-((5-((4-Fluorophenyl)(pyridin-2-ylmethyl)carbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>60</b>)</h4><div class="NLM_p last">According to method C, <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-2-yl-methyl-6-mercapto-nicotinamide intermediate <b>73a</b> (2.9 g, 8.7 mmol) and 2-bromomethyl-phenylboronic acid (2.9 g, 8.7 mmol) were suspended in EtOH (100 mL). One N NaOH (8.7 mL, 8.7 mmol) was added and the suspension brought to reflux. After 2 h, the mixture was concentrated <i>in vacuo</i> and partioned between ethyl acetate and water. The ethyl acetate was extracted 3× with water and evaporated to yield 2.9 g (70%) of compound <b>60</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 473.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52 (d, <i>J</i> = 4.4 Hz, 1H), 8.37 (s, 1H), 8.17 (s, 2H), 7.77 (t, <i>J</i> = 8.0 Hz, 7.4 Hz, 1H), 7.51–7.47 (m, 3H), 7.32–7.23 (m, 5H), 7.21–7.16 (m, 2H), 7.11 (t, <i>J</i> = 8.6 Hz, 2H), 5.15 (s, 2H), 4.56 (s, 2H). HPLC (gradient B): RT = 16.08 min, purity 95.9%.</div></div><div id="sec4_2_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 2-((5-((4-Fluorophenyl)(pyridin-4-ylmethyl)carbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>61</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>60</b> and starting from the <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-4-yl-methyl-6-mercapto-nicotinamide intermediate <b>73b</b> (2.8 g, 8.0 mmol) and 2-bromomethyl-phenylboronic acid (1.72 g, 8.0 mmol), workup yielded 2.88 g (76%) of compound <b>61</b> as a light yellow foam. An analytical sample was purified by flash silica gel chromatography (97:3 ethyl acetate:MeOH). ESI-MS: <i>m</i>/<i>z</i> = 473.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52–8.49 (m, 2H), 8.40–8.37 (m, 1H), 8.18 (s, 2H), 7.52–7.51 (m, 2H), 7.37 (d, <i>J</i> = 4.1 Hz, 2H), 7.33–7.17 (m, 5H), 7.14–7.10 (m, 2H), 7.06–7.03 (m, 1H), 5.12 (s, 2H), 4.56 (s, 2H). Anal. Calcd for C<sub>25</sub>H<sub>21</sub>BFN<sub>3</sub>O<sub>3</sub>S: C, 63.44%; H, 4.47%; N, 8.88%. Found: C, 63.70%; H, 4.55%; N, 8.80%. HPLC (gradient B): RT = 13.13 min, purity 96.8%.</div></div><div id="sec4_2_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 2-((5-((4-Fluorophenyl)(piperidin-2-ylmethyl)carbamoyl)pyridin-2-ylthio)methyl)phenylboronic acid (<b>62</b>)</h4><div class="NLM_p last">Thiol alkylation was achieved according to method C by suspending the thionicotinamide intermediate <b>73c</b> (90 mg, 1 equiv) and 2-bromomethylphenyl boronic acid (50 mg, 1.1 equiv) in EtOH (1 mL). Then 1 N NaOH (0.2 mL, 1 equiv) was added and the solution gently refluxed for 2 h. Alkylated product <b>74a</b> was extracted with ethyl acetate (3 × 5 mL), washed with water (3 × 5 mL), brine (3 × 5 mL), and dried over MgSO<sub>4</sub>. The organic layer was filtered to remove MgSO<sub>4</sub>, and then removed by rotary evaporation and dried in vacuo to afford 90 mg of the Boc-protected piperidine boronic acid. The Boc group was then removed by adding 4 M HCl in dioxane (1 mL) to the Boc-protected piperidine boronic acid (20 mg). The resulting piperidine compound was then purified using preparative HPLC (80:20:0.1 water:acetonitrile:formic acid to 70:30:0.1 water:acetonitrile:formic acid over 30 min) to yield 5 mg (29%) of <b>62</b> as a white solid. ESI-MS: <i>m</i>/<i>z</i> = 480.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O): δ 8.35 (s, 1H), 8.08 (s, 1H), 7.41–7.37 (m, 2H), 7.28–7.15 (m, 4H), 7.05 (d, <i>J</i> = 7.6 Hz, 1H), 6.96–6.92 (m, 2H), 4.30 (s, 3H), 3.87 (dd, <i>J</i> = 14.8 Hz, 3.7 Hz, 1H), 3.38 (d, <i>J</i> = 10.8 Hz, 1H), 3.28 (br s, 1H), 2.88–2.84 (m, 1H), 1.78 (d, <i>J</i> = 7.7 Hz, 3H), 1.61–1.56 (m, 1H), 1.48–1.43 (m, 1H), 1.39–1.36 (m, 1H). HPLC (gradient B): RT = 19.29 min, purity 90.1%.</div></div><div id="sec4_2_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 2-(6-(2-Boronobenzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamido)acetic acid (<b>63</b>)</h4><div class="NLM_p last">The thionicotinamide <b>73d</b> (110 mg, 0.3 mmol) and 2-bromomethyl-phenylboronic acid were coupled using method B to yield the <i>tert</i>-butyl ester thionicotinamide intermediate <b>74b</b> (138 mg, 93%). TLC (ethyl acetate): <i>R</i><sub><i>f</i></sub> = 0.6; ESI-MS: <i>m</i>/<i>z</i> = 496.9 [M + H]<sup>+</sup>. The intermediate was dissolved in 90% aq TFA and incubated at room temperature for 2 h. The TFA was removed by rotary evaporation to and the crude material purified by preparative HPLC (65:35:01 water:acetonitrile:formic acid isocratic) to yield 74 mg (61%) of compound <b>63</b> as a white hygroscopic solid. ESI-MS: <i>m</i>/<i>z</i> = 440.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.95 (br s, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 7.53 (d, <i>J</i> = 5.9 Hz, 1H), 7.41–6.92 (br m, 10H), 4.57 (s, 2H), 4.46 (s, 2H). HPLC (gradient B): RT = 16.75 min, purity 96.6%.</div></div><div id="sec4_2_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> <i>N</i>-(4-Fluoro-phenyl)-6-mercaptonicotinamide (<b>64</b>)</h4><div class="NLM_p last">To 150 mL DMF was added and stirred 6-mercapto-nicotinic acid (50 mmol, 7.76 g). To the stirred solution, 4-fluoroaniline (50 mmol, 4.8 mL) was added followed by the addition of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ, 50 mmol, 12.36 g). The dark brown mixture was stirred for 12 h. The mixture was then diluted with water (500 mL), and the precipitate collected by filtration and washed repeatedly with water. The off-white solid was dried in an oven (50 °C) for 72 h to afford 6.42 g (52%) of the thionicotinamide product. ESI-MS: <i>m</i>/<i>z</i> = 248.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.87 (s, 1H), 10.23 (s, 1H), 8.32 (s, 1H), 7.89 (dd, <i>J</i> = 8.8 Hz, 2.2 Hz, 1H), 7.74–7.71 (m, 2H), 7.38 (d, <i>J</i> = 9.3 Hz, 1H), 7.19 (t, <i>J</i> = 8.7 Hz, 2H). TLC (ethyl acetate/hexanes/MeOH 1:1:0.1): <i>R</i><sub><i>f</i></sub> = 0.7.</div></div><div id="sec4_2_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 6-(Cyanomethylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>65</b>)</h4><div class="NLM_p last">Thionicotinamide 64 (248 mg. 1.00 mmol) dissolved in anhydrous DMF (3 mL) with chloroacetonitrile (63 μL, 1.0 mmol) was then added, followed by triethylamine (140 μL, 1.00 mmol). The reaction was heated to 100 °C for 30 min. After cooling to room temperature, the solution was diluted into water (60 mL), and the resulting precipitate was filtered and washed with water to yield the cyano-intermediate <b>65</b> as a white solid (259 mg, 90%). ESI-MS: <i>m</i>/<i>z</i> = 288.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.47 (s, 1H), 9.06 (dd, <i>J</i> = 2.4 Hz, 0.9 Hz, 1H), 8.22 (dd, <i>J</i> = 8.4, 2.4 Hz, Hz, 1H), 7.78 (dd, <i>J</i> = 9.0 Hz, 4.8 Hz, 2H), 7.64 (dd, <i>J</i> = 8.4 Hz, 0.6 Hz, 1H), 7.22 (t, <i>J</i> = 8.7 Hz, 2 H), 4.36 (s, 2H).</div></div><div id="sec4_2_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 6-(2-Cyanobenzylthio)-<i>N</i>-(4-fluorophenyl)nicotinamide (<b>66</b>)</h4><div class="NLM_p last">Prepared via method B using thionicotinamide <b>64</b> (0.5 mmol) and α-bromo-o-tolunitrile (0.5 mmol) to yield 137 mg (75%) of <b>66</b> as an off-white solid. TLC (ethyl acetate/hexane, 1:1): <i>R</i><sub><i>f</i></sub> = 0.44. ESI-MS: <i>m</i>/<i>z</i> = 364.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.38 (s, 1H), 8.97 (d, <i>J</i> = 1.6 Hz, 1H), 8.11 (dd, <i>J</i> = 9.5 Hz, 2.1 Hz, 1H), 7.81 (d, <i>J</i> = 7.5 Hz, 1H), 7.75–7.68 (m, 3H), 7.62 (t, <i>J</i> = 7.3 Hz, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 1H), 7.42 (t, <i>J</i> = 8.3 Hz, 1H), 7.17 (t, <i>J</i> = 9.0 Hz, 2H), 4.64 (s, 2H).</div></div><div id="sec4_2_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 6-(2-Boronobenzylthio)nicotinic acid (<b>67</b>)</h4><div class="NLM_p last">6-Mercaptonicotinic acid (1.55 g, 10 mmol) and 2-bromomethyl-phenylboronic acid (2.14 g, 10 mmol) were dissolved in anhydrous DMF (20 mL), and then TEA (2.78 mL, 20 mmol) was added. The mixture was warmed to 60 °C for 1 h, and then removed from heat and let cool to room temperature. The solution was acidified with 1 N HCl and extracted with ethyl acetate. The ethyl acetate layer was washed with water, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to yield intermediate <b>67</b> as a yellow solid (1.54 g, 53%). TLC (AcOH/ethyl acetate/EtOH, 0.1:80:20): <i>R</i><sub><i>f</i></sub> = 0.52; ESI-MS: <i>m</i>/<i>z</i> = 290.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.23 (br s, 1H), 8.92 (s, 1H), 8.19 (br s, 2H), 8.05 (dd, <i>J</i> = 8.4 Hz, 2.0 Hz, 1H), 7.53 (d, <i>J</i> = 7.3 Hz, 1H), 7.43–7.36 (m, 2H), 7.29 (t, <i>J</i> = 7.3 Hz, 1H), 7.21 (t, <i>J</i> = 7.4 Hz, 1H), 4.67 (s, 2H). HPLC (gradient B): RT = 14.03 min, purity 83.4%.</div></div><div id="sec4_2_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 6-(2-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzylthio)nicotinic pivalic anhydride (<b>68</b>)</h4><div class="NLM_p last">Intermediate <b>67</b> (290 mg, 1 mmol) and neopentyl glycol (1 mmol) were suspended in anhydrous toluene (5 mL) and set to reflux over 24 h. Without isolation, the resulting mixture containing the boronic ester was cooled in an ice bath under argon. Pivaloyl chloride (120 μL, 1 mmol) and triethylamine (140 μL, 1 mmol) were then added to the cooled solution. The reaction was allowed to proceed at the lowered temperature for 1 h, and then warmed to room temperature for an additional hour. The resulting crystalline triethylammonium salt was filtered away, and the reaction mixture concentrated by rotary evaporation. The resulting oil containing <b>70</b> was diluted with anhydrous DMF (3 mL). This solution was used without further isolation.</div></div><div id="sec4_2_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>N</i>-(4-Fluoro-phenyl)-6-chloro-nicotinamide (<b>69</b>)</h4><div class="NLM_p last">4-Fluoroaniline (5.8 mL, 60 mmol) was stirred in THF (300 mL) and potassium carbonate (16.6 g, 120 mmol) was added, followed by 6-chloronicotinoyl chloride (10.6 g, 60 mmol) and stirred overnight. The salts were removed by filtration, and the organic solution was cooled in an ice bath and diluted with water while stirring. The resulting white precipitate was filtered to yield 8.3 g (55%) of <b>69</b>. TLC (ethyl acetate/hexanes 1:1) <i>R</i><sub><i>f</i></sub> = 0.51. ESI-MS: <i>m</i>/<i>z</i> = 251.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.53 (s, 1H), 8.95 (d, <i>J</i> = 2.5 Hz, 1H), 8.37 (dd, <i>J</i> = 8.4 Hz, 2.5 Hz, 1H), 7.81–7.70 (m, 3H), 7.26–7.18 (m, 2H). HPLC (gradient B): RT = 13.8 min, purity 94.3%.</div></div><div id="sec4_2_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>tert</i>-Butyl 2-((4-fluorophenylamino)methyl)piperidine-1-carboxylate (<b>70a</b>)</h4><div class="NLM_p last">N-Boc-2-piperidinecarbaldehyde (1.1 g, 1 eq., Combi-Blocks, San Diego, CA) and 4-fluoroaniline (481 μL, 1 equiv) were dissolved in DCE (20 mL). Under an inert atmosphere, NaBH(OAc)<sub>3</sub> (1.5 g, 1.4 equiv) and glacial acetic acid (294 μL, 1 equiv) were added, and the reaction was monitored by TLC and LC–MS. The mixture was diluted with ethyl acetate and washed with 10% citric acid (×3), brine (×1) and dried over MgSO<sub>4</sub>. The mixture was filtered and the solvent removed by rotary evaporation and dried in vacuo to afford 1.4 g of the secondary aniline <b>70a</b> (90% yield). The intermediate was carried forward without further characterization. ESI-MS: <i>m</i>/<i>z</i> = 309.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> <i>tert</i>-Butyl 2-(4-fluorophenylamino)acetate (<b>70b</b>)</h4><div class="NLM_p last">A solution of 4-fluoroaniline (1.00 mL, 10 mmol) and DIPEA (1.74 mL, 10 mmol) in anhydrous DMF (10 mL) was warmed to 80 °C, and then a solution of <i>tert</i>-butyl bromoacetate (1.47 mL, 10 mmol) in anhydrous DMF (10 mL) was added dropwise over 1 h. After addition, the mixture was kept at 80 °C for 4 h. The mixture was then concentrated by rotary evaporation and then partitioned between ethyl acetate and water. The organic layer was washed with water and then evaporated to yield <b>70b</b> as a dark brown liquid (1.96 g, 87%). A sample was purified by flash silica gel chromatography (1:10 ethyl acetate/hexanes). TLC (ethyl acetate/hexanes, 1:4) <i>R</i><sub><i>f</i></sub> = 0.31. ESI-MS: <i>m</i>/<i>z</i> = 225.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.94–6.90 (m, 2H), 6.55–6.52 (m, 2H), 5.85 (s, 1H), 3.75 (d, <i>J</i> = 4.3 Hz, 2H), 1.41 (s, 9H). HPLC (gradient B): RT = 18.78 min, purity 86.5%.</div></div><div id="sec4_2_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>tert</i>-Butyl 2-((6-chloro-<i>N</i>-(4-fluorophenyl)nicotinamido)methyl)piperidine-1-carboxylate (<b>71a</b>)</h4><div class="NLM_p last">The secondary aniline intermediate <b>70a</b> (0.5 g, 1 equiv) was stirred in DMF (5 mL) at 80 °C followed by the addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 240 μL, 1 equiv) and 6-chloronicotinoyl chloride (0.3 g, 1 equiv). The reaction was monitored by TLC and LC–MS and was stirred overnight at 80 °C. The mixture was then diluted with ethyl acetate (25 mL), washed with water, saturated NaHCO<sub>3</sub>, water, 10% citric acid, water, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The organic solvent was then removed by rotary evaporation and dried in vacuo to afford 0.56 g of the <i>N</i>-substituted <i>N</i>-(4-fluorophenyl)-6-chloro-nicotinamide <b>71a</b> (78% yield). The intermediate was carried forward without further purification. ESI-MS: <i>m</i>/<i>z</i> = 448.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> <i>tert</i>-Butyl 2-(6-chloro-<i>N</i>-(4-fluorophenyl)nicotinamido)acetate (<b>71b</b>)</h4><div class="NLM_p last">The disubstituted aniline <b>70b</b> (0.41 g, 2.31 mmol) was coupled to 6-chloronicotinoyl chloride (0.52 g, 2.31 mmol) in anhydrous DMF (2 mL) using DBU (344 mL, 2.31 mmol). The mixture was heated to 65 °C for 48 h, diluted with ethyl acetate, and then the organic layer washed with water, saturated NaHCO<sub>3</sub>, water, 10% citric acid, water, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The crude material was concentrated by rotary evaporation, and purified by flash chromatography (ethyl acetate/hex 1:2) to yield 387 mg (46%) of 6-chloronicotinamide intermediate <b>71b</b> as a clear oil. TLC (ethyl acetate/hexanes, 1:2) <i>R</i><sub><i>f</i></sub> = 0.28; ESI-MS: <i>m</i>/<i>z</i> = 364.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.25 (s, 1H), 7.69 (d, <i>J</i> = 7.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.7 Hz, 1H), 7.30–7.26 (m, 2H), 7.17 (t, <i>J</i> = 8.8 Hz, 2H), 4.48 (s, 2H), 1.42 (s, 9H). HPLC (gradient B): RT = 19.88 min, purity 83.5%.</div></div><div id="sec4_2_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 6-Chloro-<i>N</i>-(4-fluorophenyl)-<i>N</i>-(pyridin-2-ylmethyl)nicotinamide (<b>72a</b>)</h4><div class="NLM_p last"><i>N</i>-(4-fluorophenyl)-6-chloro-nicotinamide 69 (1.0 g, 4.0 mmol) and 2-bromomethyl-pyridine hydrobromide (1.01 g, 4.0 mmol) were suspended in toluene (5 mL). 50% aqueous NaOH (3.0 mL) was added to the mixture, followed by tetra-<i>n</i>-butyl-ammonium hydroxide (TBAH, 100 μL). The biphasic reaction mixture was vigorously stirred overnight and the aqueous layer removed by pipet. The organic layer was diluted with ethyl acetate and washed with water (3 × 25 mL) and saturated aqueous NaCl (3 × 25 mL). The water washes were back-extracted once with ethyl acetate (25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried by rotary evaporation to yield 1.3 g (96%) of <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-2-ylmethyl-6-chloro-nicotinamide intermediate <b>72a</b> as an off-white solid. ESI-MS: <i>m</i>/<i>z</i> = 341.9, 343.9 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52 (d, <i>J</i> = 4.3 Hz, 1H), 8.35 (d, <i>J</i> = 2.3 Hz, 1H), 7.79–7.73 (m, 2H), 7.50 (d, <i>J</i> = 5.4 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 1H), 7.33–7.27 (m, 3H), 7.10 (t, <i>J</i> = 8.6 Hz, 2H), 5.16 (s, 2H).</div></div><div id="sec4_2_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 6-Chloro-<i>N</i>-(4-fluorophenyl)-<i>N</i>-(pyridin-4-ylmethyl)nicotinamide (<b>72b</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>72a</b> and starting from the <i>N</i>-(4-fluorophenyl)-6-chloro-nicotinamide <b>69</b> (3.0 g, 12 mmol, 1.2 equiv) and 4-bromomethyl-pyridine hydrobromide (2.5 g, 10 mmol, 1.0 equiv), workup yielded 2.5 g (74%) of the <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-4-ylmethyl-6-chloro-nicotinamide intermediate <b>72b</b>. ESI-MS: <i>m</i>/<i>z</i> = 342.1, 344.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52 (s, 1H), 8.35 (s, 1H), 7.79–7.76 (m, 2H), 7.49 (br s, 1H), 7.47 (d, <i>J</i> = 7.9 Hz, 1H), 7.33–7.31 (m, 2H), 7.28 (t, <i>J</i> = 6.1 Hz, 1H), 7.10 (t, <i>J</i> = 8.1 Hz, 2H), 5.16 (s, 2H). HPLC (gradient B): RT = 13.45 min, purity 99.1%.</div></div><div id="sec4_2_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> <i>N</i>-(4-Fluorophenyl)-6-mercapto-<i>N</i>-(pyridin-2-ylmethyl)nicotinamide (<b>73a</b>)</h4><div class="NLM_p last"><i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-2-ylmethyl-6-chloro-nicotinamide intermediate <b>72a</b> (3.4 g, 10 mmol) and anhydrous sodium hydrogen sulfide (1.1 g, 20 mmol) were suspended in anhydrous DMF (30 mL). The suspension was heated to reflux, and the mixture turned a deep green color. After 2 h, the mixture was diluted with ethyl acetate (150 mL) and extracted with water. The aqueous layer was acidified with glacial AcOH to pH 6–7 and back extracted with ethyl acetate (4 × 50 mL), and the organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated by rotary evaporation to yield 2.9 g (87%) of <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-2-ylmethyl-6-mercapto-nicotinamide intermediate <b>73a</b> as a dark yellow oil. TLC (ethyl acetate/hexanes, 2:1): <i>R</i><sub><i>f</i></sub> = 0.1; ESI-MS: <i>m</i>/<i>z</i> = 339.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>N</i>-(4-Fluorophenyl)-6-mercapto-<i>N</i>-(pyridin-4-ylmethyl)nicotinamide (<b>73b</b>)</h4><div class="NLM_p last">Following the same procedure described for <b>73a</b> and starting from the <i>N</i>-(4-fluorophenyl)-<i>N</i>-pyridin-4-ylmethyl-6-chloro-nicotinamide intermediate <b>72b</b> (2.5 g, 7.4 mmol), workup yielded 2.8 g (quant.) of compound crude <b>72b</b>, which was carried forward without further purification. TLC (ethyl acetate/hexanes, 2:1): <i>R</i><sub><i>f</i></sub> = 0.1; ESI-MS: <i>m</i>/<i>z</i> = 339.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>tert</i>-Butyl 2-((<i>N</i>-(4-fluorophenyl)-6-mercaptonicotinamido)methyl)piperidine-1-carboxylate (<b>73c</b>)</h4><div class="NLM_p last">Thiolation of <b>71a</b> was achieved by suspending the tertiary amide (0.56 g, 1 equiv) and sodium hydrogen sulfide (0.14 g, 2 equiv) in anhydrous DMF (2 mL) under an inert atmosphere. The reaction was gently refluxed for 2 h and then diluted with ethyl acetate (30 mL) and extracted with water (3 × 20 mL). The aqueous layer was then acidified with 10% citric acid and stored at 2–8 °C. The fine white precipitate was then collected by filtration to afford 90 mg of thionicotinamide intermediate <b>73c</b> (16% yield). The intermediate was carried forward without further purification.</div></div><div id="sec4_2_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> <i>tert</i>-Butyl 2-(<i>N</i>-(4-fluorophenyl)-6-mercaptonicotinamido)acetate (<b>73d</b>)</h4><div class="NLM_p last">The 6-chloronicotinamide <b>71b</b> (211 mg, 0.58 mmol) and sodium hydrogen sulfide (74 mg) were dissolved in DMF (1 mL). The mixture was heated to 85 °C for 15 min, and then allowed to cool to room temperature. The mixture was diluted in ethyl acetate, washed with water, saturated NaHCO<sub>3</sub>, water, 10% citric acid, water, saturated NaCl, and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude material was filtered and evaporated to yield 123 mg (58%) of <b>73d</b> as a yellow oil, which was carried forward without further purification. TLC (ethyl acetate): <i>R</i><sub><i>f</i></sub> = 0.53; ESI-MS: <i>m</i>/<i>z</i> = 362.9 [M + H]<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm500827t" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean Y. Maeda</span> - <span class="hlFld-Affiliation affiliation">Syntrix
Biosystems, 215 Clay
Street, Auburn, Washington 98001, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#debab3bfbbbabf9eada7b0aaacb7a6bcb7b1f0bdb1b3"><span class="__cf_email__" data-cfemail="6e0a030f0b0a0f2e1d17001a1c07160c0701400d0103">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela M. Peck</span> - <span class="hlFld-Affiliation affiliation">Syntrix
Biosystems, 215 Clay
Street, Auburn, Washington 98001, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron D. Schuler</span> - <span class="hlFld-Affiliation affiliation">Syntrix
Biosystems, 215 Clay
Street, Auburn, Washington 98001, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark T. Quinn</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Montana
State University, 960
Technology Boulevard, Bozeman, Montana 59717, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liliya N. Kirpotina</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Montana
State University, 960
Technology Boulevard, Bozeman, Montana 59717, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Winston N. Wicomb</span> - <span class="hlFld-Affiliation affiliation">Infectious
Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guo-Huang Fan</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Meharry Medical College, 1005 Dr. DB Todd Boulevard, Nashville, Tennessee 37208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John A. Zebala</span> - <span class="hlFld-Affiliation affiliation">Syntrix
Biosystems, 215 Clay
Street, Auburn, Washington 98001, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.M.P. and A.D.S. contributed equally to this manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d351e5687-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i120">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Institutes of Health Grant R44HL072614 (D.Y.M.) from the National Heart Lung and Blood Institute. We thank both Dr. Joel Morgan and David Nguyen (Syntrix Biosystems, Inc.) for careful review of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i121" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i121"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i122" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i122"> Abbreviations Used</h2><tr><td class="NLM_term">CXCR1</td><td class="NLM_def"><p class="first last">CXC receptor 1</p></td></tr><tr><td class="NLM_term">CXCR2</td><td class="NLM_def"><p class="first last">CXC receptor 2</p></td></tr><tr><td class="NLM_term">CXCL1</td><td class="NLM_def"><p class="first last">CXC ligand 1</p></td></tr><tr><td class="NLM_term">CXCL8</td><td class="NLM_def"><p class="first last">CXC ligand 8</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">C5a</td><td class="NLM_def"><p class="first last">complement component 5a</p></td></tr><tr><td class="NLM_term">fMLF</td><td class="NLM_def"><p class="first last">formyl-methionyl-leucyl-phenylalanine</p></td></tr><tr><td class="NLM_term">PAF</td><td class="NLM_def"><p class="first last">platelet-activating factor</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">PMN</td><td class="NLM_def"><p class="first last">polymorphonuclear cells</p></td></tr><tr><td class="NLM_term">hPMN</td><td class="NLM_def"><p class="first last">human PMN</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure activity relationship</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i123">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">International union of pharmacology. XXII. Nomenclature for chemokine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=145-176&author=P.+M.+Murphyauthor=M.+Baggioliniauthor=I.+F.+Charoauthor=C.+A.+Hebertauthor=R.+Horukauthor=K.+Matsushimaauthor=L.+H.+Millerauthor=J.+J.+Oppenheimauthor=C.+A.+Power&title=International+union+of+pharmacology.+XXII.+Nomenclature+for+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DBaggiolini%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DHebert%26aufirst%3DC.%2BA.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DL.%2BH.%26aulast%3DOppenheim%26aufirst%3DJ.%2BJ.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXII.%2520Nomenclature%2520for%2520chemokine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D145%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Petersen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flad, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, E.</span><span> </span><span class="NLM_article-title">Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways: Discrepancies in binding affinities, receptor densities, and biologic effects</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">2467</span><span class="NLM_x">–</span> <span class="NLM_lpage">2478</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=2467-2478&author=F.+Petersenauthor=H.+D.+Fladauthor=E.+Brandt&title=Neutrophil-activating+peptides+NAP-2+and+IL-8+bind+to+the+same+sites+on+neutrophils+but+interact+in+different+ways%3A+Discrepancies+in+binding+affinities%2C+receptor+densities%2C+and+biologic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DF.%26aulast%3DFlad%26aufirst%3DH.%2BD.%26aulast%3DBrandt%26aufirst%3DE.%26atitle%3DNeutrophil-activating%2520peptides%2520NAP-2%2520and%2520IL-8%2520bind%2520to%2520the%2520same%2520sites%2520on%2520neutrophils%2520but%2520interact%2520in%2520different%2520ways%253A%2520Discrepancies%2520in%2520binding%2520affinities%252C%2520receptor%2520densities%252C%2520and%2520biologic%2520effects%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D2467%26epage%3D2478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Neptune, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iiri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, H. R.</span><span> </span><span class="NLM_article-title">G alpha(i) is not required for chemotaxis mediated by G(i)-coupled receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">2824</span><span class="NLM_x">–</span> <span class="NLM_lpage">2828</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=2824-2828&author=E.+R.+Neptuneauthor=T.+Iiriauthor=H.+R.+Bourne&title=G+alpha%28i%29+is+not+required+for+chemotaxis+mediated+by+G%28i%29-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeptune%26aufirst%3DE.%2BR.%26aulast%3DIiri%26aufirst%3DT.%26aulast%3DBourne%26aufirst%3DH.%2BR.%26atitle%3DG%2520alpha%2528i%2529%2520is%2520not%2520required%2520for%2520chemotaxis%2520mediated%2520by%2520G%2528i%2529-coupled%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D2824%26epage%3D2828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thelen, M.</span><span> </span><span class="NLM_article-title">A Comparison of postreceptor signal-transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2 - chemokine mediated activation of P42/P44 MAP-Kinase (ERK-2)</span> <span class="citation_source-journal">Febs Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=1995&pages=211-214&author=S.+A.+Jonesauthor=B.+Moserauthor=M.+Thelen&title=A+Comparison+of+postreceptor+signal-transduction+events+in+Jurkat+cells+transfected+with+either+IL-8R1+or+IL-8R2+-+chemokine+mediated+activation+of+P42%2FP44+MAP-Kinase+%28ERK-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoser%26aufirst%3DB.%26aulast%3DThelen%26aufirst%3DM.%26atitle%3DA%2520Comparison%2520of%2520postreceptor%2520signal-transduction%2520events%2520in%2520Jurkat%2520cells%2520transfected%2520with%2520either%2520IL-8R1%2520or%2520IL-8R2%2520-%2520chemokine%2520mediated%2520activation%2520of%2520P42%252FP44%2520MAP-Kinase%2520%2528ERK-2%2529%26jtitle%3DFebs%2520Lett.%26date%3D1995%26volume%3D364%26spage%3D211%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Schorr, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swandulla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeilhofer, H. U.</span><span> </span><span class="NLM_article-title">Mechanisms of IL-8-induced Ca2+ signaling in human neutrophil granulocytes</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=897-904&author=W.+Schorrauthor=D.+Swandullaauthor=H.+U.+Zeilhofer&title=Mechanisms+of+IL-8-induced+Ca2%2B+signaling+in+human+neutrophil+granulocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchorr%26aufirst%3DW.%26aulast%3DSwandulla%26aufirst%3DD.%26aulast%3DZeilhofer%26aufirst%3DH.%2BU.%26atitle%3DMechanisms%2520of%2520IL-8-induced%2520Ca2%252B%2520signaling%2520in%2520human%2520neutrophil%2520granulocytes%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1999%26volume%3D29%26spage%3D897%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kurdowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, S. C.</span><span> </span><span class="NLM_article-title">Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1097%2F00003246-200210000-00024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12394964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=2335-2337&author=A.+Kurdowskaauthor=J.+M.+Nobleauthor=I.+S.+Grantauthor=C.+R.+Robertsonauthor=C.+Haslettauthor=S.+C.+Donnelly&title=Anti-interleukin-8+autoantibodies+in+patients+at+risk+for+acute+respiratory+distress+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome</span></div><div class="casAuthors">Kurdowska, Anna; Noble, James M.; Grant, Ian S.; Robertson, Colin R.; Haslett, Christopher; Donnelly, Seamas C.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2335-2337</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE: To test the hypothesis that elevated concns. of interleukin-8 assocd. with anti-interleukin-8 autoantibodies (anti-interleukin-8:interleukin-8 complexes) are found in patients at risk for acute respiratory distress syndrome who developed the disease.  DESIGN: Measurement of anti-interleukin-8:interleukin-8 complex concns. in previously collected bronchoalveolar lavage fluids.  These fluids were obtained from patients at risk for acute respiratory distress syndrome who subsequently either recovered or developed acute respiratory distress syndrome.  PATIENTS: A unique population of patients at risk for acute respiratory distress syndrome was studied.  There were 26 patients at risk for acute respiratory distress syndrome who were divided into three groups.  Group I patients had high interleukin-8 concns. and developed acute respiratory distress syndrome, group II had high interleukin-8 concns. and did not develop acute respiratory distress syndrome, and group III had low interleukin-8 concns. and did not develop acute respiratory distress syndrome.  These patients were selected to test the hypothesis that presence of elevated concns. of anti-interleukin-8:interleukin-8 complexes differentiates patients at risk for acute respiratory distress syndrome who developed acute respiratory distress syndrome from patients who did not.  MEASUREMENTS AND MAIN RESULTS: Bronchoalveolar lavage fluid concns. of interleukin-8 assocd. with the anti-interleukin-8 autoantibodies were significantly different between groups (p <.03).  The amt. of interleukin-8 bound to the anti-interleukin-8 autoantibody was higher in group I than in group II and group III.  CONCLUSIONS: Bronchoalveolar lavage fluid concn. of anti-interleukin-8:interleukin-8 complexes may serve as a marker of disease progression in patients at risk for acute respiratory distress syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbBDq_HqzKILVg90H21EOLACvtfcHk0lhf55yMKhPKHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOisLo%253D&md5=63d53673ede83fec816bfe9e74773d72</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00003246-200210000-00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200210000-00024%26sid%3Dliteratum%253Aachs%26aulast%3DKurdowska%26aufirst%3DA.%26aulast%3DNoble%26aufirst%3DJ.%2BM.%26aulast%3DGrant%26aufirst%3DI.%2BS.%26aulast%3DRobertson%26aufirst%3DC.%2BR.%26aulast%3DHaslett%26aufirst%3DC.%26aulast%3DDonnelly%26aufirst%3DS.%2BC.%26atitle%3DAnti-interleukin-8%2520autoantibodies%2520in%2520patients%2520at%2520risk%2520for%2520acute%2520respiratory%2520distress%2520syndrome%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D2335%26epage%3D2337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Erdem, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simsek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musabak, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turan, M.</span><span> </span><span class="NLM_article-title">Different ELR(+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet’s disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis</span> <span class="citation_source-journal">Rheumatol. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2Fs00296-004-0524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15672235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=162-167&author=H.+Erdemauthor=S.+Payauthor=M.+Serdarauthor=I.+Simsekauthor=A.+Dincauthor=U.+Musabakauthor=A.+Pekelauthor=M.+Turan&title=Different+ELR%28%2B%29+angiogenic+CXC+chemokine+profiles+in+synovial+fluid+of+patients+with+Behcet%E2%80%99s+disease%2C+familial+Mediterranean+fever%2C+rheumatoid+arthritis%2C+and+osteoarthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis</span></div><div class="casAuthors">Erdem, Hakan; Pay, Salih; Serdar, Muhittin; Simsek, Ismail; Dinc, Ayhan; Musabak, Ugur; Pekel, Aysel; Turan, Mustafa</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology International</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-167</span>CODEN:
                <span class="NLM_cas:coden">RHINDE</span>;
        ISSN:<span class="NLM_cas:issn">0172-8172</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The aim of the present study was to det. synovial levels of ELR (+) CXC chemokines, known to attract mainly neutrophils to inflamed tissues by binding the neutrophil chemokine receptors CXCR1 and CXCR2 and promoting neovascularization in patients with various inflammatory disorders.  The study group consisted of 14 patients with Behcet's disease and nine with familial Mediterranean fever.  Fourteen patients with rheumatoid arthritis and 16 with osteoarthritis served as controls.  Synovial chemokine levels were measured by two-step sandwich ELISA, and significant differences were found in the various chemokines studied.  In addn. to its angiogenic properties, increased synovial levels of interleukin-8 by attraction of more neutrophils to synovial fluids might also be responsible for the acute synovitis in patients with Behcet's disease.  However, the absence of chronic changes with the eventual development of pannus and erosions might result from relatively lower expression of interleukin-8 and the transient, short-lived nature of the arthritis obsd. in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVRbyfU9gJi7Vg90H21EOLACvtfcHk0lh6_xj1ro7w7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtbzM&md5=13da6410557b24061d53040bbec6887d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00296-004-0524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00296-004-0524-3%26sid%3Dliteratum%253Aachs%26aulast%3DErdem%26aufirst%3DH.%26aulast%3DPay%26aufirst%3DS.%26aulast%3DSerdar%26aufirst%3DM.%26aulast%3DSimsek%26aufirst%3DI.%26aulast%3DDinc%26aufirst%3DA.%26aulast%3DMusabak%26aufirst%3DU.%26aulast%3DPekel%26aufirst%3DA.%26aulast%3DTuran%26aufirst%3DM.%26atitle%3DDifferent%2520ELR%2528%252B%2529%2520angiogenic%2520CXC%2520chemokine%2520profiles%2520in%2520synovial%2520fluid%2520of%2520patients%2520with%2520Behcet%25E2%2580%2599s%2520disease%252C%2520familial%2520Mediterranean%2520fever%252C%2520rheumatoid%2520arthritis%252C%2520and%2520osteoarthritis%26jtitle%3DRheumatol.%2520Int.%26date%3D2005%26volume%3D26%26spage%3D162%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lally, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainger, G. E.</span><span> </span><span class="NLM_article-title">A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3460</span><span class="NLM_x">–</span> <span class="NLM_lpage">3469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fart.21394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16255036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Krur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=3460-3469&author=F.+Lallyauthor=E.+Smithauthor=A.+Filerauthor=M.+A.+Stoneauthor=J.+S.+Shawauthor=G.+B.+Nashauthor=C.+D.+Buckleyauthor=G.+E.+Rainger&title=A+novel+mechanism+of+neutrophil+recruitment+in+a+coculture+model+of+the+rheumatoid+synovium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium</span></div><div class="casAuthors">Lally, Frank; Smith, Emily; Filer, Andrew; Stone, Michael A.; Shaw, John S.; Nash, Gerard B.; Buckley, Christopher D.; Rainger, G. Ed</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3460-3469</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Rheumatoid arthritis (RA) is classically thought of as a Th1, T lymphocyte-driven disease of the adaptive immune system.  However, cells of the innate immune system, including neutrophils, are prevalent within the diseased joint, and accumulate in large nos.  This study was undertaken to det. whether cells of the rheumatoid stromal microenvironment could establish an inflammatory environment in which endothelial cells are conditioned in a disease-specific manner to support neutrophil recruitment.  Methods. Human umbilical vein endothelial cells (ECs) and fibroblasts isolated from the synovium or skin of RA patients were established in coculture on opposite sides of porous transwell filters.  After 24 h of EC conditioning, the membranes were incorporated into a parallel-plate, flow-based adhesion assay and levels of neutrophil adhesion to ECs were measured.  Results. ECs cocultured with synovial, but not skin, fibroblasts could recruit neutrophils in a manner that was dependent on the no. of fibroblasts.  Antibody blockade of P-selectin or E-selectin reduced neutrophil adhesion, and an antibody against CD18 (the β2 integrin) abolished adhesion.  Blockade of CXCR2, but not CXCR1, also greatly inhibited neutrophil recruitment.  Interleukin-6 (IL-6) was detectable in coculture supernatants, and both IL-6 and neutrophil adhesion were reduced in a dose-dependent manner by hydrocortisone added to cocultures.  Antibody blockade of IL-6 also effectively abolished neutrophil adhesion.  Conclusion. Synovial fibroblasts from the rheumatoid joint play an important role in regulating the recruitment of inflammatory leukocytes during active disease.  This process may depend on a previously unsuspected route of IL-6-mediated crosstalk between fibroblasts and endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1U5CxPynJ_bVg90H21EOLACvtfcHk0lh6_xj1ro7w7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Krur7J&md5=a8ddf4312cefed71146e9e5bf519bc97</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fart.21394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21394%26sid%3Dliteratum%253Aachs%26aulast%3DLally%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DFiler%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DNash%26aufirst%3DG.%2BB.%26aulast%3DBuckley%26aufirst%3DC.%2BD.%26aulast%3DRainger%26aufirst%3DG.%2BE.%26atitle%3DA%2520novel%2520mechanism%2520of%2520neutrophil%2520recruitment%2520in%2520a%2520coculture%2520model%2520of%2520the%2520rheumatoid%2520synovium%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D3460%26epage%3D3469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Reich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaschke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westphal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, C.</span><span> </span><span class="NLM_article-title">Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2001&pages=319-329&author=K.+Reichauthor=C.+Garbeauthor=V.+Blaschkeauthor=C.+Maurerauthor=P.+Middelauthor=G.+Westphalauthor=U.+Lippertauthor=C.+Neumann&title=Response+of+psoriasis+to+interleukin-10+is+associated+with+suppression+of+cutaneous+type+1+inflammation%2C+downregulation+of+the+epidermal+interleukin-8%2FCXCR2+pathway+and+normalization+of+keratinocyte+maturation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DK.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DBlaschke%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DC.%26aulast%3DMiddel%26aufirst%3DP.%26aulast%3DWestphal%26aufirst%3DG.%26aulast%3DLippert%26aufirst%3DU.%26aulast%3DNeumann%26aufirst%3DC.%26atitle%3DResponse%2520of%2520psoriasis%2520to%2520interleukin-10%2520is%2520associated%2520with%2520suppression%2520of%2520cutaneous%2520type%25201%2520inflammation%252C%2520downregulation%2520of%2520the%2520epidermal%2520interleukin-8%252FCXCR2%2520pathway%2520and%2520normalization%2520of%2520keratinocyte%2520maturation%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2001%26volume%3D116%26spage%3D319%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Banks, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheron, N.</span><span> </span><span class="NLM_article-title">Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn’s disease</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">199</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fpath.1245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12474223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFenug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2003&pages=28-35&author=C.+Banksauthor=A.+Batemanauthor=R.+Payneauthor=P.+Johnsonauthor=N.+Sheron&title=Chemokine+expression+in+IBD.+Mucosal+chemokine+expression+is+unselectively+increased+in+both+ulcerative+colitis+and+Crohn%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease</span></div><div class="casAuthors">Banks, Charmian; Bateman, Adrian; Payne, Richard; Johnson, Penny; Sheron, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Mucosal changes in inflammatory bowel disease (IBD) are characterized by ulcerative lesions accompanied by prominent cellular infiltrates in the bowel wall.  Chemokines are chemotactic cytokines that are able to promote leukocyte migration to areas of inflammation and are also able to initiate cell activation events.  They have recently been implicated in the pathophysiol. of many disease states.  The aim of this study was to detail the degree and distribution of specific chemokines, interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, -2, and -3, and macrophage inflammatory protein (MIP)-1α and -1β, in IBD mucosa.  Thirty-nine patients were included, ten controls, 20 ulcerative colitis (UC), and nine Crohn's disease (CD), with a range of disease activity.  Colonic mucosal biopsies were collected from UC, CD, and control patients and embedded in glycol methacrylate.  Two-micrometre-thick sections were cut and stained using immunohistochem. for chemokine protein expression.  Sections were analyzed using a light microscope.  Expression of all types of chemokine protein was detected in colonic mucosa from both control and IBD patients.  Patterns of staining between IBD patients and controls differed significantly, but CD and UC patients demonstrated similar patterns of staining.  Individual chemokine expression was found to be significantly up-regulated in IBD when patients were compared with the non-diseased group in all areas of the mucosal sections.  Up-regulated chemokine expression correlated with increasing activity of the disease.  It is concluded that human colonic chemokine expression is non-selectively up-regulated in IBD.  The results supported the hypothesis that the degree of local inflammation and tissue damage in UC and CD is dependent on local expression of specific chemokines within IBD tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDzTulRo8ok7Vg90H21EOLACvtfcHk0lh6_xj1ro7w7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFenug%253D%253D&md5=85eef8d1093f262a1bd11a11b962396d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.1245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1245%26sid%3Dliteratum%253Aachs%26aulast%3DBanks%26aufirst%3DC.%26aulast%3DBateman%26aufirst%3DA.%26aulast%3DPayne%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSheron%26aufirst%3DN.%26atitle%3DChemokine%2520expression%2520in%2520IBD.%2520Mucosal%2520chemokine%2520expression%2520is%2520unselectively%2520increased%2520in%2520both%2520ulcerative%2520colitis%2520and%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pathol.%26date%3D2003%26volume%3D199%26spage%3D28%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culpitt, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Neutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B-4</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1240</span><span class="NLM_x">–</span> <span class="NLM_lpage">1247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=1240-1247&author=K.+M.+Beehauthor=O.+Kornmannauthor=R.+Buhlauthor=S.+V.+Culpittauthor=M.+A.+Giembyczauthor=P.+J.+Barnes&title=Neutrophil+chemotactic+activity+of+sputum+from+patients+with+COPD%3A+Role+of+interleukin+8+and+leukotriene+B-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DCulpitt%26aufirst%3DS.%2BV.%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNeutrophil%2520chemotactic%2520activity%2520of%2520sputum%2520from%2520patients%2520with%2520COPD%253A%2520Role%2520of%2520interleukin%25208%2520and%2520leukotriene%2520B-4%26jtitle%3DChest%26date%3D2003%26volume%3D123%26spage%3D1240%26epage%3D1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Keatings, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1164%2Fajrccm.153.2.8564092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=8564092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A280%3ADyaK287mtVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1996&pages=530-534&author=V.+M.+Keatingsauthor=P.+D.+Collinsauthor=D.+M.+Scottauthor=P.+J.+Barnes&title=Differences+in+interleukin-8+and+tumor+necrosis+factor-alpha+in+induced+sputum+from+patients+with+chronic+obstructive+pulmonary+disease+or+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma</span></div><div class="casAuthors">Keatings V M; Collins P D; Scott D M; Barnes P J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">530-4</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Asthma and chronic obstructive pulmonary disease are characterized by chronic airway inflammation.  Studies using bronchoalveolar lavage (BAL) have shown an increased proportion of eosinophils in the BAL fluid from asthmatics compared with that from normal subjects, whereas studies of chronic obstructive pulmonary disease (COPD) have shown increased numbers of neutrophils.  Induced sputum allows sampling of respiratory tract secretions from patients and control subjects, providing a noninvasive method of studying airway secretions and allowing characterization of cells and measurement of soluble markers.  We investigated whether induced sputum was a useful method of studying airway fluid from patients with moderate to severe COPD and whether it could be used to compare inflammation in this condition with that in asthma.  An initial reproducibility study was undertaken.  Sputum was induced twice in 13 patients with severe COPD at a 14-d interval.  Total and differential cell counts were carried out and were found to be reproducible over this period.  Sputum was then induced in 14 patients with COPD, 23 patients with asthma, 12 healthy cigarette smokers, and 16 normal nonsmoking control subjects.  We found a significant increase in neutrophils and increased concentrations of tumor necrosis factor-alpha (TNF alpha) and interleukin-8 (IL-8) in the patients with COPD compared with the smoking and nonsmoking control subjects.  Interleukin-8, but not TNF alpha, was significantly higher in the COPD group than in the asthmatic group.  We conclude that the cytokines TNF alpha and IL-8 may be involved in the inflammation in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2AjKRSKODju_Q9URG6Dx8fW6udTcc2eYXN0Q8kaVH0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287mtVGmug%253D%253D&md5=51b69cba104ea9db57d9e763fb9a254d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.153.2.8564092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.153.2.8564092%26sid%3Dliteratum%253Aachs%26aulast%3DKeatings%26aufirst%3DV.%2BM.%26aulast%3DCollins%26aufirst%3DP.%2BD.%26aulast%3DScott%26aufirst%3DD.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DDifferences%2520in%2520interleukin-8%2520and%2520tumor%2520necrosis%2520factor-alpha%2520in%2520induced%2520sputum%2520from%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520or%2520asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1996%26volume%3D153%26spage%3D530%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">CXCR2 antagonists for the treatment of pulmonary disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.pharmthera.2008.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19026683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=55-68&author=R.+W.+Chapmanauthor=J.+E.+Phillipsauthor=R.+W.+Hipkinauthor=A.+K.+Curranauthor=D.+Lundellauthor=J.+S.+Fine&title=CXCR2+antagonists+for+the+treatment+of+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonists for the treatment of pulmonary disease</span></div><div class="casAuthors">Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chemokines have long been implicated in the initiation and amplification of inflammatory responses by virtue of their role in leukocyte chemotaxis.  The expression of one of the receptors for these chemokines, CXCR2, on a variety of cell types and tissues suggests that these receptors may have a broad functional role under both constitutive conditions and in the pathophysiol. of a no. of acute and chronic diseases.  With the development of several pharmacol., immunol. and genetic tools to study CXCR2 function, an important role for this CXC chemokine receptor subtype has been identified in chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.  Interference with CXCR2 receptor function has demonstrated different effects in the lungs including inhibition of pulmonary damage induced by neutrophils (PMNs), antigen or irritant-induced goblet cell hyperplasia and angiogenesis/collagen deposition caused by lung injury.  Many of these features are common to inflammatory and fibrotic disorders of the lung.  Clin. trials evaluating small mol. CXCR2 antagonists in COPD, asthma and cystic fibrosis are currently underway.  These studies hold considerable promise for identifying novel and efficacious treatments of pulmonary disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf1-c-1ciWrVg90H21EOLACvtfcHk0lhyrMxRxjt9hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ&md5=37a5047ab1b8a37739311d273dd7d854</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DCurran%26aufirst%3DA.%2BK.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DCXCR2%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D121%26spage%3D55%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Donnelly, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Chemokine receptor CXCR2 antagonism to prevent airways inflammation</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1358%2Fdof.2011.036.06.1622072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ShtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=465-472&author=L.+E.+Donnellyauthor=P.+J.+Barnes&title=Chemokine+receptor+CXCR2+antagonism+to+prevent+airways+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CXCR2 antagonism to prevent airways inflamation</span></div><div class="casAuthors">Donnelly, L. E.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Neutrophilic inflammation is assocd. with several pulmonary conditions, including chronic obstructive pulmonary disease (COPD), severe asthma and cystic fibrosis, and contributes to disease pathophysiol.  The underlying inflammation in each of these diseases is resistant to glucocorticosteroid therapy and is therefore persistent and difficult to treat.  The chemokine receptor CXCR2 is highly expressed on the surface of neutrophils and has been targeted by a no. of pharmaceutical companies as a potential antiinflammatory therapy.  CXCR2 receptor antagonists have been shown to inhibit neutrophil accumulation in a no. of preclin. models of pulmonary inflammation and show good selectivity in human cells ex vivo.  Few CXCR2 receptor antagonists have been reported in clin. trials, although SCH-527123 and SB-656933 have both been shown to be effective in reducing ozone-induced airways neutrophilia in healthy volunteers.  Studies are now under way in patients with COPD and preliminary data have indicated efficacy for SCH-527123.  Further studies on the effects of CXCR2 receptor antagonists are required; however, they appear to be promising, novel antiinflammatory therapies for a no. of pulmonary inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMuCzlrky8ALVg90H21EOLACvtfcHk0lhyrMxRxjt9hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ShtLvK&md5=5e515c7bd5f602ec293bc1b21b145fbe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.06.1622072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.06.1622072%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChemokine%2520receptor%2520CXCR2%2520antagonism%2520to%2520prevent%2520airways%2520inflammation%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D465%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansom, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R.</span><span> </span><span class="NLM_article-title">Inhibition of neutrophil chemokine receptor CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2012&pages=190-190&author=M.+Clarkeauthor=T.+Jamiesonauthor=C.+Steeleauthor=M.+Olsonauthor=M.+Samuelauthor=S.+Dasauthor=O.+Sansomauthor=R.+Nibbs&title=Inhibition+of+neutrophil+chemokine+receptor+CXCR2+profoundly+suppresses+inflammation-driven+and+spontaneous+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DJamieson%26aufirst%3DT.%26aulast%3DSteele%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DM.%26aulast%3DSamuel%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DSansom%26aufirst%3DO.%26aulast%3DNibbs%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520neutrophil%2520chemokine%2520receptor%2520CXCR2%2520profoundly%2520suppresses%2520inflammation-driven%2520and%2520spontaneous%2520tumorigenesis%26jtitle%3DImmunology%26date%3D2012%26volume%3D137%26spage%3D190%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumpian, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caetano, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la Garza, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapid, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirabolfathinejad, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, S. J.</span><span> </span><span class="NLM_article-title">Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1186%2F1476-4598-12-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=23418729" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=14&author=L.+Gongauthor=A.+M.+Cumpianauthor=M.+S.+Caetanoauthor=C.+E.+Ochoaauthor=M.+M.+De+la+Garzaauthor=D.+J.+Lapidauthor=S.+G.+Mirabolfathinejadauthor=B.+F.+Dickeyauthor=Q.+H.+Zhouauthor=S.+J.+Moghaddam&title=Promoting+effect+of+neutrophils+on+lung+tumorigenesis+is+mediated+by+CXCR2+and+neutrophil+elastase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-14%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DCumpian%26aufirst%3DA.%2BM.%26aulast%3DCaetano%26aufirst%3DM.%2BS.%26aulast%3DOchoa%26aufirst%3DC.%2BE.%26aulast%3DDe%2Bla%2BGarza%26aufirst%3DM.%2BM.%26aulast%3DLapid%26aufirst%3DD.%2BJ.%26aulast%3DMirabolfathinejad%26aufirst%3DS.%2BG.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DZhou%26aufirst%3DQ.%2BH.%26aulast%3DMoghaddam%26aufirst%3DS.%2BJ.%26atitle%3DPromoting%2520effect%2520of%2520neutrophils%2520on%2520lung%2520tumorigenesis%2520is%2520mediated%2520by%2520CXCR2%2520and%2520neutrophil%2520elastase%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma</span> <span class="citation_source-journal">Med. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2466</span><span class="NLM_x">–</span> <span class="NLM_lpage">2472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2Fs12032-011-0152-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22274915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2466-2472&author=L.+Hanauthor=B.+Jiangauthor=H.+Wuauthor=X.+D.+Wangauthor=X.+J.+Tangauthor=J.+F.+Huangauthor=J.+Zhu&title=High+expression+of+CXCR2+is+associated+with+tumorigenesis%2C+progression%2C+and+prognosis+of+laryngeal+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma</span></div><div class="casAuthors">Han, Liang; Jiang, Bin; Wu, Hao; Wang, Xudong; Tang, Xiaojun; Huang, Jianfei; Zhu, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2466-2472</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The laryngeal squamous cell carcinoma (LSCC) is one of the most common cancers threatening people's life.  CXC-chemokine receptor type 2 (CXCR2) was reported to play crit. roles in angiogenesis, tumorigenesis, and metastasis of several cancers such as colon cancer, melanoma, lung cancer, and so on.  However, the expression of CXCR2 in LSCC and its assocn. with clin. characters of LSCC remain unclear.  Quant. real-time reverse transcription-PCR and immunohistochem. were used, resp., to analyze the mRNA level and protein level of CXCR2 in 109 cases of LSCC tissues and 28 cases of tumor-adjacent normal tissues.  The expression of CXCR2 in LSCC was significantly higher than that in tumor-adjacent tissues.  Moreover, the expression level of CXCR2 protein in LSCC was significantly related to lymph node metastasis (P = .022), histopathol. grade (P = .038), and 5 years' survival (P = .007).  Cox regression anal. revealed that CXCR2 expression (P = .031), as well as lymphatic metastasis (P = .026) and TNM classification (P = .042), is an independent prognostic marker of LSCC.  High expression of CXCR2 is also assocd. with short survival of LSCC patients.  Our data indicate that the expression of CXCR2 is assocd. with the development and progression of LSCC.  CXCR2 expression may serve as an independent prognostic marker for LSCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOmgyHIlOCU7Vg90H21EOLACvtfcHk0liGxYtUEcS14A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqt7fN&md5=1981ff72be9fb1a993cc5976ef108020</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12032-011-0152-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-011-0152-1%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%2BD.%26aulast%3DTang%26aufirst%3DX.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DHigh%2520expression%2520of%2520CXCR2%2520is%2520associated%2520with%2520tumorigenesis%252C%2520progression%252C%2520and%2520prognosis%2520of%2520laryngeal%2520squamous%2520cell%2520carcinoma%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26spage%3D2466%26epage%3D2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Jamieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansom, O. J.</span><span> </span><span class="NLM_article-title">Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=3127-3144&author=T.+Jamiesonauthor=M.+Clarkeauthor=C.+W.+Steeleauthor=M.+S.+Samuelauthor=J.+Neumannauthor=A.+Jungauthor=D.+Huelsauthor=M.+F.+Olsonauthor=S.+Dasauthor=R.+J.+B.+Nibbsauthor=O.+J.+Sansom&title=Inhibition+of+CXCR2+profoundly+suppresses+inflammation-driven+and+spontaneous+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DT.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DSteele%26aufirst%3DC.%2BW.%26aulast%3DSamuel%26aufirst%3DM.%2BS.%26aulast%3DNeumann%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DHuels%26aufirst%3DD.%26aulast%3DOlson%26aufirst%3DM.%2BF.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26atitle%3DInhibition%2520of%2520CXCR2%2520profoundly%2520suppresses%2520inflammation-driven%2520and%2520spontaneous%2520tumorigenesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D3127%26epage%3D3144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Katoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daikoku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dey, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, R. N.</span><span> </span><span class="NLM_article-title">CXCR2-Expressing Myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=631-644&author=H.+Katohauthor=D.+Z.+Wangauthor=T.+Daikokuauthor=H.+Y.+Sunauthor=S.+K.+Deyauthor=R.+N.+DuBois&title=CXCR2-Expressing+Myeloid-derived+suppressor+cells+are+essential+to+promote+colitis-associated+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BZ.%26aulast%3DDaikoku%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DDey%26aufirst%3DS.%2BK.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DCXCR2-Expressing%2520Myeloid-derived%2520suppressor%2520cells%2520are%2520essential%2520to%2520promote%2520colitis-associated%2520tumorigenesis%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26spage%3D631%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Balkwill, F. R.</span><span> </span><span class="NLM_article-title">The chemokine system and cancer</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fpath.3029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=21989643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=148-157&author=F.+R.+Balkwill&title=The+chemokine+system+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine system and cancer</span></div><div class="casAuthors">Balkwill, Frances R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-157</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemokines (chemo-attractant cytokines) are a group of small proteins that act together with their cell surface receptors, in development, normal physiol. and immune responses, to direct cells to specific locations throughout the body.  Cancer cells acquire the ability to subvert the chemokine system, such that these mols. and their receptors become important regulators of cell movement into and out of the tumor microenvironment and major players in cancer biol.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmfqm_WcXk_7Vg90H21EOLACvtfcHk0lhSiPjDqRCcWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3K&md5=6df65c653856e9cd5cca4f028123e4ac</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fpath.3029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3029%26sid%3Dliteratum%253Aachs%26aulast%3DBalkwill%26aufirst%3DF.%2BR.%26atitle%3DThe%2520chemokine%2520system%2520and%2520cancer%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D148%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.2174%2F15680266106061345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16918453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1345-1352&author=J.+Busch-Petersen&title=Small+molecule+antagonists+of+the+CXCR2+and+CXCR1+chemokine+receptors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Busch-Petersen, Jakob</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1352</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past eight years, numerous series of small mol. CXCR2 and CXCR1 antagonists have been disclosed.  These compds. have proved to be effective inhibitors of ELR+ chemokine-induced chemotaxis of neutrophils and other immune cells in vitro and have also been efficacious in several animal models of inflammatory disease.  Although some of these compds. have been reported to be in clin. development, no data on clin. studies in patients with inflammatory disease has been revealed to date.  This review details the medicinal chem. and pharmacol. of the aforementioned antagonist series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCATg8ZJMoxLVg90H21EOLACvtfcHk0lhSiPjDqRCcWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D&md5=0054b0053f9a9a45adeac60677960085</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F15680266106061345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266106061345%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520CXCR2%2520and%2520CXCR1%2520chemokine%2520receptors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1345%26epage%3D1352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bello, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantucci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4312</span><span class="NLM_x">–</span> <span class="NLM_lpage">4331</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049082i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4312-4331&author=M.+Allegrettiauthor=R.+Bertiniauthor=M.+C.+Cestaauthor=C.+Bizzarriauthor=R.+Di+Bitondoauthor=V.+Di+Cioccioauthor=E.+Gallieraauthor=V.+Berdiniauthor=A.+Topaiauthor=G.+Zampellaauthor=V.+Russoauthor=N.+Di+Belloauthor=G.+Nanoauthor=L.+Nicoliniauthor=M.+Locatiauthor=P.+Fantucciauthor=S.+Florioauthor=F.+Colotta&title=2-Arylpropionic+CXC+chemokine+receptor+1+%28CXCR1%29+ligands+as+novel+noncompetitive+CXCL8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm049082i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049082i%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DTopai%26aufirst%3DA.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DV.%26aulast%3DDi%2BBello%26aufirst%3DN.%26aulast%3DNano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DL.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DFantucci%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3D2-Arylpropionic%2520CXC%2520chemokine%2520receptor%25201%2520%2528CXCR1%2529%2520ligands%2520as%2520novel%2520noncompetitive%2520CXCL8%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4312%26epage%3D4331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriconi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervellera, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anniballe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anacardio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutrin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalieri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainiero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strippoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Girolamo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghezzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">11791</span><span class="NLM_x">–</span> <span class="NLM_lpage">11796</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11791-11796&author=R.+Bertiniauthor=M.+Allegrettiauthor=C.+Bizzarriauthor=A.+Moriconiauthor=M.+Locatiauthor=G.+Zampellaauthor=M.+N.+Cervelleraauthor=V.+Di+Cioccioauthor=M.+C.+Cestaauthor=E.+Gallieraauthor=F.+O.+Martinezauthor=R.+Di+Bitondoauthor=G.+Troianiauthor=V.+Sabbatiniauthor=G.+D%E2%80%99Anniballeauthor=R.+Anacardioauthor=J.+C.+Cutrinauthor=B.+Cavalieriauthor=F.+Mainieroauthor=R.+Strippoliauthor=P.+Villaauthor=M.+Di+Girolamoauthor=F.+Martinauthor=M.+Gentileauthor=A.+Santoniauthor=D.+Cordaauthor=G.+Poliauthor=A.+Mantovaniauthor=P.+Ghezziauthor=F.+Colotta&title=Noncompetitive+allosteric+inhibitors+of+the+inflammatory+chemokine+receptors+CXCR1+and+CXCR2%3A+Prevention+of+reperfusion+injury"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DTroiani%26aufirst%3DG.%26aulast%3DSabbatini%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Anniballe%26aufirst%3DG.%26aulast%3DAnacardio%26aufirst%3DR.%26aulast%3DCutrin%26aufirst%3DJ.%2BC.%26aulast%3DCavalieri%26aufirst%3DB.%26aulast%3DMainiero%26aufirst%3DF.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DDi%2BGirolamo%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DGentile%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCorda%26aufirst%3DD.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3DNoncompetitive%2520allosteric%2520inhibitors%2520of%2520the%2520inflammatory%2520chemokine%2520receptors%2520CXCR1%2520and%2520CXCR2%253A%2520Prevention%2520of%2520reperfusion%2520injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D11791%26epage%3D11796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">10095</span><span class="NLM_x">–</span> <span class="NLM_lpage">10098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=9553055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span></div><div class="casAuthors">White, John R.; Lee, Judithann M.; Young, Peter R.; Hertzberg, Robert P.; Jurewicz, Anthony J.; Chaikin, Margery A.; Widdowson, Katherine; Foley, James J.; Martin, Lenox D.; Griswold, Don E.; Sarau, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10095-10098</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) and closely related Glu-Leu-Arg (ELR) contg. CXC chemokines, including growth-related oncogene (GRO)α, GROβ, GROγ, and epithelial cell-derived neutrophil-activating peptide-78 (ENA-78), are potent neutrophil chemotactic and activating peptides, which are proposed to be major mediators of inflammation.  IL-8 activates neutrophils by binding to two distinct seven-transmembrane (7-TMR) G-protein coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROα, GROβ, GROγ, and ENA-78 bind to and activate only CXCR2.  A chem. lead, which selectively inhibited CXCR2 was discovered by high throughput screening and chem. optimized.  SB 225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea) is the first reported potent and selective non-peptide inhibitor of a chemokine receptor.  It is an antagonist of 125I-IL-8 binding to CXCR2 with an IC50 = 22 nM.  SB 225002 showed > 150-fold selectivity over CXCR1 and four other 7-TMRs tested.  In vitro, SB 225002 potently inhibited human and rabbit neutrophil chemotaxis induced by both IL-8 and GROα.  In vivo, SB 225002 selectively blocked IL-8-induced neutrophil margination in rabbits.  The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8.  This selective antagonist will be a useful tool compd. to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO6PNyFAVGW7Vg90H21EOLACvtfcHk0ljy3WMUx47crw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D&md5=28b894f2ff3672653a92f3ff5230d1ac</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D10095%26epage%3D10098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Podolin, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognese, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">6435</span><span class="NLM_x">–</span> <span class="NLM_lpage">6444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=6435-6444&author=P.+L.+Podolinauthor=B.+J.+Bologneseauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=P.+T.+Buckleyauthor=K.+L.+Widdowsonauthor=Q.+Jinauthor=J.+R.+Whiteauthor=J.+M.+Leeauthor=R.+B.+Goodmanauthor=T.+R.+Hagenauthor=O.+Kajikawaauthor=L.+A.+Marshallauthor=D.+W.+Hayauthor=H.+M.+Sarau&title=A+potent+and+selective+nonpeptide+antagonist+of+CXCR2+inhibits+acute+and+chronic+models+of+arthritis+in+the+rabbit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DGoodman%26aufirst%3DR.%2BB.%26aulast%3DHagen%26aufirst%3DT.%2BR.%26aulast%3DKajikawa%26aufirst%3DO.%26aulast%3DMarshall%26aufirst%3DL.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DA%2520potent%2520and%2520selective%2520nonpeptide%2520antagonist%2520of%2520CXCR2%2520inhibits%2520acute%2520and%2520chronic%2520models%2520of%2520arthritis%2520in%2520the%2520rabbit%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26spage%3D6435%26epage%3D6444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Traves, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1189%2Fjlb.1003495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15155777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=441-450&author=S.+L.+Travesauthor=S.+J.+Smithauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Specific+CXC+but+not+CC+chemokines+cause+elevated+monocyte+migration+in+COPD%3A+A+role+for+CXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span></div><div class="casAuthors">Traves, Suzanne L.; Smith, Susan J.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Leukocyte migration is crit. to maintaining host defense, but uncontrolled cellular infiltration into tissues can lead to chronic inflammation.  In the lung, such diseases include chronic obstructive pulmonary disease (COPD), a debilitating, respiratory condition characterized by progressive and largely irreversible airflow limitation for which cigarette smoking is the major risk factor.  COPD is assocd. with an increased inflammatory cell influx including increased macrophage nos. in the airways and tissue.  Alveolar macrophages develop from immigrating blood monocytes and have the capacity to cause the pathol. changes assocd. with COPD.  This study addressed the hypothesis that increased macrophage nos. in COPD are a result of increased recruitment of monocytes from the circulation.  Chemotaxis assays of peripheral blood mononuclear cells (PBMC)/monocytes from nonsmokers, smokers, and COPD patients demonstrated increased chemotactic responses for cells from COPD patients when compared with controls toward growth-related oncogene (GRO)α and neutrophil-activating peptide (NAP)-2 but not toward monocyte chemoattractant protein, interleukin-8, or epithelial-derived NAP(ENA)-78.  The enhanced chemotactic response toward GROα and NAP-2 was not mediated by differences in expression of their cellular receptors, CXCR1 or CXCR2.  Receptor expression studies using flow cytometry indicated that in COPD, monocyte expression of CXCR2 is regulated differently from nonsmokers and smokers, which may account for the enhanced migration toward GROα and NAP-2.  The results highlight the potential of CXCR2 antagonists as therapy for COPD and demonstrate that an enhanced PBMC/monocyte response to specific CXC chemokines in these patients may contribute to increased recruitment and activation of macrophages in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99e2ZPsnEhrVg90H21EOLACvtfcHk0ljy3WMUx47crw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D&md5=96ff850e7ae1ffaa342c196b785380ac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003495%26sid%3Dliteratum%253Aachs%26aulast%3DTraves%26aufirst%3DS.%2BL.%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DSpecific%2520CXC%2520but%2520not%2520CC%2520chemokines%2520cause%2520elevated%2520monocyte%2520migration%2520in%2520COPD%253A%2520A%2520role%2520for%2520CXCR2%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D76%26spage%3D441%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biju, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Ezel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terminelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozgur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7603</span><span class="NLM_x">–</span> <span class="NLM_lpage">7606</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0609622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7603-7606&author=M.+P.+Dwyerauthor=Y.+Yuauthor=J.+Chaoauthor=C.+Akiauthor=P.+Bijuauthor=V.+Girijavallabhanauthor=D.+Rindgenauthor=R.+Bondauthor=R.+Mayer-Ezelauthor=J.+Jakwayauthor=R.+W.+Hipkinauthor=J.+Fossettaauthor=W.+Gonsiorekauthor=H.+Bianauthor=X.+Fanauthor=C.+Terminelliauthor=J.+Fineauthor=D.+Lundellauthor=J.+R.+Merrittauthor=L.+L.+Rokoszauthor=B.+Kaiserauthor=G.+Liauthor=W.+Wangauthor=T.+Staufferauthor=L.+Ozgurauthor=J.+Baldwinauthor=A.+G.+Taveras&title=Discovery+of+2-hydroxy-N%2CN-dimethyl-3-%7B2-%5B%5B%28R%29-1-%285-methylfuran-2-yl%29propyl%5Damino%5D-3%2C4-dioxocyclobut-1-enylamino%7Dbenzamide+%28SCH+527123%29%3A+A+potent%2C+orally+bioavailable+CXCR2%2FCXCR1+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0609622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609622%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DBiju%26aufirst%3DP.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DMayer-Ezel%26aufirst%3DR.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DTerminelli%26aufirst%3DC.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DStauffer%26aufirst%3DT.%26aulast%3DOzgur%26aufirst%3DL.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-hydroxy-N%252CN-dimethyl-3-%257B2-%255B%255B%2528R%2529-1-%25285-methylfuran-2-yl%2529propyl%255Damino%255D-3%252C4-dioxocyclobut-1-enylamino%257Dbenzamide%2520%2528SCH%2520527123%2529%253A%2520A%2520potent%252C%2520orally%2520bioavailable%2520CXCR2%252FCXCR1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7603%26epage%3D7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Aul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plumb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span> </span><span class="NLM_article-title">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.intimp.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22561413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-231&author=R.+Aulauthor=S.+Patelauthor=S.+Summerhillauthor=I.+Kiltyauthor=J.+Plumbauthor=D.+Singh&title=LPS+challenge+in+healthy+subjects%3A+An+investigation+of+neutrophil+chemotaxis+mechanisms+involving+CXCR1+and+CXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span></div><div class="casAuthors">Aul, Raminder; Patel, Sheena; Summerhill, Susan; Kilty, Iain; Plumb, Jonathan; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process.14 healthy non-smoking subjects inhaled 30 μg of LPS.  Sputum was induced at baseline, 6 and 24 h post-LPS challenge.  Differential cell counts were detd. and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured.  Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis expts. using sputum supernatant.  To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested.  LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24 h resp.  LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1.  Neutrophil chemotaxis significantly increased (2.7 fold) at 24 h compared to baseline.  Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933.  We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is assocd. with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBzkQc4_KA7Vg90H21EOLACvtfcHk0ljzyjER0P8h1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D&md5=c196cbe3264f545d5e2d90b1b95a6c05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAul%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DLPS%2520challenge%2520in%2520healthy%2520subjects%253A%2520An%2520investigation%2520of%2520neutrophil%2520chemotaxis%2520mechanisms%2520involving%2520CXCR1%2520and%2520CXCR2%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2012%26volume%3D13%26spage%3D225%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexis, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits <i>ex vivo</i> neutrophil activation and ozone-induced airway inflammation in humans</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0ljzyjER0P8h1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Moss, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilewski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Investigators, C. F.</span><span> </span><span class="NLM_article-title">Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.jcf.2012.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22995323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2lu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=241-248&author=R.+B.+Mossauthor=S.+J.+Mistryauthor=M.+W.+Konstanauthor=J.+M.+Pilewskiauthor=E.+Keremauthor=R.+Tal-Singerauthor=A.+L.+Lazaarauthor=C.+F.+Investigators&title=Safety+and+early+treatment+effects+of+the+CXCR2+antagonist+SB-656933+in+patients+with+cystic+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis</span></div><div class="casAuthors">Moss, Richard B.; Mistry, Sunil J.; Konstan, Michael W.; Pilewski, Joseph M.; Kerem, Eitan; Tal-Singer, Ruth; Lazaar, Aili L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is hypothesized that a CXCR2 receptor antagonist would inhibit the recruitment and activation of neutrophils and other inflammatory cells into the lung in subjects with cystic fibrosis.  The objective of this study was to evaluate the safety, tolerability and pharmacodynamics of SB-656933, an oral CXCR2 antagonist.146 adult CF patients were randomized to receive either placebo or SB-656933 20 mg or 50 mg once daily for 28 days.  The primary endpoint was safety; secondary endpoints included pharmacokinetics, blood and sputum biomarkers, sputum microbiol., pulmonary function and respiratory symptoms.  SB-656933 was generally well tolerated.  The most frequent adverse event was headache.  Five subjects were withdrawn due to adverse events.  In subjects receiving SB-656933 50 mg, sputum neutrophils and elastase were reduced compared to baseline (probability of a true redn., 0.889 and 0.882 resp.), and free DNA reduced compared to placebo (probability of a true redn., 0.967), while blood levels of fibrinogen, CRP and CXCL8 were increased.  There were no changes in lung function or respiratory symptoms.  Av. plasma concns. of SB-656933 were lower than predicted based on previous studies, only breaching IC50 for ∼ 4 h at the 50 mg dose.  SB-656933 was well-tolerated in adult patients with cystic fibrosis.  Patients receiving a daily dose of 50 mg showed trends for improvement in sputum inflammatory biomarkers despite potential blunting of effects by lower than expected plasma concns.  Although the increase in systemic inflammatory markers requires further evaluation, CXCR2 antagonism may be a useful approach for modulating airway inflammation in patients with cystic fibrosis.  Clin. trial registered with www.clinicaltrials.gov (NCT00903201).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQVyIOt9Ix6LVg90H21EOLACvtfcHk0lgMdlb1m3Ek0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2lu7s%253D&md5=6ac4fe6aea45ac5b1d5b043f24e4f20a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2012.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2012.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DR.%2BB.%26aulast%3DMistry%26aufirst%3DS.%2BJ.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DPilewski%26aufirst%3DJ.%2BM.%26aulast%3DKerem%26aufirst%3DE.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DInvestigators%26aufirst%3DC.%2BF.%26atitle%3DSafety%2520and%2520early%2520treatment%2520effects%2520of%2520the%2520CXCR2%2520antagonist%2520SB-656933%2520in%2520patients%2520with%2520cystic%2520fibrosis%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2013%26volume%3D12%26spage%3D241%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Holz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalilieh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig-Sengpiel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryszak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 × 106 mL-1) compared with prednisolone (0.84 × 106/mL-1; p < 0.001) or placebo (2.98 × 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0lgMdlb1m3Ek0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D564%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. N.</span><span> </span><span class="NLM_article-title">CXCR2 modulators: a patent review (2009–2013)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1517%2F13543776.2014.887682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=24555661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=519-534&author=M.+P.+Dwyerauthor=Y.+N.+Yu&title=CXCR2+modulators%3A+a+patent+review+%282009%E2%80%932013%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 modulators: a patent review (2009 - 2013)</span></div><div class="casAuthors">Dwyer, Michael P.; Yu, Younong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-534</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Small-mol. antagonists of CXC chemokine receptor 2 (CXCR2) have attracted a considerable amt. of attention due to the key central role that this receptor plays in inflammatory conditions.  Recently, several CXCR2 receptor antagonists have demonstrated promising proof of activity in early pulmonary clin. trials, which has stimulated addnl. efforts to identify new CXCR2 receptor antagonists.  Areas covered: During the period 2009 - 2013, there were numerous patent publications from various companies claiming the discovery of novel CXCR2 receptor antagonists.  Herein, an interpretation of these new patent publications combined with emerging disclosures from the peer-reviewed literature during this time frame is given.  This review highlights the preferred or representative compds. from the patent applications along with relevant biol. characterization.  Expert opinion: Many of the new CXCR2 receptor antagonists described in this review represent closely related analogs to previously disclosed clin. candidates.  With the recent discontinuation of several CXCR2 receptor antagonists in the clinic, addnl. clin. trial information for CXCR2 receptor antagonists, both past and present, will det. the long-term therapeutic potential of these compds. for the treatment of a variety of inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLzyTSdxdHbVg90H21EOLACvtfcHk0lgMdlb1m3Ek0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D&md5=c1b5bd8730268cd12851722a3880a118</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.887682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.887682%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%2BN.%26atitle%3DCXCR2%2520modulators%253A%2520a%2520patent%2520review%2520%25282009%25E2%2580%25932013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D519%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Virtala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekman, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardell, L. O.</span><span> </span><span class="NLM_article-title">Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2222.2011.03921.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22192144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVentbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=590-596&author=R.+Virtalaauthor=A.+K.+Ekmanauthor=L.+Janssonauthor=U.+Westinauthor=L.+O.+Cardell&title=Airway+inflammation+evaluated+in+a+human+nasal+lipopolysaccharide+challenge+model+by+investigating+the+effect+of+a+CXCR2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor</span></div><div class="casAuthors">Virtala, R.; Ekman, A.-K.; Jansson, L.; Westin, U.; Cardell, L. O.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-596</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The existence of a link between inflammation in upper and lower airways is well established.  It may therefore be assumed that the nose could be used to study inflammatory events in the lower airways.  Objective: This study aimed to evaluate a lipopolysaccharide (LPS) nasal challenge model by investigating the effect of the CXCR2 inhibitor AZD8309 on neutrophilic inflammation.  Methods: A total of 18 healthy volunteers were randomized in a placebo-controlled, double-blind, cross-over study.  AZD8309 or placebo was dosed for 3 days.  Subjects were challenged nasally with LPS (50 μg/nostril), and nasal lavage was performed 6 and 24 h later.  Leukocytes, neutrophils and inflammatory mediators were assessed in the lavage fluid.  The outcome was compared with data from analogous expts. performed in a model of inhaled LPS followed by induced sputum.  This trial was registered in the Current Controlled Trials register (ISRCTN trial no.: ISRCTN46666382).  Results: The leukocytes in nasal lavage consisted to 99% of neutrophils on av.  Treatment with AZD8309 reduced the leukocyte count to 48% of placebo 6 h after the LPS challenge.  There was also a redn. in LTB4 levels to 45% of placebo after 6 h and in the neutrophil elastase activity after 24 h.  No major adverse events were seen with either AZD8309 or placebo.  The nasal LPS model induced only minimal local irritation and no signs of systemic inflammation.  Conclusions and Clin. Relevance: LPS-induced neutrophil recruitment was reduced by inhibition of CXCR2.  This outcome mimicked the response previously seen in a lower airway LPS model.  Hence, the nasal model offers a convenient and well-tolerated alternative for pharmacol. evaluation of anti-inflammatory drugs affecting neutrophilic migration and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfyFgE2oSUDbVg90H21EOLACvtfcHk0lg2K1Fk29y58w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVentbw%253D&md5=b7829eb66040540a01997baaba10c43b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2011.03921.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2011.03921.x%26sid%3Dliteratum%253Aachs%26aulast%3DVirtala%26aufirst%3DR.%26aulast%3DEkman%26aufirst%3DA.%2BK.%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DWestin%26aufirst%3DU.%26aulast%3DCardell%26aufirst%3DL.%2BO.%26atitle%3DAirway%2520inflammation%2520evaluated%2520in%2520a%2520human%2520nasal%2520lipopolysaccharide%2520challenge%2520model%2520by%2520investigating%2520the%2520effect%2520of%2520a%2520CXCR2%2520inhibitor%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2012%26volume%3D42%26spage%3D590%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Cutshall, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, N. C.</span><span> </span><span class="NLM_article-title">Nicotinanilides as inhibitors of neutrophil chemotaxis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1517-1520&author=N.+S.+Cutshallauthor=K.+A.+Kuceraauthor=R.+Ursinoauthor=J.+Lathamauthor=N.+C.+Ihle&title=Nicotinanilides+as+inhibitors+of+neutrophil+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCutshall%26aufirst%3DN.%2BS.%26aulast%3DKucera%26aufirst%3DK.%2BA.%26aulast%3DUrsino%26aufirst%3DR.%26aulast%3DLatham%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DN.%2BC.%26atitle%3DNicotinanilides%2520as%2520inhibitors%2520of%2520neutrophil%2520chemotaxis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1517%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Maeda, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schepetkin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotina, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zebala, J. A.</span><span> </span><span class="NLM_article-title">Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.109.159020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19779130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=145-152&author=D.+Y.+Maedaauthor=M.+T.+Quinnauthor=I.+A.+Schepetkinauthor=L.+N.+Kirpotinaauthor=J.+A.+Zebala&title=Nicotinamide+glycolates+antagonize+CXCR2+activity+through+an+intracellular+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism</span></div><div class="casAuthors">Maeda, Dean Y.; Quinn, Mark T.; Schepetkin, Igor A.; Kirpotina, Liliya N.; Zebala, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease.  Several classes of allosteric small-mol. CXCR1/2 antagonists have been developed.  The data presented here describe the cellular pharmacol. of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8.  Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/CXCR2 binding and CXCL1-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange.  Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125I-CXCL8/CXCR2 binding and CXCL1-stimulated [35S]GTPγS exchange.  The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process.  The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior.  Neutrophil efflux of the acid was probenecid-sensitive, consistent with an org. acid transporter.  These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site.  Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI_AT4uMMh7Vg90H21EOLACvtfcHk0lg2K1Fk29y58w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yqsw%253D%253D&md5=8b86e6eca136c2884f6267085ebe0779</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.159020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.159020%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DNicotinamide%2520glycolates%2520antagonize%2520CXCR2%2520activity%2520through%2520an%2520intracellular%2520mechanism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26spage%3D145%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Webb, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span> </span><span class="NLM_article-title">A facile oxidation of boronic acids and boronic esters</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">5117</span><span class="NLM_x">–</span> <span class="NLM_lpage">5118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=5117-5118&author=K.+S.+Webbauthor=D.+Levy&title=A+facile+oxidation+of+boronic+acids+and+boronic+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DK.%2BS.%26aulast%3DLevy%26aufirst%3DD.%26atitle%3DA%2520facile%2520oxidation%2520of%2520boronic%2520acids%2520and%2520boronic%2520esters%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D5117%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wittenberger, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, B. G.</span><span> </span><span class="NLM_article-title">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4139</span><span class="NLM_x">–</span> <span class="NLM_lpage">4141</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=4139-4141&author=S.+J.+Wittenbergerauthor=B.+G.+Donner&title=Dialkyltin+oxide+mediated+addition+of+trimethylsilyl+azide+to+nitriles.+A+novel+preparation+of+5-substituted+tetrazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a058%26sid%3Dliteratum%253Aachs%26aulast%3DWittenberger%26aufirst%3DS.%2BJ.%26aulast%3DDonner%26aufirst%3DB.%2BG.%26atitle%3DDialkyltin%2520oxide%2520mediated%2520addition%2520of%2520trimethylsilyl%2520azide%2520to%2520nitriles.%2520A%2520novel%2520preparation%2520of%25205-substituted%2520tetrazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D4139%26epage%3D4141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Hunter, P.</span><span> </span><span class="NLM_article-title">Not boring at all Boron is the new carbon in the quest for novel drug candidates</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">U110</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-U110&author=P.+Hunter&title=Not+boring+at+all+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3DU110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Yang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. H.</span><span> </span><span class="NLM_article-title">Boronic acid compounds as potential pharmaceutical agents</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fmed.10043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12647314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=346-368&author=W.+Q.+Yangauthor=X.+M.+Gaoauthor=B.+H.+Wang&title=Boronic+acid+compounds+as+potential+pharmaceutical+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic acid compounds as potential pharmaceutical agents</span></div><div class="casAuthors">Yang, Wenqian; Gao, Xingming; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-368</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Boronic acid compds. have been used, because of their unique structural features, for the development of potent enzyme inhibitors, boron neutron capture agents for cancer therapy, and as antibody mimics that recognize biol. important saccharides.  Consequently, there has been a surge of interests in boronic acid compds.  This study reviews the recent development in this area during the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CvJjV10BbVg90H21EOLACvtfcHk0lg2K1Fk29y58w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D&md5=0b841477e2113218d55991e23133bd60</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fmed.10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10043%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DGao%26aufirst%3DX.%2BM.%26aulast%3DWang%26aufirst%3DB.%2BH.%26atitle%3DBoronic%2520acid%2520compounds%2520as%2520potential%2520pharmaceutical%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D346%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hall, D. G.</span> <span class="citation_source-book">Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine</span>; <span class="NLM_publisher-name">WILEY-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2F3527606548" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+G.+Hall&title=Boronic+Acids%3A+Preparation+and+Applications+in+Organic+Synthesis+and+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2F3527606548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527606548%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%2BG.%26btitle%3DBoronic%2520Acids%253A%2520Preparation%2520and%2520Applications%2520in%2520Organic%2520Synthesis%2520and%2520Medicine%26pub%3DWILEY-VCH%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Cutshall, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, N. C.</span><span> </span><span class="NLM_article-title">Nicotinamide N-oxides as CXCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1951-1954&author=N.+S.+Cutshallauthor=R.+Ursinoauthor=K.+A.+Kuceraauthor=J.+Lathamauthor=N.+C.+Ihle&title=Nicotinamide+N-oxides+as+CXCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCutshall%26aufirst%3DN.%2BS.%26aulast%3DUrsino%26aufirst%3DR.%26aulast%3DKucera%26aufirst%3DK.%2BA.%26aulast%3DLatham%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DN.%2BC.%26atitle%3DNicotinamide%2520N-oxides%2520as%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1951%26epage%3D1954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1038%2Fnrd746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12120504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFCltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=198-210&author=A.+Christopoulos&title=Allosteric+binding+sites+on+cell-surface+receptors%3A+Novel+targets+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric binding sites on cell-surface receptors: novel targets for drug discovery</span></div><div class="casAuthors">Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-210</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cell-surface receptors are the targets for more than 60% of current drugs.  Traditionally, optimizing the interaction of lead mols. with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action.  However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor mol. that are distinct from the orthosteric site, known as allosteric sites.  Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gwh2HPhjn7Vg90H21EOLACvtfcHk0ljNrNYg_bocjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFCltrc%253D&md5=10f885e2f54f745d9b7dcbf2c6cc583f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd746%26sid%3Dliteratum%253Aachs%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520binding%2520sites%2520on%2520cell-surface%2520receptors%253A%2520Novel%2520targets%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D198%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">de Kruijf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Heteren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Lee, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auld, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkmans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">329</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.108.148387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19190236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=783-790&author=P.+de+Kruijfauthor=J.+van+Heterenauthor=H.+D.+Limauthor=P.+G.+Contiauthor=M.+M.+van+der+Leeauthor=L.+Boschauthor=K.+K.+Hoauthor=D.+Auldauthor=M.+Ohlmeyerauthor=M.+J.+Smitauthor=J.+C.+Wijkmansauthor=G.+J.+Zamanauthor=M.+J.+Smitauthor=R.+Leurs&title=Nonpeptidergic+allosteric+antagonists+differentially+bind+to+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor</span></div><div class="casAuthors">de Kruijf, Petra; van Heteren, Jane; Lim, Herman D.; Conti, Paolo G. M.; van der Lee, Miranda M. C.; Bosch, Leontien; Ho, Koc-Kan; Auld, Douglas; Ohlmeyer, Michael; Smit, Martin J.; Wijkmans, Jac C. H. M.; Zaman, Guido J. R.; Smit, Martine J.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine receptor CXCR2 is involved in different inflammatory diseases, like chronic obstructive pulmonary disease, psoriasis, rheumatoid arthritis, and ulcerative colitis; therefore, it is considered an attractive drug target.  Different classes of small CXCR2 antagonists have been developed.  In this study, seven CXCR2 antagonists were selected from the diarylurea, imidazolylpyrimide, and thiazolopyrimidine class and their mechanisms of action at human CXCR2 were studied.  All compds. are able to displace 125I-CXCL8 and inhibit CXCL8-induced β-arrestin2 recruitment.  Detailed studies with representatives of each class showed that these compds. displace and antagonize CXCL8, most probably via a non-competitive, allosteric mechanism.  In addn., the high-affinity CXCR2 antagonist SB265610 [1-(2-bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]-triazol-7-yl)urea] was radiolabeled and [3H]SB265610 was subjected to a detailed anal.  The binding of this radioligand was saturable and reversible.  Using [3H]SB265610, it was found that compds. of the different chem. classes bind to distinct binding sites.  Hence, the use of a radiolabeled low-mol. wt. CXCR2 antagonist serves as a tool to investigate the different binding sites of CXCR2 antagonists in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk1OTdlwM-sLVg90H21EOLACvtfcHk0ljNrNYg_bocjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1OlsLs%253D&md5=cdb5fcac62aa5c0cc1fff0b66f81557a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.148387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.148387%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKruijf%26aufirst%3DP.%26aulast%3Dvan%2BHeteren%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DConti%26aufirst%3DP.%2BG.%26aulast%3Dvan%2Bder%2BLee%26aufirst%3DM.%2BM.%26aulast%3DBosch%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DK.%2BK.%26aulast%3DAuld%26aufirst%3DD.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3DWijkmans%26aufirst%3DJ.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DNonpeptidergic%2520allosteric%2520antagonists%2520differentially%2520bind%2520to%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mueller, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schraw, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, A.</span><span> </span><span class="NLM_article-title">Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">8207</span><span class="NLM_x">–</span> <span class="NLM_lpage">8214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=8207-8214&author=S.+G.+Muellerauthor=J.+R.+Whiteauthor=W.+P.+Schrawauthor=V.+Lamauthor=A.+Richmond&title=Ligand-induced+desensitization+of+the+human+CXC+chemokine+receptor-2+is+modulated+by+multiple+serine+residues+in+the+carboxyl-terminal+domain+of+the+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DS.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DSchraw%26aufirst%3DW.%2BP.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DRichmond%26aufirst%3DA.%26atitle%3DLigand-induced%2520desensitization%2520of%2520the%2520human%2520CXC%2520chemokine%2520receptor-2%2520is%2520modulated%2520by%2520multiple%2520serine%2520residues%2520in%2520the%2520carboxyl-terminal%2520domain%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D8207%26epage%3D8214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Shyamala, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoja, H.</span><span> </span><span class="NLM_article-title">Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">15918</span><span class="NLM_x">–</span> <span class="NLM_lpage">15924</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi9811415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=15918-15924&author=V.+Shyamalaauthor=H.+Khoja&title=Interleukin-8+receptors+R1+and+R2+activate+mitogen-activated+protein+kinases+and+induce+c-fos%2C+independent+of+Ras+and+Raf-1+in+Chinese+hamster+ovary+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fbi9811415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9811415%26sid%3Dliteratum%253Aachs%26aulast%3DShyamala%26aufirst%3DV.%26aulast%3DKhoja%26aufirst%3DH.%26atitle%3DInterleukin-8%2520receptors%2520R1%2520and%2520R2%2520activate%2520mitogen-activated%2520protein%2520kinases%2520and%2520induce%2520c-fos%252C%2520independent%2520of%2520Ras%2520and%2520Raf-1%2520in%2520Chinese%2520hamster%2520ovary%2520cells%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D15918%26epage%3D15924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Hammond, M. E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullenbach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekampolson, P.</span><span> </span><span class="NLM_article-title">IL-8 induces neutrophil chemotaxis predominantly via type-I IL-8 receptors</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">1428</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=1428-1433&author=M.+E.+W.+Hammondauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=S.+Hiltauthor=C.+A.+Gallegosauthor=C.+A.+Gordonauthor=M.+A.+Giedlinauthor=G.+Mullenbachauthor=P.+Tekampolson&title=IL-8+induces+neutrophil+chemotaxis+predominantly+via+type-I+IL-8+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DM.%2BE.%2BW.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DHilt%26aufirst%3DS.%26aulast%3DGallegos%26aufirst%3DC.%2BA.%26aulast%3DGordon%26aufirst%3DC.%2BA.%26aulast%3DGiedlin%26aufirst%3DM.%2BA.%26aulast%3DMullenbach%26aufirst%3DG.%26aulast%3DTekampolson%26aufirst%3DP.%26atitle%3DIL-8%2520induces%2520neutrophil%2520chemotaxis%2520predominantly%2520via%2520type-I%2520IL-8%2520receptors%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D1428%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Posadas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terencio, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandiz, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coloma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, M. J.</span><span> </span><span class="NLM_article-title">Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation</span> <span class="citation_source-journal">N-S Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2000&pages=98-106&author=I.+Posadasauthor=M.+C.+Terencioauthor=I.+Guillenauthor=M.+L.+Ferrandizauthor=J.+Colomaauthor=M.+Payaauthor=M.+J.+Alcaraz&title=Co-regulation+between+cyclo-oxygenase-2+and+inducible+nitric+oxide+synthase+expression+in+the+time-course+of+murine+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPosadas%26aufirst%3DI.%26aulast%3DTerencio%26aufirst%3DM.%2BC.%26aulast%3DGuillen%26aufirst%3DI.%26aulast%3DFerrandiz%26aufirst%3DM.%2BL.%26aulast%3DColoma%26aufirst%3DJ.%26aulast%3DPaya%26aufirst%3DM.%26aulast%3DAlcaraz%26aufirst%3DM.%2BJ.%26atitle%3DCo-regulation%2520between%2520cyclo-oxygenase-2%2520and%2520inducible%2520nitric%2520oxide%2520synthase%2520expression%2520in%2520the%2520time-course%2520of%2520murine%2520inflammation%26jtitle%3DN-S%2520Arch.%2520Pharmacol.%26date%3D2000%26volume%3D361%26spage%3D98%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Moriconi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervellera, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coniglio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colagioia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beccari, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavicchia, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Benedetto, P.</span><span> </span><span class="NLM_article-title">Vigilante, P.; Bertini, R.; Allegretti, M. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3984</span><span class="NLM_x">–</span> <span class="NLM_lpage">4002</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061469t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3984-4002&author=A.+Moriconiauthor=M.+C.+Cestaauthor=M.+N.+Cervelleraauthor=A.+Araminiauthor=S.+Coniglioauthor=S.+Colagioiaauthor=A.+R.+Beccariauthor=C.+Bizzarriauthor=M.+R.+Cavicchiaauthor=M.+Locatiauthor=E.+Gallieraauthor=P.+Di+Benedetto&title=Vigilante%2C+P.%3B+Bertini%2C+R.%3B+Allegretti%2C+M.+Design+of+noncompetitive+interleukin-8+inhibitors+acting+on+CXCR1+and+CXCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm061469t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061469t%26sid%3Dliteratum%253Aachs%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3DAramini%26aufirst%3DA.%26aulast%3DConiglio%26aufirst%3DS.%26aulast%3DColagioia%26aufirst%3DS.%26aulast%3DBeccari%26aufirst%3DA.%2BR.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DCavicchia%26aufirst%3DM.%2BR.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DDi%2BBenedetto%26aufirst%3DP.%26atitle%3DVigilante%252C%2520P.%253B%2520Bertini%252C%2520R.%253B%2520Allegretti%252C%2520M.%2520Design%2520of%2520noncompetitive%2520interleukin-8%2520inhibitors%2520acting%2520on%2520CXCR1%2520and%2520CXCR2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3984%26epage%3D4002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0li1TPWZLiHvAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span> </span><span class="NLM_article-title">Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">6682</span><span class="NLM_x">–</span> <span class="NLM_lpage">6686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=6682-6686&author=S.+A.+Jonesauthor=M.+Wolfauthor=S.+Qinauthor=C.+R.+Mackayauthor=M.+Baggiolini&title=Different+functions+for+the+interleukin+8+receptors+%28IL-8R%29+of+human+neutrophil+leukocytes%3A+NADPH+oxidase+and+phospholipase+D+are+activated+through+IL-8R1+but+not+IL-8R2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DBaggiolini%26aufirst%3DM.%26atitle%3DDifferent%2520functions%2520for%2520the%2520interleukin%25208%2520receptors%2520%2528IL-8R%2529%2520of%2520human%2520neutrophil%2520leukocytes%253A%2520NADPH%2520oxidase%2520and%2520phospholipase%2520D%2520are%2520activated%2520through%2520IL-8R1%2520but%2520not%2520IL-8R2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D6682%26epage%3D6686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Geiser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewald, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrengruber, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarklewis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span> </span><span class="NLM_article-title">The interleukin-8-related chemotactic cytokines GRO-alpha, GRO-beta, and GRO-gamma activate human neutrophil and basophil leukocytes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">15419</span><span class="NLM_x">–</span> <span class="NLM_lpage">15424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=15419-15424&author=T.+Geiserauthor=B.+Dewaldauthor=M.+U.+Ehrengruberauthor=I.+Clarklewisauthor=M.+Baggiolini&title=The+interleukin-8-related+chemotactic+cytokines+GRO-alpha%2C+GRO-beta%2C+and+GRO-gamma+activate+human+neutrophil+and+basophil+leukocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeiser%26aufirst%3DT.%26aulast%3DDewald%26aufirst%3DB.%26aulast%3DEhrengruber%26aufirst%3DM.%2BU.%26aulast%3DClarklewis%26aufirst%3DI.%26aulast%3DBaggiolini%26aufirst%3DM.%26atitle%3DThe%2520interleukin-8-related%2520chemotactic%2520cytokines%2520GRO-alpha%252C%2520GRO-beta%252C%2520and%2520GRO-gamma%2520activate%2520human%2520neutrophil%2520and%2520basophil%2520leukocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D15419%26epage%3D15424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Kaur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span> </span><span class="NLM_article-title">Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: The role of CXCL8 and the receptors CXCR1/CXCR2</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.112.201855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=23912333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=173-180&author=M.+Kaurauthor=D.+Singh&title=Neutrophil+chemotaxis+caused+by+chronic+obstructive+pulmonary+disease+alveolar+macrophages%3A+The+role+of+CXCL8+and+the+receptors+CXCR1%2FCXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2</span></div><div class="casAuthors">Kaur, Manminder; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Alveolar macrophages produce neutrophil chemoattractants; this cellular cross-talk contributes to neutrophilic airway inflammation in chronic obstructive pulmonary disease (COPD).  We have investigated the chemotaxis cross-talk mechanisms between these cells using COPD alveolar macrophages.  Using conditioned media from stimulated COPD alveolar macrophages, we investigated the relative contributions of growth-related oncogene (CXCL1), interleukin-8 (CXCL8), and regulated on activation normal T cell expressed and secreted (CCL5) to neutrophil chemotaxis and evaluated the effect of blocking the chemokine receptors CXCR1 and CXCR2 on chemotaxis caused by macrophage-conditioned media.  Furthermore, we evaluated whether corticosteroid treatment of stimulated alveolar macrophages inhibited the chemotaxis ability of conditioned media.  Alveolar macrophages isolated from COPD (n = 8) and smoker (S) (n = 8) lungs were treated with ultra-pure lipopolysaccharide in the presence and absence of dexamethasone (1 μM).  Supernatants were used for neutrophil chemotaxis assays.  SB656933 (2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide) (CXCR2 antagonist) and Sch527123 [1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea, 3-(2-chloro-3-fluoro-phenyl)-1-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonyl-phenyl)urea] (dual CXCR1 and CXCR2 antagonist) and blocking antibodies for CXCL8, CXCL1, and CCL5 were assessed.  Conditioned media caused neutrophil chemotaxis in COPD and smokers (60.5 and 79.9% of total cells, resp.).  Dexamethasone did not significantly reduce neutrophil chemotaxis in COPD or S. SB656933 and Sch527123 inhibited chemotaxis in a concn.-dependent manner, with the dual antagonist Sch527123 causing greater inhibition of chemotaxis.  CXCL8 antibody inhibited neutrophil chemotaxis to basal levels, although there was no significant effect of blocking either CXCL1 or CCL5 (P > 0.05).  CXCL8 plays a major role in neutrophil chemotaxis caused by alveolar macrophage-derived conditioned media, and this is most effectively inhibited by dual antagonism of CXCR1 and CXCR2.  Corticosteroids do not inhibit chemotaxis caused by macrophage-derived chemokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsoYyZrJgEbrVg90H21EOLACvtfcHk0lj-iVENpobSmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7vL&md5=4f381dffd65c9a5e87e4c02877c7d96e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201855%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DNeutrophil%2520chemotaxis%2520caused%2520by%2520chronic%2520obstructive%2520pulmonary%2520disease%2520alveolar%2520macrophages%253A%2520The%2520role%2520of%2520CXCL8%2520and%2520the%2520receptors%2520CXCR1%252FCXCR2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D173%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">May, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avlani, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors</span> <span class="citation_source-journal">Curr. Pharm. Design</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.2174%2F1381612043384303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15279541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=2003-2013&author=L.+T.+Mayauthor=V.+A.+Avlaniauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+modulation+of+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors</span></div><div class="casAuthors">May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2003-2013</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action.  Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, i.e., the site recognized by the endogenous agonist for that receptor.  However, it is now evident that GPCRs possess addnl., extracellular, allosteric binding sites that can be recognized by a variety of small mol. modulator ligands.  Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety.  However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators.  More recently, there have been a no. of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated.  In addn., a no. of powerful anal. techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs.  Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clin. setting and yield novel therapeutic entities for the treatment of numerous disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiEpajFz3ILVg90H21EOLACvtfcHk0lj-iVENpobSmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCntbs%253D&md5=c4448105f37b36763b935b215383f2bb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1381612043384303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043384303%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DAvlani%26aufirst%3DV.%2BA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DCurr.%2520Pharm.%2520Design%26date%3D2004%26volume%3D10%26spage%3D2003%26epage%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1476-5381.2009.00182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19422399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=328-338&author=M.+E.+Bradleyauthor=M.+E.+Bondauthor=J.+Maniniauthor=Z.+Brownauthor=S.+J.+Charlton&title=SB265610+is+an+allosteric%2C+inverse+agonist+at+the+human+CXCR2+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor</span></div><div class="casAuthors">Bradley, M. E.; Bond, M. E.; Manini, J.; Brown, Z.; Charlton, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">328-338</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: In several previous studies, the C-X-C chemokine receptor (CXCR)2 antagonist 1-(2-bromophenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea (SB265610) has been described as binding competitively with the endogenous agonist.  This is in contrast to many other chemokine receptor antagonists, where the mechanism of antagonism has been described as allosteric.  Exptl. approach: To det. whether it displays a unique mechanism among the chemokine receptor antagonists, the mode of action of SB265610 was investigated at the CXCR2 receptor using radioligand and [35S]-GTPγS binding approaches in addn. to chemotaxis of human neutrophils.  Key results: In equil. satn. binding studies, SB265610 depressed the maximal binding of [125I]-interleukin-8 ([125I]-IL-8) without affecting the Kd.  In contrast, IL-8 was unable to prevent binding of [3H]-SB265610.  Kinetic binding expts. demonstrated that this was not an artifact of irreversible or slowly reversible binding.  In functional expts., SB265610 caused a rightward shift of the concn.-response curves to IL-8 and growth-related oncogene α, but also a redn. in maximal response elicited by each agonist.  Fitting these data to an operational allosteric ternary complex model suggested that, once bound, SB265610 completely blocks receptor activation.  SB265610 also inhibited basal [35S]-GTPγS binding in this prepn.  Conclusions and implications: Taken together, these data suggest that SB265610 behaves as an allosteric inverse agonist at the CXCR2 receptor, binding at a region distinct from the agonist binding site to prevent receptor activation, possibly by interfering with G protein coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquo8b-CAGzn7Vg90H21EOLACvtfcHk0lj-iVENpobSmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsrzF&md5=33b692e981e8ea5ef3f8527843451748</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00182.x%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBond%26aufirst%3DM.%2BE.%26aulast%3DManini%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DZ.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DSB265610%2520is%2520an%2520allosteric%252C%2520inverse%2520agonist%2520at%2520the%2520human%2520CXCR2%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D328%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Nicholls, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomkinson, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brammall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grahames, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meghani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallinder, P. R.</span><span> </span><span class="NLM_article-title">Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1193-1202&author=D.+J.+Nichollsauthor=N.+P.+Tomkinsonauthor=K.+E.+Wileyauthor=A.+Brammallauthor=L.+Bowersauthor=C.+Grahamesauthor=A.+Gawauthor=P.+Meghaniauthor=P.+Sheltonauthor=T.+J.+Wrightauthor=P.+R.+Mallinder&title=Identification+of+a+putative+intracellular+allosteric+antagonist+binding-site+in+the+CXC+chemokine+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DTomkinson%26aufirst%3DN.%2BP.%26aulast%3DWiley%26aufirst%3DK.%2BE.%26aulast%3DBrammall%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DL.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DMeghani%26aufirst%3DP.%26aulast%3DShelton%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DT.%2BJ.%26aulast%3DMallinder%26aufirst%3DP.%2BR.%26atitle%3DIdentification%2520of%2520a%2520putative%2520intracellular%2520allosteric%2520antagonist%2520binding-site%2520in%2520the%2520CXC%2520chemokine%2520receptors%25201%2520and%25202%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1193%26epage%3D1202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">de Kruijf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renjaan, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auld, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkmans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Identification of a novel allosteric binding site in the CXCR2 chemokine receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=1108-1118&author=P.+de+Kruijfauthor=H.+D.+Limauthor=L.+Roumenauthor=V.+A.+Renjaanauthor=J.+Zhaoauthor=M.+L.+Webbauthor=D.+S.+Auldauthor=J.+C.+Wijkmansauthor=G.+J.+Zamanauthor=M.+J.+Smitauthor=C.+de+Graafauthor=R.+Leurs&title=Identification+of+a+novel+allosteric+binding+site+in+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKruijf%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DRenjaan%26aufirst%3DV.%2BA.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DWijkmans%26aufirst%3DJ.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520a%2520novel%2520allosteric%2520binding%2520site%2520in%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D1108%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Onuffer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokines, chemokine receptors and small-molecule antagonists: Recent developments</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=459-467&author=J.+J.+Onufferauthor=R.+Horuk&title=Chemokines%2C+chemokine+receptors+and+small-molecule+antagonists%3A+Recent+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOnuffer%26aufirst%3DJ.%2BJ.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokines%252C%2520chemokine%2520receptors%2520and%2520small-molecule%2520antagonists%253A%2520Recent%2520developments%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D459%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+Structure+of+the+Boronic+Acid-Based+Proteasome+Inhibitor+Bortezomib+in+Complex+with+the+Yeast+20S+Proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lieIVBR7241tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Boronic%2520Acid-Based%2520Proteasome%2520Inhibitor%2520Bortezomib%2520in%2520Complex%2520with%2520the%2520Yeast%252020S%2520Proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Hu, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. L.</span><span> </span><span class="NLM_article-title">Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate</span> <span class="citation_source-journal">Mol. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2958.2005.05036.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16468986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Shsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1417-1428&author=G.+Q.+Huauthor=G.+Linauthor=M.+Wangauthor=L.+Dickauthor=R.+M.+Xuauthor=C.+Nathanauthor=H.+L.+Li&title=Structure+of+the+Mycobacterium+tuberculosis+proteasome+and+mechanism+of+inhibition+by+a+peptidyl+boronate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate</span></div><div class="casAuthors">Hu, Guiqing; Lin, Gang; Wang, Ming; Dick, Lawrence; Xu, Rui-Ming; Nathan, Carl; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1417-1428</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) has the remarkable ability to resist killing by human macrophages.  The 750 kDa proteasome, not available in most eubacteria except Actinomycetes, appears to contribute to Mtb's resistance.  The crystal structure of the Mtb proteasome at 3.0 Å resoln. reveals a substrate-binding pocket with composite features of the distinct β1, β2 and β5 substrate binding sites of eukaryotic proteasomes, accounting for the broad specificity of the Mtb proteasome towards oligopeptides described in the companion article.  The substrate entrance at the end of the cylindrical proteasome appears open in the crystal structure due to partial disorder of the α-subunit N-terminal residues.  However, cryo-electron microscopy of the core particle reveals a closed end, compatible with the d. obsd. in neg.-staining electron microscopy that depended on the presence of the N-terminal octapetides of the α-subunits in the companion article, suggesting that the Mtb proteasome has a gated structure.  We det. for the first time the proteasomal inhibition mechanism of the dipeptidyl boronate N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid (MLN-273), an analog of the antimyeloma drug bortezomib.  The structure improves prospects for designing Mtb-specific proteasomal inhibitors as a novel approach to chemotherapy of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosRye2y6oNzLVg90H21EOLACvtfcHk0lieIVBR7241tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Shsb0%253D&md5=25d9f52eb39604629dc5e86f9527c0b5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2005.05036.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2005.05036.x%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DG.%2BQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%2BM.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%2BL.%26atitle%3DStructure%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520proteasome%2520and%2520mechanism%2520of%2520inhibition%2520by%2520a%2520peptidyl%2520boronate%26jtitle%3DMol.%2520Microbiol.%26date%3D2006%26volume%3D59%26spage%3D1417%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Tsilikounas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">B-11 NMR-spectroscopy of peptide boronic acid inhibitor complexes of alpha-lytic protease: Direct evidence for tetrahedral boron in both boron histidine and boron serine adduct complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">12651</span><span class="NLM_x">–</span> <span class="NLM_lpage">12655</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00210a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=12651-12655&author=E.+Tsilikounasauthor=C.+A.+Kettnerauthor=W.+W.+Bachovchin&title=B-11+NMR-spectroscopy+of+peptide+boronic+acid+inhibitor+complexes+of+alpha-lytic+protease%3A+Direct+evidence+for+tetrahedral+boron+in+both+boron+histidine+and+boron+serine+adduct+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fbi00210a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00210a013%26sid%3Dliteratum%253Aachs%26aulast%3DTsilikounas%26aufirst%3DE.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DB-11%2520NMR-spectroscopy%2520of%2520peptide%2520boronic%2520acid%2520inhibitor%2520complexes%2520of%2520alpha-lytic%2520protease%253A%2520Direct%2520evidence%2520for%2520tetrahedral%2520boron%2520in%2520both%2520boron%2520histidine%2520and%2520boron%2520serine%2520adduct%2520complexes%26jtitle%3DBiochemistry%26date%3D1993%26volume%3D32%26spage%3D12651%26epage%3D12655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Farrjones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Crystal versus solution structure of enzymes: NMR-spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">6922</span><span class="NLM_x">–</span> <span class="NLM_lpage">6924</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=6922-6924&author=S.+Farrjonesauthor=S.+O.+Smithauthor=C.+A.+Kettnerauthor=R.+G.+Griffinauthor=W.+W.+Bachovchin&title=Crystal+versus+solution+structure+of+enzymes%3A+NMR-spectroscopy+of+a+peptide+boronic+acid-serine+protease+complex+in+the+crystalline+state"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarrjones%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BO.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DGriffin%26aufirst%3DR.%2BG.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DCrystal%2520versus%2520solution%2520structure%2520of%2520enzymes%253A%2520NMR-spectroscopy%2520of%2520a%2520peptide%2520boronic%2520acid-serine%2520protease%2520complex%2520in%2520the%2520crystalline%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D6922%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrjones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenvi, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span> </span><span class="NLM_article-title">N-15 NMR-spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">7689</span><span class="NLM_x">–</span> <span class="NLM_lpage">7697</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00420a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=7689-7697&author=W.+W.+Bachovchinauthor=W.+Y.+L.+Wongauthor=S.+Farrjonesauthor=A.+B.+Shenviauthor=C.+A.+Kettner&title=N-15+NMR-spectroscopy+of+the+catalytic-triad+histidine+of+a+serine+protease+in+peptide+boronic+acid+inhibitor+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fbi00420a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00420a018%26sid%3Dliteratum%253Aachs%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DWong%26aufirst%3DW.%2BY.%2BL.%26aulast%3DFarrjones%26aufirst%3DS.%26aulast%3DShenvi%26aufirst%3DA.%2BB.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26atitle%3DN-15%2520NMR-spectroscopy%2520of%2520the%2520catalytic-triad%2520histidine%2520of%2520a%2520serine%2520protease%2520in%2520peptide%2520boronic%2520acid%2520inhibitor%2520complexes%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D7689%26epage%3D7697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Bone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenvi, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span> </span><span class="NLM_article-title">Serine protease mechanism: Structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">7609</span><span class="NLM_x">–</span> <span class="NLM_lpage">7614</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00398a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=7609-7614&author=R.+Boneauthor=A.+B.+Shenviauthor=C.+A.+Kettnerauthor=D.+A.+Agard&title=Serine+protease+mechanism%3A+Structure+of+an+inhibitory+complex+of+alpha-lytic+protease+and+a+tightly+bound+peptide+boronic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fbi00398a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00398a012%26sid%3Dliteratum%253Aachs%26aulast%3DBone%26aufirst%3DR.%26aulast%3DShenvi%26aufirst%3DA.%2BB.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26atitle%3DSerine%2520protease%2520mechanism%253A%2520Structure%2520of%2520an%2520inhibitory%2520complex%2520of%2520alpha-lytic%2520protease%2520and%2520a%2520tightly%2520bound%2520peptide%2520boronic%2520acid%26jtitle%3DBiochemistry%26date%3D1987%26volume%3D26%26spage%3D7609%26epage%3D7614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Siemsen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schepetkin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotina, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. T.</span><span> </span><span class="NLM_article-title">Neutrophil isolation from nonhuman species</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2F978-1-59745-467-4_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=18453103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A280%3ADC%252BD1c3pt1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2007&pages=21-34&author=D.+W.+Siemsenauthor=I.+A.+Schepetkinauthor=L.+N.+Kirpotinaauthor=B.+Leiauthor=M.+T.+Quinn&title=Neutrophil+isolation+from+nonhuman+species"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil isolation from nonhuman species</span></div><div class="casAuthors">Siemsen Daniel W; Schepetkin Igor A; Kirpotina Liliya N; Lei Benfang; Quinn Mark T</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-34</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">Advances in the understanding of neutrophil biochemistry require the development of effective procedures for isolating purified neutrophil populations.  Although methods for human neutrophil isolation are now standard, similar procedures for isolating neutrophils from many of the nonhuman species used to model human diseases are not as well developed.  Because neutrophils are reactive cells, the method of isolation is extremely important to avoid isolation technique-induced alterations in cell function.  We present methods here for reproducibly isolating highly-purified neutrophils from large (cow, horse, sheep) and small (mouse, rabbit) animal models and describe optimized details for obtaining the highest cell purity, yield, and viability.  We also describe methods to verify phagocytic capacity in the purified cell populations using a flow cytometry-based phagocytosis assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREXeD7T5ENZcve_zCu79I8fW6udTcc2eatN5sntnOfL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3pt1OjsQ%253D%253D&md5=d5df703ae008bb8fe6185c08ee67f7ab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-467-4_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-467-4_3%26sid%3Dliteratum%253Aachs%26aulast%3DSiemsen%26aufirst%3DD.%2BW.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DLei%26aufirst%3DB.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26atitle%3DNeutrophil%2520isolation%2520from%2520nonhuman%2520species%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2007%26volume%3D412%26spage%3D21%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Hall, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, H.</span><span> </span><span class="NLM_article-title">Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: A comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1038%2Fsj.bjp.0702329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=10188995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=810-818&author=D.+A.+Hallauthor=I.+J.+Beresfordauthor=C.+Browningauthor=H.+Giles&title=Signalling+by+CXC-chemokine+receptors+1+and+2+expressed+in+CHO+cells%3A+A+comparison+of+calcium+mobilization%2C+inhibition+of+adenylyl+cyclase+and+stimulation+of+GTPgammaS+binding+induced+by+IL-8+and+GROalpha"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL-8 and GROα</span></div><div class="casAuthors">Hall, David A.; Beresford, Isabel J. M.; Browning, Christopher; Giles, Heather</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-818</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The effect of interleukin-8 (IL-8) and growth-related oncogene α (GROα) on [35S]-guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPγS) binding, forskolin-stimulated cAMP accumulation and cytosolic calcium concn. were detd. in recombinant CHO cells expressing HA-tagged CXC-chemokine receptors 1 and 2 (CXCR1 and CXCR2).  Radioligand binding assays confirmed that the binding profiles of the recombinant receptors were similar to those of the native proteins.  IL-8 displaced [125I]-IL-8 binding to CXCR1 and CXCR2 with pKi values of 8.89±0.05 and 9.27±0.03, resp.  GROα, a selective CXCR2 ligand, had a pKi value of 9.66±0.39 at CXCR2 but a pKi>8 at CXCR1.  Calcium mobilization expts. were also consistent with previous reports on native receptors.  Activation of both receptors resulted in stimulation of [35S]GTPγS binding and inhibition of adenylyl cyclase.  A comparison of the functional data at CXCR1 showed that a similar potency order (IL-8> >GROα) was obtained in all three assays.  However, at CXCR2 while the potency orders for calcium mobilization and inhibition of adenylyl cyclase were similar (IL-8≥GROα), the order was reversed for stimulation of [35S]GTPγS binding (GROα>IL-8).  All of the functional responses at both receptors were inhibited by pertussis toxin (PTX), suggesting coupling to a Gi/Go protein.  However, the calcium mobilization induced by IL-8 at CXCR1 was not fully inhibited by PTX, suggesting an interaction with a G-protein of the Gq family.  Our results with pertussis toxin also suggested that, in the [35S]GTPγS binding assay, CXCR1 displays some constitutive activity.  Thus, we have characterized the binding and several functional responses at HA-tagged CXCRs 1 and 2 and have shown that their pharmacol. agrees well with that of the native receptors.  We also have preliminary evidence that CXCR1 displays constitutive activity in our cell line and that CXCR2 may traffic between different PTX sensitive G-proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CdsolstFrrVg90H21EOLACvtfcHk0ljG_X5Ty_AmWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWitLc%253D&md5=76e8dca183c59752a227a35616766d31</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702329%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DBeresford%26aufirst%3DI.%2BJ.%26aulast%3DBrowning%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DH.%26atitle%3DSignalling%2520by%2520CXC-chemokine%2520receptors%25201%2520and%25202%2520expressed%2520in%2520CHO%2520cells%253A%2520A%2520comparison%2520of%2520calcium%2520mobilization%252C%2520inhibition%2520of%2520adenylyl%2520cyclase%2520and%2520stimulation%2520of%2520GTPgammaS%2520binding%2520induced%2520by%2520IL-8%2520and%2520GROalpha%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D810%26epage%3D818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jinxin Che, Zhilong Wang, Zheyuan Shen, Weihao Zhuang, Huazhou Ying, Yongzhou Hu, Youhong Hu, Xin Xie, <span class="NLM_string-name hlFld-ContribAuthor">Xiaowu Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,5-Dihydro-4H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 836-845. <a href="https://doi.org/10.1021/acsmedchemlett.1c00113" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00113%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B1%25252C5-Dihydro-4H-imidazol-4-one%252BDerivatives%252Bas%252BPotent%25252C%252BSelective%252BAntagonists%252Bof%252BCXC%252BChemokine%252BReceptor%252B2%26aulast%3DChe%26aufirst%3DJinxin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23022021%26date%3D05042021%26date%3D08042021%26volume%3D12%26issue%3D5%26spage%3D836%26epage%3D845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heng  Xu</span>, <span class="hlFld-ContribAuthor ">Hongfu  Lu</span>, <span class="hlFld-ContribAuthor ">Zhongmiao  Xu</span>, <span class="hlFld-ContribAuthor ">Linbo  Luan</span>, <span class="hlFld-ContribAuthor ">Chengyong  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Kelly  Dong</span>, <span class="hlFld-ContribAuthor ">Jinqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiong  Li</span>, <span class="hlFld-ContribAuthor ">Yvonne  Li</span>, <span class="hlFld-ContribAuthor ">Gentao  Liu</span>, <span class="hlFld-ContribAuthor ">Sophie  Gong</span>, <span class="hlFld-ContribAuthor ">Yong-Gang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ailian  Liu</span>, <span class="hlFld-ContribAuthor ">Yueting  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Cai</span>, <span class="hlFld-ContribAuthor ">Jia-Ning  Xiang</span>, <span class="hlFld-ContribAuthor ">John D.  Elliott</span>, and <span class="hlFld-ContribAuthor ">Xichen  Lin</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (4)
                                     , 397-402. <a href="https://doi.org/10.1021/acsmedchemlett.5b00489" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00489%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BCNS%252BPenetrant%252BCXCR2%252BAntagonists%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BCNS%252BDemyelinating%252BDisorders%26aulast%3DXu%26aufirst%3DHeng%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D18122015%26date%3D08022016%26date%3D11022016%26date%3D14042016%26date%3D08022016%26volume%3D7%26issue%3D4%26spage%3D397%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helen  Ha</span>, <span class="hlFld-ContribAuthor ">Bikash  Debnath</span>, <span class="hlFld-ContribAuthor ">Srinivas  Odde</span>, <span class="hlFld-ContribAuthor ">Tim  Bensman</span>, <span class="hlFld-ContribAuthor ">Henry  Ho</span>, <span class="hlFld-ContribAuthor ">Paul M.  Beringer</span>, and <span class="hlFld-ContribAuthor ">Nouri  Neamati</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (8)
                                     , 1720-1738. <a href="https://doi.org/10.1021/acs.jcim.5b00181" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BNovel%252BCXCR2%252BInhibitors%252BUsing%252BLigand-Based%252BPharmacophore%252BModels%26aulast%3DHa%26aufirst%3DHelen%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01042015%26date%3D23072015%26date%3D24082015%26date%3D08072015%26volume%3D55%26issue%3D8%26spage%3D1720%26epage%3D1738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laxmidhar  Rout</span>, <span class="hlFld-ContribAuthor ">Tharmalingam  Punniyamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in transition-metal-mediated Csp2-B and Csp2-P cross-coupling reactions. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>431 </em>, 213675. <a href="https://doi.org/10.1016/j.ccr.2020.213675" title="DOI URL">https://doi.org/10.1016/j.ccr.2020.213675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2020.213675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2020.213675%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Btransition-metal-mediated%252BCsp2-B%252Band%252BCsp2-P%252Bcross-coupling%252Breactions%26aulast%3DRout%26aufirst%3DLaxmidhar%26date%3D2021%26volume%3D431%26spage%3D213675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dylan Scott  Eiger</span>, <span class="hlFld-ContribAuthor ">Noelia  Boldizsar</span>, <span class="hlFld-ContribAuthor ">Christopher Cole  Honeycutt</span>, <span class="hlFld-ContribAuthor ">Julia  Gardner</span>, <span class="hlFld-ContribAuthor ">Sudarshan  Rajagopal</span>. </span><span class="cited-content_cbyCitation_article-title">Biased agonism at chemokine receptors. </span><span class="cited-content_cbyCitation_journal-name">Cellular Signalling</span><span> <strong>2021,</strong> <em>78 </em>, 109862. <a href="https://doi.org/10.1016/j.cellsig.2020.109862" title="DOI URL">https://doi.org/10.1016/j.cellsig.2020.109862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cellsig.2020.109862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cellsig.2020.109862%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Signalling%26atitle%3DBiased%252Bagonism%252Bat%252Bchemokine%252Breceptors%26aulast%3DEiger%26aufirst%3DDylan%2BScott%26date%3D2021%26volume%3D78%26spage%3D109862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucas A.  Horn</span>, <span class="hlFld-ContribAuthor ">Kristen  Fousek</span>, <span class="hlFld-ContribAuthor ">Claudia  Palena</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor Plasticity and Resistance to Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Trends in Cancer</span><span> <strong>2020,</strong> <em>6 </em>
                                    (5)
                                     , 432-441. <a href="https://doi.org/10.1016/j.trecan.2020.02.001" title="DOI URL">https://doi.org/10.1016/j.trecan.2020.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trecan.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trecan.2020.02.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cancer%26atitle%3DTumor%252BPlasticity%252Band%252BResistance%252Bto%252BImmunotherapy%26aulast%3DHorn%26aufirst%3DLucas%2BA.%26date%3D2020%26volume%3D6%26issue%3D5%26spage%3D432%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Rui  Song</span>, <span class="hlFld-ContribAuthor ">Binhui  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111853. <a href="https://doi.org/10.1016/j.ejmech.2019.111853" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111853%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BCXCR1%25252F2%25253A%252BThe%252Bmedicinal%252Bpotential%252Bas%252Bcancer%252Bimmunotherapy%252Bagents%25252C%252Bantagonists%252Bresearch%252Bhighlights%252Band%252Bchallenges%252Bahead%26aulast%3DChe%26aufirst%3DJinxin%26date%3D2020%26volume%3D185%26spage%3D111853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guilherme Felipe Santos  Fernandes</span>, <span class="hlFld-ContribAuthor ">William Alexander  Denny</span>, <span class="hlFld-ContribAuthor ">Jean Leandro  Dos Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 791-804. <a href="https://doi.org/10.1016/j.ejmech.2019.06.092" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBoron%252Bin%252Bdrug%252Bdesign%25253A%252BRecent%252Badvances%252Bin%252Bthe%252Bdevelopment%252Bof%252Bnew%252Btherapeutic%252Bagents%26aulast%3DFernandes%26aufirst%3DGuilherme%2BFelipe%2BSantos%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Mengwei  Xia</span>, <span class="hlFld-ContribAuthor ">Yanhui  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaomin  Fu</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The journey of total synthesis toward nannocystin Ax. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (12)
                                     , 1781-1794. <a href="https://doi.org/10.1016/j.tet.2018.12.021" title="DOI URL">https://doi.org/10.1016/j.tet.2018.12.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.12.021%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DThe%252Bjourney%252Bof%252Btotal%252Bsynthesis%252Btoward%252Bnannocystin%252BAx%26aulast%3DLiu%26aufirst%3DRong%26date%3D2019%26volume%3D75%26issue%3D12%26spage%3D1781%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. А.  Potapov</span>, <span class="hlFld-ContribAuthor ">R. S.  Ishigeev</span>, <span class="hlFld-ContribAuthor ">M. V.  Musalov</span>, <span class="hlFld-ContribAuthor ">S. V.  Amosova</span>. </span><span class="cited-content_cbyCitation_article-title">Bis(tetrahydro-2H-pyran-2-ylmethyl)sulfide and -Sulfoxide from Sulfur Dichloride and 5-Hexen-1-ol. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2018,</strong> <em>88 </em>
                                    (12)
                                     , 2689-2690. <a href="https://doi.org/10.1134/S1070363218120356" title="DOI URL">https://doi.org/10.1134/S1070363218120356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363218120356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363218120356%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DBis%252528tetrahydro-2H-pyran-2-ylmethyl%252529sulfide%252Band%252B-Sulfoxide%252Bfrom%252BSulfur%252BDichloride%252Band%252B5-Hexen-1-ol%26aulast%3DPotapov%26aufirst%3DV.%2B%25D0%2590.%26date%3D2018%26date%3D2019%26volume%3D88%26issue%3D12%26spage%3D2689%26epage%3D2690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiyang  Dai</span>, <span class="hlFld-ContribAuthor ">Wenmin  Chen</span>, <span class="hlFld-ContribAuthor ">Bikash  Debnath</span>, <span class="hlFld-ContribAuthor ">Yong  Wu</span>, <span class="hlFld-ContribAuthor ">Nouri  Neamati</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structure–Activity Relationship Studies, and ADMET Properties of 3‐Aminocyclohex‐2‐en‐1‐ones as Chemokine Receptor 2 (CXCR2) Antagonists. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (9)
                                     , 916-930. <a href="https://doi.org/10.1002/cmdc.201800027" title="DOI URL">https://doi.org/10.1002/cmdc.201800027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800027%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%25252C%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%25252C%252Band%252BADMET%252BProperties%252Bof%252B3%2525E2%252580%252590Aminocyclohex%2525E2%252580%2525902%2525E2%252580%252590en%2525E2%252580%2525901%2525E2%252580%252590ones%252Bas%252BChemokine%252BReceptor%2525E2%252580%2525852%252B%252528CXCR2%252529%252BAntagonists%26aulast%3DDai%26aufirst%3DWeiyang%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D916%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suresh  Thareja</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Xingyue  Ji</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Boron-based small molecules in disease detection and treatment (2013–2016). </span><span class="cited-content_cbyCitation_journal-name">Heterocyclic Communications</span><span> <strong>2017,</strong> <em>23 </em>
                                    (3)
                                     , 137-153. <a href="https://doi.org/10.1515/hc-2017-0086" title="DOI URL">https://doi.org/10.1515/hc-2017-0086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/hc-2017-0086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fhc-2017-0086%26sid%3Dliteratum%253Aachs%26jtitle%3DHeterocyclic%2520Communications%26atitle%3DBoron-based%252Bsmall%252Bmolecules%252Bin%252Bdisease%252Bdetection%252Band%252Btreatment%252B%2525282013%2525E2%252580%2525932016%252529%26aulast%3DThareja%26aufirst%3DSuresh%26date%3D2017%26volume%3D23%26issue%3D3%26spage%3D137%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick-Denis  St-Coeur</span>, <span class="hlFld-ContribAuthor ">Samantha  Kinley</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Vogels</span>, <span class="hlFld-ContribAuthor ">Andreas  Decken</span>, <span class="hlFld-ContribAuthor ">Pier  Jr. Morin</span>, <span class="hlFld-ContribAuthor ">Stephen A.  Westcott</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization, and anticancer properties of iminophosphineplatinum(II) complexes containing boronate esters. </span><span class="cited-content_cbyCitation_journal-name">Canadian Journal of Chemistry</span><span> <strong>2017,</strong> <em>95 </em>
                                    (2)
                                     , 207-213. <a href="https://doi.org/10.1139/cjc-2016-0570" title="DOI URL">https://doi.org/10.1139/cjc-2016-0570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1139/cjc-2016-0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1139%2Fcjc-2016-0570%26sid%3Dliteratum%253Aachs%26jtitle%3DCanadian%2520Journal%2520of%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcharacterization%25252C%252Band%252Banticancer%252Bproperties%252Bof%252Biminophosphineplatinum%252528II%252529%252Bcomplexes%252Bcontaining%252Bboronate%252Besters%26aulast%3DSt-Coeur%26aufirst%3DPatrick-Denis%26date%3D2017%26volume%3D95%26issue%3D2%26spage%3D207%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Congreve</span>, <span class="hlFld-ContribAuthor ">A.  Bortolato</span>, <span class="hlFld-ContribAuthor ">G.  Brown</span>, <span class="hlFld-ContribAuthor ">R.M.  Cooke</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling and Design for Membrane Protein Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 145-188. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12358-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12358-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12358-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12358-3%26sid%3Dliteratum%253Aachs%26atitle%3DModeling%252Band%252BDesign%252Bfor%252BMembrane%252BProtein%252BTargets%26aulast%3DCongreve%26aufirst%3DM.%26date%3D2017%26spage%3D145%26epage%3D188%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alyssa E.  Patterson</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Flewelling</span>, <span class="hlFld-ContribAuthor ">Trevor N.  Clark</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Geier</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Vogels</span>, <span class="hlFld-ContribAuthor ">Jason D.  Masuda</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Gray</span>, <span class="hlFld-ContribAuthor ">Stephen A.  Westcott</span>. </span><span class="cited-content_cbyCitation_article-title">Antimicrobial and antimycobacterial activities of aliphatic amines derived from vanillin. </span><span class="cited-content_cbyCitation_journal-name">Canadian Journal of Chemistry</span><span> <strong>2015,</strong> <em>93 </em>
                                    (11)
                                     , 1305-1311. <a href="https://doi.org/10.1139/cjc-2015-0400" title="DOI URL">https://doi.org/10.1139/cjc-2015-0400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1139/cjc-2015-0400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1139%2Fcjc-2015-0400%26sid%3Dliteratum%253Aachs%26jtitle%3DCanadian%2520Journal%2520of%2520Chemistry%26atitle%3DAntimicrobial%252Band%252Bantimycobacterial%252Bactivities%252Bof%252Baliphatic%252Bamines%252Bderived%252Bfrom%252Bvanillin%26aulast%3DPatterson%26aufirst%3DAlyssa%2BE.%26date%3D2015%26volume%3D93%26issue%3D11%26spage%3D1305%26epage%3D1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron D.  Schuler</span>, <span class="hlFld-ContribAuthor ">Courtney A.  Engles</span>, <span class="hlFld-ContribAuthor ">Dean Y.  Maeda</span>, <span class="hlFld-ContribAuthor ">Mark T.  Quinn</span>, <span class="hlFld-ContribAuthor ">Liliya N.  Kirpotina</span>, <span class="hlFld-ContribAuthor ">Winston N.  Wicomb</span>, <span class="hlFld-ContribAuthor ">S. Nicholas  Mason</span>, <span class="hlFld-ContribAuthor ">Richard L.  Auten</span>, <span class="hlFld-ContribAuthor ">John A.  Zebala</span>. </span><span class="cited-content_cbyCitation_article-title">Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (18)
                                     , 3793-3797. <a href="https://doi.org/10.1016/j.bmcl.2015.07.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBoronic%252Bacid-containing%252Baminopyridine-%252Band%252Baminopyrimidinecarboxamide%252BCXCR1%25252F2%252Bantagonists%25253A%252BOptimization%252Bof%252Baqueous%252Bsolubility%252Band%252Boral%252Bbioavailability%26aulast%3DSchuler%26aufirst%3DAaron%2BD.%26date%3D2015%26volume%3D25%26issue%3D18%26spage%3D3793%26epage%3D3797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dean Y.  Maeda</span>, <span class="hlFld-ContribAuthor ">Angela M.  Peck</span>, <span class="hlFld-ContribAuthor ">Aaron D.  Schuler</span>, <span class="hlFld-ContribAuthor ">Mark T.  Quinn</span>, <span class="hlFld-ContribAuthor ">Liliya N.  Kirpotina</span>, <span class="hlFld-ContribAuthor ">Winston N.  Wicomb</span>, <span class="hlFld-ContribAuthor ">Richard L.  Auten</span>, <span class="hlFld-ContribAuthor ">Rambabu  Gundla</span>, <span class="hlFld-ContribAuthor ">John A.  Zebala</span>. </span><span class="cited-content_cbyCitation_article-title">Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (11)
                                     , 2280-2284. <a href="https://doi.org/10.1016/j.bmcl.2015.04.041" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.04.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.04.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBoronic%252Bacid-containing%252BCXCR1%25252F2%252Bantagonists%25253A%252BOptimization%252Bof%252Bmetabolic%252Bstability%25252C%252Bin%252Bvivo%252Bevaluation%25252C%252Band%252Ba%252Bproposed%252Breceptor%252Bbinding%252Bmodel%26aulast%3DMaeda%26aufirst%3DDean%2BY.%26date%3D2015%26volume%3D25%26issue%3D11%26spage%3D2280%26epage%3D2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. CXCR1 and CXCR2 receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of S-Substituted <i>N</i>-(4-Fluoro-phenyl)-6-mercapto-nicotinamides <b>9</b>–<b>45</b>, <b>47</b>–<b>48</b>, <b>52</b>, and <b>55</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 4-fluoroaniline, EEDQ, DMF, rt; (ii) method A: Br-CH<sub>2</sub>–R, solid-phase base (<i>N</i>-methylmorpholino-substituted resin), DMF, 60 °C; method B: Br-CH<sub>2</sub>–R or Cl-CH<sub>2</sub>–R, DMF, base (TEA, DIPEA, or), rt; method C: Br-CH<sub>2</sub>–R, EtOH, 1 N NaOH, reflux.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>S</i>-Substituted <i>N</i>-(4-Fluoro-phenyl)-6-mercapto-nicotinamides <b>8, 44, 47, 49, 51–52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) TMS-N<sub>3</sub>, Bu<sub>2</sub>SnO, toluene, reflux; (ii) 1 N NaOH, MeOH, rt; and (iii) oxone, aq NaHCO<sub>3</sub>, acetone, 4 °C</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Anilide Derivatives of 6-(Thiobenzyl-2-borono)-nicotinamides <b>54–59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 2-bromomethyl-phenylboronic acid, DMF, TEA, 60 °C; (ii) neopentyl glycol, toluene, reflux; (iii) pivaloyl chloride, TEA, toluene, 0 °C to rt; and (iv) aniline derivative, TEA, DMF, 60 °C.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Substituted 6-(Thiobenzyl-2-borono)-nicotinamides <b>60–63</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) 4-fluoroaniline, K<sub>2</sub>CO<sub>3</sub>, THF, rt; (ii) <i>N</i>-Boc-2-piperidinecarbaldehyde, NaBH(OAc)<sub>3</sub>, DCE, glacial AcOH, rt; (iii) <i>tert</i>-butyl bromoacetate, DIPEA, DMF, 80 °C; (iv) phase-transfer reaction: bromomethylpyridine, toluene, 50% aq NaOH, TBAH, rt; (v) 6-chloronicotinoyl chloride, DBU, DMF, heat; (vi) NaHS, DMF, heat; (vii) 2-bromomethyl-phenylboronic acid, EtOH, 1 N aq NaOH, reflux; (viii) 2-bromomethyl-phenylboronic acid, DMF, TEA; (ix) 4 M HCl, dioxane, rt; and (x) 90% aq TFA, rt.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of chemokine-stimulated [<sup>35</sup>S]GTPγS binding by compound <b>7</b>. HEK293 cells stably expressing CXCR2 were incubated with different concentrations of compound (from 10<sup>–10</sup> to 10<sup>–4</sup> M) at 37 °C for 60 min, and then the membranes were prepared by lysis and centrifugation. The membranes were then incubated in buffer containing 50 μM GDP, 8 nM [<sup>35</sup>S]GTPγS, and 10 nM CXCL8 at 30 °C for another 60 min. Membranes were harvested by rapid filtration and membrane-bound [<sup>35</sup>S]GTPγS quantitated. Data, expressed as a percentage of basal [<sup>35</sup>S]GTPγS bound in the absence of CXCL8, are the mean ± SE from three independent experiments, each done in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Competition binding assay with <b>7</b> and CXCL8 at human CXCR2. Membranes from recombinant HEK293-CXCR2 cells were incubated with the compound at the indicated concentrations and 25 pM [<sup>125</sup>I]-CXCL8. Radioligand binding to the membranes was measured by scintillation. Data show the mean ± SD (<i>n</i> = 3) radioligand binding, expressed as the percent of control specific radioligand binding with vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>7</b> on the cell surface expression of CXCR2. HEK293 cells stably expressing CXCR2 were pretreated with 1% DMSO (vehicle) or 10 μM compound (cpd. <b>7</b>) for 60 min. HEK293 cells not expressing CXCR2 served as a negative isotype control (isotype). All cells were then incubated with <i>R</i>-phycoerythrin (<i>PE</i>)-conjugated antihuman CXCR2 mouse monoclonal antibody at 4 °C for 60 min. Cells were washed, fixed in 2% formaldehyde in PBS, and subjected to flow cytometric fluorescence-activated cell sorting (FACS) analysis of the PE signal. Results are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of Compound <b>7</b> on CXCR2-induced ERK1/2 phosphorylation. HEK293 cells stably expressing CXCR2 were stimulated with CXCL8 (100 ng/mL) for 0–30 min in the presence of vehicle or 10 μM compound <b>7</b>. Phosphorylated ERK1/2 and total ERK were determined by Western blotting using antiphospho-ERK1/2 (<i>P-ERK1/2</i>) and antitotal ERK1/2 (<i>T-ERK1/2</i>) antibodies, respectively. Data are representative of three independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/medium/jm-2014-00827t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. An air-pouch was formed on the backs of 10–15 week old, male CD1 Swiss mice in four cohorts (<i>n</i> = 5 animals per cohort). Compound dissolved in vehicle (0.02 mg/kg and 0.20 mg/kg cohorts) or vehicle alone (positive and negative cohorts) was administered intravenously. After 3 h, each air pouch was injected with 1 mL of PBS (negative cohort) or 2% carrageenan in PBS (positive, 0.02 mg/kg and 0.20 mg/kg cohorts). After 4 h, the pouch fluid was collected and combined with an additional 2 mL PBS wash of the pouch. The cells in the combined fluid were stained with trypan blue and manually counted on a hemocytometer. Data show the mean ± SE of the absolute pouch cell count per cohort. Student’s <i>t-</i>test: **<i>p</i> < 0.01 vs positive cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500827t/20150925/images/large/jm-2014-00827t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500827t&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i123">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">International union of pharmacology. XXII. Nomenclature for chemokine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=145-176&author=P.+M.+Murphyauthor=M.+Baggioliniauthor=I.+F.+Charoauthor=C.+A.+Hebertauthor=R.+Horukauthor=K.+Matsushimaauthor=L.+H.+Millerauthor=J.+J.+Oppenheimauthor=C.+A.+Power&title=International+union+of+pharmacology.+XXII.+Nomenclature+for+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DBaggiolini%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DHebert%26aufirst%3DC.%2BA.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DL.%2BH.%26aulast%3DOppenheim%26aufirst%3DJ.%2BJ.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XXII.%2520Nomenclature%2520for%2520chemokine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D145%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Petersen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flad, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, E.</span><span> </span><span class="NLM_article-title">Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways: Discrepancies in binding affinities, receptor densities, and biologic effects</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">2467</span><span class="NLM_x">–</span> <span class="NLM_lpage">2478</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=2467-2478&author=F.+Petersenauthor=H.+D.+Fladauthor=E.+Brandt&title=Neutrophil-activating+peptides+NAP-2+and+IL-8+bind+to+the+same+sites+on+neutrophils+but+interact+in+different+ways%3A+Discrepancies+in+binding+affinities%2C+receptor+densities%2C+and+biologic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DF.%26aulast%3DFlad%26aufirst%3DH.%2BD.%26aulast%3DBrandt%26aufirst%3DE.%26atitle%3DNeutrophil-activating%2520peptides%2520NAP-2%2520and%2520IL-8%2520bind%2520to%2520the%2520same%2520sites%2520on%2520neutrophils%2520but%2520interact%2520in%2520different%2520ways%253A%2520Discrepancies%2520in%2520binding%2520affinities%252C%2520receptor%2520densities%252C%2520and%2520biologic%2520effects%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D2467%26epage%3D2478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Neptune, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iiri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, H. R.</span><span> </span><span class="NLM_article-title">G alpha(i) is not required for chemotaxis mediated by G(i)-coupled receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">2824</span><span class="NLM_x">–</span> <span class="NLM_lpage">2828</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=2824-2828&author=E.+R.+Neptuneauthor=T.+Iiriauthor=H.+R.+Bourne&title=G+alpha%28i%29+is+not+required+for+chemotaxis+mediated+by+G%28i%29-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeptune%26aufirst%3DE.%2BR.%26aulast%3DIiri%26aufirst%3DT.%26aulast%3DBourne%26aufirst%3DH.%2BR.%26atitle%3DG%2520alpha%2528i%2529%2520is%2520not%2520required%2520for%2520chemotaxis%2520mediated%2520by%2520G%2528i%2529-coupled%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D2824%26epage%3D2828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thelen, M.</span><span> </span><span class="NLM_article-title">A Comparison of postreceptor signal-transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2 - chemokine mediated activation of P42/P44 MAP-Kinase (ERK-2)</span> <span class="citation_source-journal">Febs Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=1995&pages=211-214&author=S.+A.+Jonesauthor=B.+Moserauthor=M.+Thelen&title=A+Comparison+of+postreceptor+signal-transduction+events+in+Jurkat+cells+transfected+with+either+IL-8R1+or+IL-8R2+-+chemokine+mediated+activation+of+P42%2FP44+MAP-Kinase+%28ERK-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DMoser%26aufirst%3DB.%26aulast%3DThelen%26aufirst%3DM.%26atitle%3DA%2520Comparison%2520of%2520postreceptor%2520signal-transduction%2520events%2520in%2520Jurkat%2520cells%2520transfected%2520with%2520either%2520IL-8R1%2520or%2520IL-8R2%2520-%2520chemokine%2520mediated%2520activation%2520of%2520P42%252FP44%2520MAP-Kinase%2520%2528ERK-2%2529%26jtitle%3DFebs%2520Lett.%26date%3D1995%26volume%3D364%26spage%3D211%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Schorr, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swandulla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeilhofer, H. U.</span><span> </span><span class="NLM_article-title">Mechanisms of IL-8-induced Ca2+ signaling in human neutrophil granulocytes</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=897-904&author=W.+Schorrauthor=D.+Swandullaauthor=H.+U.+Zeilhofer&title=Mechanisms+of+IL-8-induced+Ca2%2B+signaling+in+human+neutrophil+granulocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchorr%26aufirst%3DW.%26aulast%3DSwandulla%26aufirst%3DD.%26aulast%3DZeilhofer%26aufirst%3DH.%2BU.%26atitle%3DMechanisms%2520of%2520IL-8-induced%2520Ca2%252B%2520signaling%2520in%2520human%2520neutrophil%2520granulocytes%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1999%26volume%3D29%26spage%3D897%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kurdowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, S. C.</span><span> </span><span class="NLM_article-title">Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1097%2F00003246-200210000-00024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12394964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=2335-2337&author=A.+Kurdowskaauthor=J.+M.+Nobleauthor=I.+S.+Grantauthor=C.+R.+Robertsonauthor=C.+Haslettauthor=S.+C.+Donnelly&title=Anti-interleukin-8+autoantibodies+in+patients+at+risk+for+acute+respiratory+distress+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome</span></div><div class="casAuthors">Kurdowska, Anna; Noble, James M.; Grant, Ian S.; Robertson, Colin R.; Haslett, Christopher; Donnelly, Seamas C.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2335-2337</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE: To test the hypothesis that elevated concns. of interleukin-8 assocd. with anti-interleukin-8 autoantibodies (anti-interleukin-8:interleukin-8 complexes) are found in patients at risk for acute respiratory distress syndrome who developed the disease.  DESIGN: Measurement of anti-interleukin-8:interleukin-8 complex concns. in previously collected bronchoalveolar lavage fluids.  These fluids were obtained from patients at risk for acute respiratory distress syndrome who subsequently either recovered or developed acute respiratory distress syndrome.  PATIENTS: A unique population of patients at risk for acute respiratory distress syndrome was studied.  There were 26 patients at risk for acute respiratory distress syndrome who were divided into three groups.  Group I patients had high interleukin-8 concns. and developed acute respiratory distress syndrome, group II had high interleukin-8 concns. and did not develop acute respiratory distress syndrome, and group III had low interleukin-8 concns. and did not develop acute respiratory distress syndrome.  These patients were selected to test the hypothesis that presence of elevated concns. of anti-interleukin-8:interleukin-8 complexes differentiates patients at risk for acute respiratory distress syndrome who developed acute respiratory distress syndrome from patients who did not.  MEASUREMENTS AND MAIN RESULTS: Bronchoalveolar lavage fluid concns. of interleukin-8 assocd. with the anti-interleukin-8 autoantibodies were significantly different between groups (p <.03).  The amt. of interleukin-8 bound to the anti-interleukin-8 autoantibody was higher in group I than in group II and group III.  CONCLUSIONS: Bronchoalveolar lavage fluid concn. of anti-interleukin-8:interleukin-8 complexes may serve as a marker of disease progression in patients at risk for acute respiratory distress syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbBDq_HqzKILVg90H21EOLACvtfcHk0lhF9wb_-04L8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOisLo%253D&md5=63d53673ede83fec816bfe9e74773d72</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2F00003246-200210000-00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003246-200210000-00024%26sid%3Dliteratum%253Aachs%26aulast%3DKurdowska%26aufirst%3DA.%26aulast%3DNoble%26aufirst%3DJ.%2BM.%26aulast%3DGrant%26aufirst%3DI.%2BS.%26aulast%3DRobertson%26aufirst%3DC.%2BR.%26aulast%3DHaslett%26aufirst%3DC.%26aulast%3DDonnelly%26aufirst%3DS.%2BC.%26atitle%3DAnti-interleukin-8%2520autoantibodies%2520in%2520patients%2520at%2520risk%2520for%2520acute%2520respiratory%2520distress%2520syndrome%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2002%26volume%3D30%26spage%3D2335%26epage%3D2337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Erdem, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simsek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musabak, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turan, M.</span><span> </span><span class="NLM_article-title">Different ELR(+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet’s disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis</span> <span class="citation_source-journal">Rheumatol. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2Fs00296-004-0524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15672235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=162-167&author=H.+Erdemauthor=S.+Payauthor=M.+Serdarauthor=I.+Simsekauthor=A.+Dincauthor=U.+Musabakauthor=A.+Pekelauthor=M.+Turan&title=Different+ELR%28%2B%29+angiogenic+CXC+chemokine+profiles+in+synovial+fluid+of+patients+with+Behcet%E2%80%99s+disease%2C+familial+Mediterranean+fever%2C+rheumatoid+arthritis%2C+and+osteoarthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis</span></div><div class="casAuthors">Erdem, Hakan; Pay, Salih; Serdar, Muhittin; Simsek, Ismail; Dinc, Ayhan; Musabak, Ugur; Pekel, Aysel; Turan, Mustafa</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology International</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-167</span>CODEN:
                <span class="NLM_cas:coden">RHINDE</span>;
        ISSN:<span class="NLM_cas:issn">0172-8172</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The aim of the present study was to det. synovial levels of ELR (+) CXC chemokines, known to attract mainly neutrophils to inflamed tissues by binding the neutrophil chemokine receptors CXCR1 and CXCR2 and promoting neovascularization in patients with various inflammatory disorders.  The study group consisted of 14 patients with Behcet's disease and nine with familial Mediterranean fever.  Fourteen patients with rheumatoid arthritis and 16 with osteoarthritis served as controls.  Synovial chemokine levels were measured by two-step sandwich ELISA, and significant differences were found in the various chemokines studied.  In addn. to its angiogenic properties, increased synovial levels of interleukin-8 by attraction of more neutrophils to synovial fluids might also be responsible for the acute synovitis in patients with Behcet's disease.  However, the absence of chronic changes with the eventual development of pannus and erosions might result from relatively lower expression of interleukin-8 and the transient, short-lived nature of the arthritis obsd. in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVRbyfU9gJi7Vg90H21EOLACvtfcHk0lhF9wb_-04L8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSjtbzM&md5=13da6410557b24061d53040bbec6887d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00296-004-0524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00296-004-0524-3%26sid%3Dliteratum%253Aachs%26aulast%3DErdem%26aufirst%3DH.%26aulast%3DPay%26aufirst%3DS.%26aulast%3DSerdar%26aufirst%3DM.%26aulast%3DSimsek%26aufirst%3DI.%26aulast%3DDinc%26aufirst%3DA.%26aulast%3DMusabak%26aufirst%3DU.%26aulast%3DPekel%26aufirst%3DA.%26aulast%3DTuran%26aufirst%3DM.%26atitle%3DDifferent%2520ELR%2528%252B%2529%2520angiogenic%2520CXC%2520chemokine%2520profiles%2520in%2520synovial%2520fluid%2520of%2520patients%2520with%2520Behcet%25E2%2580%2599s%2520disease%252C%2520familial%2520Mediterranean%2520fever%252C%2520rheumatoid%2520arthritis%252C%2520and%2520osteoarthritis%26jtitle%3DRheumatol.%2520Int.%26date%3D2005%26volume%3D26%26spage%3D162%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lally, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainger, G. E.</span><span> </span><span class="NLM_article-title">A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3460</span><span class="NLM_x">–</span> <span class="NLM_lpage">3469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fart.21394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16255036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Krur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=3460-3469&author=F.+Lallyauthor=E.+Smithauthor=A.+Filerauthor=M.+A.+Stoneauthor=J.+S.+Shawauthor=G.+B.+Nashauthor=C.+D.+Buckleyauthor=G.+E.+Rainger&title=A+novel+mechanism+of+neutrophil+recruitment+in+a+coculture+model+of+the+rheumatoid+synovium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium</span></div><div class="casAuthors">Lally, Frank; Smith, Emily; Filer, Andrew; Stone, Michael A.; Shaw, John S.; Nash, Gerard B.; Buckley, Christopher D.; Rainger, G. Ed</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3460-3469</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Rheumatoid arthritis (RA) is classically thought of as a Th1, T lymphocyte-driven disease of the adaptive immune system.  However, cells of the innate immune system, including neutrophils, are prevalent within the diseased joint, and accumulate in large nos.  This study was undertaken to det. whether cells of the rheumatoid stromal microenvironment could establish an inflammatory environment in which endothelial cells are conditioned in a disease-specific manner to support neutrophil recruitment.  Methods. Human umbilical vein endothelial cells (ECs) and fibroblasts isolated from the synovium or skin of RA patients were established in coculture on opposite sides of porous transwell filters.  After 24 h of EC conditioning, the membranes were incorporated into a parallel-plate, flow-based adhesion assay and levels of neutrophil adhesion to ECs were measured.  Results. ECs cocultured with synovial, but not skin, fibroblasts could recruit neutrophils in a manner that was dependent on the no. of fibroblasts.  Antibody blockade of P-selectin or E-selectin reduced neutrophil adhesion, and an antibody against CD18 (the β2 integrin) abolished adhesion.  Blockade of CXCR2, but not CXCR1, also greatly inhibited neutrophil recruitment.  Interleukin-6 (IL-6) was detectable in coculture supernatants, and both IL-6 and neutrophil adhesion were reduced in a dose-dependent manner by hydrocortisone added to cocultures.  Antibody blockade of IL-6 also effectively abolished neutrophil adhesion.  Conclusion. Synovial fibroblasts from the rheumatoid joint play an important role in regulating the recruitment of inflammatory leukocytes during active disease.  This process may depend on a previously unsuspected route of IL-6-mediated crosstalk between fibroblasts and endothelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1U5CxPynJ_bVg90H21EOLACvtfcHk0lifZH9Pjhozbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Krur7J&md5=a8ddf4312cefed71146e9e5bf519bc97</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fart.21394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21394%26sid%3Dliteratum%253Aachs%26aulast%3DLally%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DFiler%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DNash%26aufirst%3DG.%2BB.%26aulast%3DBuckley%26aufirst%3DC.%2BD.%26aulast%3DRainger%26aufirst%3DG.%2BE.%26atitle%3DA%2520novel%2520mechanism%2520of%2520neutrophil%2520recruitment%2520in%2520a%2520coculture%2520model%2520of%2520the%2520rheumatoid%2520synovium%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D3460%26epage%3D3469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Reich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaschke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westphal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, C.</span><span> </span><span class="NLM_article-title">Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2001&pages=319-329&author=K.+Reichauthor=C.+Garbeauthor=V.+Blaschkeauthor=C.+Maurerauthor=P.+Middelauthor=G.+Westphalauthor=U.+Lippertauthor=C.+Neumann&title=Response+of+psoriasis+to+interleukin-10+is+associated+with+suppression+of+cutaneous+type+1+inflammation%2C+downregulation+of+the+epidermal+interleukin-8%2FCXCR2+pathway+and+normalization+of+keratinocyte+maturation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DK.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DBlaschke%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DC.%26aulast%3DMiddel%26aufirst%3DP.%26aulast%3DWestphal%26aufirst%3DG.%26aulast%3DLippert%26aufirst%3DU.%26aulast%3DNeumann%26aufirst%3DC.%26atitle%3DResponse%2520of%2520psoriasis%2520to%2520interleukin-10%2520is%2520associated%2520with%2520suppression%2520of%2520cutaneous%2520type%25201%2520inflammation%252C%2520downregulation%2520of%2520the%2520epidermal%2520interleukin-8%252FCXCR2%2520pathway%2520and%2520normalization%2520of%2520keratinocyte%2520maturation%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2001%26volume%3D116%26spage%3D319%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Banks, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheron, N.</span><span> </span><span class="NLM_article-title">Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn’s disease</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">199</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fpath.1245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12474223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFenug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2003&pages=28-35&author=C.+Banksauthor=A.+Batemanauthor=R.+Payneauthor=P.+Johnsonauthor=N.+Sheron&title=Chemokine+expression+in+IBD.+Mucosal+chemokine+expression+is+unselectively+increased+in+both+ulcerative+colitis+and+Crohn%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease</span></div><div class="casAuthors">Banks, Charmian; Bateman, Adrian; Payne, Richard; Johnson, Penny; Sheron, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Mucosal changes in inflammatory bowel disease (IBD) are characterized by ulcerative lesions accompanied by prominent cellular infiltrates in the bowel wall.  Chemokines are chemotactic cytokines that are able to promote leukocyte migration to areas of inflammation and are also able to initiate cell activation events.  They have recently been implicated in the pathophysiol. of many disease states.  The aim of this study was to detail the degree and distribution of specific chemokines, interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, -2, and -3, and macrophage inflammatory protein (MIP)-1α and -1β, in IBD mucosa.  Thirty-nine patients were included, ten controls, 20 ulcerative colitis (UC), and nine Crohn's disease (CD), with a range of disease activity.  Colonic mucosal biopsies were collected from UC, CD, and control patients and embedded in glycol methacrylate.  Two-micrometre-thick sections were cut and stained using immunohistochem. for chemokine protein expression.  Sections were analyzed using a light microscope.  Expression of all types of chemokine protein was detected in colonic mucosa from both control and IBD patients.  Patterns of staining between IBD patients and controls differed significantly, but CD and UC patients demonstrated similar patterns of staining.  Individual chemokine expression was found to be significantly up-regulated in IBD when patients were compared with the non-diseased group in all areas of the mucosal sections.  Up-regulated chemokine expression correlated with increasing activity of the disease.  It is concluded that human colonic chemokine expression is non-selectively up-regulated in IBD.  The results supported the hypothesis that the degree of local inflammation and tissue damage in UC and CD is dependent on local expression of specific chemokines within IBD tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDzTulRo8ok7Vg90H21EOLACvtfcHk0lgXsTllERk95w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFenug%253D%253D&md5=85eef8d1093f262a1bd11a11b962396d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.1245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.1245%26sid%3Dliteratum%253Aachs%26aulast%3DBanks%26aufirst%3DC.%26aulast%3DBateman%26aufirst%3DA.%26aulast%3DPayne%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSheron%26aufirst%3DN.%26atitle%3DChemokine%2520expression%2520in%2520IBD.%2520Mucosal%2520chemokine%2520expression%2520is%2520unselectively%2520increased%2520in%2520both%2520ulcerative%2520colitis%2520and%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pathol.%26date%3D2003%26volume%3D199%26spage%3D28%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culpitt, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Neutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B-4</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1240</span><span class="NLM_x">–</span> <span class="NLM_lpage">1247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=1240-1247&author=K.+M.+Beehauthor=O.+Kornmannauthor=R.+Buhlauthor=S.+V.+Culpittauthor=M.+A.+Giembyczauthor=P.+J.+Barnes&title=Neutrophil+chemotactic+activity+of+sputum+from+patients+with+COPD%3A+Role+of+interleukin+8+and+leukotriene+B-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DCulpitt%26aufirst%3DS.%2BV.%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNeutrophil%2520chemotactic%2520activity%2520of%2520sputum%2520from%2520patients%2520with%2520COPD%253A%2520Role%2520of%2520interleukin%25208%2520and%2520leukotriene%2520B-4%26jtitle%3DChest%26date%3D2003%26volume%3D123%26spage%3D1240%26epage%3D1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Keatings, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1164%2Fajrccm.153.2.8564092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=8564092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A280%3ADyaK287mtVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1996&pages=530-534&author=V.+M.+Keatingsauthor=P.+D.+Collinsauthor=D.+M.+Scottauthor=P.+J.+Barnes&title=Differences+in+interleukin-8+and+tumor+necrosis+factor-alpha+in+induced+sputum+from+patients+with+chronic+obstructive+pulmonary+disease+or+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma</span></div><div class="casAuthors">Keatings V M; Collins P D; Scott D M; Barnes P J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">530-4</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Asthma and chronic obstructive pulmonary disease are characterized by chronic airway inflammation.  Studies using bronchoalveolar lavage (BAL) have shown an increased proportion of eosinophils in the BAL fluid from asthmatics compared with that from normal subjects, whereas studies of chronic obstructive pulmonary disease (COPD) have shown increased numbers of neutrophils.  Induced sputum allows sampling of respiratory tract secretions from patients and control subjects, providing a noninvasive method of studying airway secretions and allowing characterization of cells and measurement of soluble markers.  We investigated whether induced sputum was a useful method of studying airway fluid from patients with moderate to severe COPD and whether it could be used to compare inflammation in this condition with that in asthma.  An initial reproducibility study was undertaken.  Sputum was induced twice in 13 patients with severe COPD at a 14-d interval.  Total and differential cell counts were carried out and were found to be reproducible over this period.  Sputum was then induced in 14 patients with COPD, 23 patients with asthma, 12 healthy cigarette smokers, and 16 normal nonsmoking control subjects.  We found a significant increase in neutrophils and increased concentrations of tumor necrosis factor-alpha (TNF alpha) and interleukin-8 (IL-8) in the patients with COPD compared with the smoking and nonsmoking control subjects.  Interleukin-8, but not TNF alpha, was significantly higher in the COPD group than in the asthmatic group.  We conclude that the cytokines TNF alpha and IL-8 may be involved in the inflammation in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2AjKRSKODju_Q9URG6Dx8fW6udTcc2eYrTIIc1stG8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287mtVGmug%253D%253D&md5=51b69cba104ea9db57d9e763fb9a254d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.153.2.8564092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.153.2.8564092%26sid%3Dliteratum%253Aachs%26aulast%3DKeatings%26aufirst%3DV.%2BM.%26aulast%3DCollins%26aufirst%3DP.%2BD.%26aulast%3DScott%26aufirst%3DD.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DDifferences%2520in%2520interleukin-8%2520and%2520tumor%2520necrosis%2520factor-alpha%2520in%2520induced%2520sputum%2520from%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520or%2520asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1996%26volume%3D153%26spage%3D530%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">CXCR2 antagonists for the treatment of pulmonary disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.pharmthera.2008.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19026683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=55-68&author=R.+W.+Chapmanauthor=J.+E.+Phillipsauthor=R.+W.+Hipkinauthor=A.+K.+Curranauthor=D.+Lundellauthor=J.+S.+Fine&title=CXCR2+antagonists+for+the+treatment+of+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonists for the treatment of pulmonary disease</span></div><div class="casAuthors">Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chemokines have long been implicated in the initiation and amplification of inflammatory responses by virtue of their role in leukocyte chemotaxis.  The expression of one of the receptors for these chemokines, CXCR2, on a variety of cell types and tissues suggests that these receptors may have a broad functional role under both constitutive conditions and in the pathophysiol. of a no. of acute and chronic diseases.  With the development of several pharmacol., immunol. and genetic tools to study CXCR2 function, an important role for this CXC chemokine receptor subtype has been identified in chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.  Interference with CXCR2 receptor function has demonstrated different effects in the lungs including inhibition of pulmonary damage induced by neutrophils (PMNs), antigen or irritant-induced goblet cell hyperplasia and angiogenesis/collagen deposition caused by lung injury.  Many of these features are common to inflammatory and fibrotic disorders of the lung.  Clin. trials evaluating small mol. CXCR2 antagonists in COPD, asthma and cystic fibrosis are currently underway.  These studies hold considerable promise for identifying novel and efficacious treatments of pulmonary disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf1-c-1ciWrVg90H21EOLACvtfcHk0lgsHFFfOILVlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ&md5=37a5047ab1b8a37739311d273dd7d854</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DCurran%26aufirst%3DA.%2BK.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DCXCR2%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D121%26spage%3D55%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Donnelly, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">Chemokine receptor CXCR2 antagonism to prevent airways inflammation</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1358%2Fdof.2011.036.06.1622072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ShtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=465-472&author=L.+E.+Donnellyauthor=P.+J.+Barnes&title=Chemokine+receptor+CXCR2+antagonism+to+prevent+airways+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CXCR2 antagonism to prevent airways inflamation</span></div><div class="casAuthors">Donnelly, L. E.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">465-472</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Neutrophilic inflammation is assocd. with several pulmonary conditions, including chronic obstructive pulmonary disease (COPD), severe asthma and cystic fibrosis, and contributes to disease pathophysiol.  The underlying inflammation in each of these diseases is resistant to glucocorticosteroid therapy and is therefore persistent and difficult to treat.  The chemokine receptor CXCR2 is highly expressed on the surface of neutrophils and has been targeted by a no. of pharmaceutical companies as a potential antiinflammatory therapy.  CXCR2 receptor antagonists have been shown to inhibit neutrophil accumulation in a no. of preclin. models of pulmonary inflammation and show good selectivity in human cells ex vivo.  Few CXCR2 receptor antagonists have been reported in clin. trials, although SCH-527123 and SB-656933 have both been shown to be effective in reducing ozone-induced airways neutrophilia in healthy volunteers.  Studies are now under way in patients with COPD and preliminary data have indicated efficacy for SCH-527123.  Further studies on the effects of CXCR2 receptor antagonists are required; however, they appear to be promising, novel antiinflammatory therapies for a no. of pulmonary inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMuCzlrky8ALVg90H21EOLACvtfcHk0lgsHFFfOILVlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ShtLvK&md5=5e515c7bd5f602ec293bc1b21b145fbe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1358%2Fdof.2011.036.06.1622072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2011.036.06.1622072%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChemokine%2520receptor%2520CXCR2%2520antagonism%2520to%2520prevent%2520airways%2520inflammation%26jtitle%3DDrugs%2520Future%26date%3D2011%26volume%3D36%26spage%3D465%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansom, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R.</span><span> </span><span class="NLM_article-title">Inhibition of neutrophil chemokine receptor CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2012&pages=190-190&author=M.+Clarkeauthor=T.+Jamiesonauthor=C.+Steeleauthor=M.+Olsonauthor=M.+Samuelauthor=S.+Dasauthor=O.+Sansomauthor=R.+Nibbs&title=Inhibition+of+neutrophil+chemokine+receptor+CXCR2+profoundly+suppresses+inflammation-driven+and+spontaneous+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DJamieson%26aufirst%3DT.%26aulast%3DSteele%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DM.%26aulast%3DSamuel%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DSansom%26aufirst%3DO.%26aulast%3DNibbs%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520neutrophil%2520chemokine%2520receptor%2520CXCR2%2520profoundly%2520suppresses%2520inflammation-driven%2520and%2520spontaneous%2520tumorigenesis%26jtitle%3DImmunology%26date%3D2012%26volume%3D137%26spage%3D190%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumpian, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caetano, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De la Garza, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapid, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirabolfathinejad, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, S. J.</span><span> </span><span class="NLM_article-title">Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1186%2F1476-4598-12-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=23418729" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=14&author=L.+Gongauthor=A.+M.+Cumpianauthor=M.+S.+Caetanoauthor=C.+E.+Ochoaauthor=M.+M.+De+la+Garzaauthor=D.+J.+Lapidauthor=S.+G.+Mirabolfathinejadauthor=B.+F.+Dickeyauthor=Q.+H.+Zhouauthor=S.+J.+Moghaddam&title=Promoting+effect+of+neutrophils+on+lung+tumorigenesis+is+mediated+by+CXCR2+and+neutrophil+elastase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-14%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DCumpian%26aufirst%3DA.%2BM.%26aulast%3DCaetano%26aufirst%3DM.%2BS.%26aulast%3DOchoa%26aufirst%3DC.%2BE.%26aulast%3DDe%2Bla%2BGarza%26aufirst%3DM.%2BM.%26aulast%3DLapid%26aufirst%3DD.%2BJ.%26aulast%3DMirabolfathinejad%26aufirst%3DS.%2BG.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DZhou%26aufirst%3DQ.%2BH.%26aulast%3DMoghaddam%26aufirst%3DS.%2BJ.%26atitle%3DPromoting%2520effect%2520of%2520neutrophils%2520on%2520lung%2520tumorigenesis%2520is%2520mediated%2520by%2520CXCR2%2520and%2520neutrophil%2520elastase%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma</span> <span class="citation_source-journal">Med. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2466</span><span class="NLM_x">–</span> <span class="NLM_lpage">2472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2Fs12032-011-0152-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22274915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2466-2472&author=L.+Hanauthor=B.+Jiangauthor=H.+Wuauthor=X.+D.+Wangauthor=X.+J.+Tangauthor=J.+F.+Huangauthor=J.+Zhu&title=High+expression+of+CXCR2+is+associated+with+tumorigenesis%2C+progression%2C+and+prognosis+of+laryngeal+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma</span></div><div class="casAuthors">Han, Liang; Jiang, Bin; Wu, Hao; Wang, Xudong; Tang, Xiaojun; Huang, Jianfei; Zhu, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2466-2472</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The laryngeal squamous cell carcinoma (LSCC) is one of the most common cancers threatening people's life.  CXC-chemokine receptor type 2 (CXCR2) was reported to play crit. roles in angiogenesis, tumorigenesis, and metastasis of several cancers such as colon cancer, melanoma, lung cancer, and so on.  However, the expression of CXCR2 in LSCC and its assocn. with clin. characters of LSCC remain unclear.  Quant. real-time reverse transcription-PCR and immunohistochem. were used, resp., to analyze the mRNA level and protein level of CXCR2 in 109 cases of LSCC tissues and 28 cases of tumor-adjacent normal tissues.  The expression of CXCR2 in LSCC was significantly higher than that in tumor-adjacent tissues.  Moreover, the expression level of CXCR2 protein in LSCC was significantly related to lymph node metastasis (P = .022), histopathol. grade (P = .038), and 5 years' survival (P = .007).  Cox regression anal. revealed that CXCR2 expression (P = .031), as well as lymphatic metastasis (P = .026) and TNM classification (P = .042), is an independent prognostic marker of LSCC.  High expression of CXCR2 is also assocd. with short survival of LSCC patients.  Our data indicate that the expression of CXCR2 is assocd. with the development and progression of LSCC.  CXCR2 expression may serve as an independent prognostic marker for LSCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOmgyHIlOCU7Vg90H21EOLACvtfcHk0liJrRTNIGLZwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqt7fN&md5=1981ff72be9fb1a993cc5976ef108020</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs12032-011-0152-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-011-0152-1%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%2BD.%26aulast%3DTang%26aufirst%3DX.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DHigh%2520expression%2520of%2520CXCR2%2520is%2520associated%2520with%2520tumorigenesis%252C%2520progression%252C%2520and%2520prognosis%2520of%2520laryngeal%2520squamous%2520cell%2520carcinoma%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26spage%3D2466%26epage%3D2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Jamieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nibbs, R. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansom, O. J.</span><span> </span><span class="NLM_article-title">Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=3127-3144&author=T.+Jamiesonauthor=M.+Clarkeauthor=C.+W.+Steeleauthor=M.+S.+Samuelauthor=J.+Neumannauthor=A.+Jungauthor=D.+Huelsauthor=M.+F.+Olsonauthor=S.+Dasauthor=R.+J.+B.+Nibbsauthor=O.+J.+Sansom&title=Inhibition+of+CXCR2+profoundly+suppresses+inflammation-driven+and+spontaneous+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DT.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DSteele%26aufirst%3DC.%2BW.%26aulast%3DSamuel%26aufirst%3DM.%2BS.%26aulast%3DNeumann%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DA.%26aulast%3DHuels%26aufirst%3DD.%26aulast%3DOlson%26aufirst%3DM.%2BF.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26atitle%3DInhibition%2520of%2520CXCR2%2520profoundly%2520suppresses%2520inflammation-driven%2520and%2520spontaneous%2520tumorigenesis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D3127%26epage%3D3144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Katoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daikoku, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dey, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, R. N.</span><span> </span><span class="NLM_article-title">CXCR2-Expressing Myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=631-644&author=H.+Katohauthor=D.+Z.+Wangauthor=T.+Daikokuauthor=H.+Y.+Sunauthor=S.+K.+Deyauthor=R.+N.+DuBois&title=CXCR2-Expressing+Myeloid-derived+suppressor+cells+are+essential+to+promote+colitis-associated+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BZ.%26aulast%3DDaikoku%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DH.%2BY.%26aulast%3DDey%26aufirst%3DS.%2BK.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DCXCR2-Expressing%2520Myeloid-derived%2520suppressor%2520cells%2520are%2520essential%2520to%2520promote%2520colitis-associated%2520tumorigenesis%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26spage%3D631%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Balkwill, F. R.</span><span> </span><span class="NLM_article-title">The chemokine system and cancer</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fpath.3029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=21989643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=148-157&author=F.+R.+Balkwill&title=The+chemokine+system+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine system and cancer</span></div><div class="casAuthors">Balkwill, Frances R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-157</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemokines (chemo-attractant cytokines) are a group of small proteins that act together with their cell surface receptors, in development, normal physiol. and immune responses, to direct cells to specific locations throughout the body.  Cancer cells acquire the ability to subvert the chemokine system, such that these mols. and their receptors become important regulators of cell movement into and out of the tumor microenvironment and major players in cancer biol.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmfqm_WcXk_7Vg90H21EOLACvtfcHk0liJrRTNIGLZwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3K&md5=6df65c653856e9cd5cca4f028123e4ac</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fpath.3029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3029%26sid%3Dliteratum%253Aachs%26aulast%3DBalkwill%26aufirst%3DF.%2BR.%26atitle%3DThe%2520chemokine%2520system%2520and%2520cancer%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D148%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.2174%2F15680266106061345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16918453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1345-1352&author=J.+Busch-Petersen&title=Small+molecule+antagonists+of+the+CXCR2+and+CXCR1+chemokine+receptors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Busch-Petersen, Jakob</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1352</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past eight years, numerous series of small mol. CXCR2 and CXCR1 antagonists have been disclosed.  These compds. have proved to be effective inhibitors of ELR+ chemokine-induced chemotaxis of neutrophils and other immune cells in vitro and have also been efficacious in several animal models of inflammatory disease.  Although some of these compds. have been reported to be in clin. development, no data on clin. studies in patients with inflammatory disease has been revealed to date.  This review details the medicinal chem. and pharmacol. of the aforementioned antagonist series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCATg8ZJMoxLVg90H21EOLACvtfcHk0liJrRTNIGLZwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D&md5=0054b0053f9a9a45adeac60677960085</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F15680266106061345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266106061345%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520CXCR2%2520and%2520CXCR1%2520chemokine%2520receptors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1345%26epage%3D1352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bello, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantucci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4312</span><span class="NLM_x">–</span> <span class="NLM_lpage">4331</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049082i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4312-4331&author=M.+Allegrettiauthor=R.+Bertiniauthor=M.+C.+Cestaauthor=C.+Bizzarriauthor=R.+Di+Bitondoauthor=V.+Di+Cioccioauthor=E.+Gallieraauthor=V.+Berdiniauthor=A.+Topaiauthor=G.+Zampellaauthor=V.+Russoauthor=N.+Di+Belloauthor=G.+Nanoauthor=L.+Nicoliniauthor=M.+Locatiauthor=P.+Fantucciauthor=S.+Florioauthor=F.+Colotta&title=2-Arylpropionic+CXC+chemokine+receptor+1+%28CXCR1%29+ligands+as+novel+noncompetitive+CXCL8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm049082i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049082i%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DTopai%26aufirst%3DA.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DV.%26aulast%3DDi%2BBello%26aufirst%3DN.%26aulast%3DNano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DL.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DFantucci%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3D2-Arylpropionic%2520CXC%2520chemokine%2520receptor%25201%2520%2528CXCR1%2529%2520ligands%2520as%2520novel%2520noncompetitive%2520CXCL8%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4312%26epage%3D4331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriconi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervellera, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anniballe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anacardio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutrin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalieri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainiero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strippoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Girolamo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghezzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">11791</span><span class="NLM_x">–</span> <span class="NLM_lpage">11796</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11791-11796&author=R.+Bertiniauthor=M.+Allegrettiauthor=C.+Bizzarriauthor=A.+Moriconiauthor=M.+Locatiauthor=G.+Zampellaauthor=M.+N.+Cervelleraauthor=V.+Di+Cioccioauthor=M.+C.+Cestaauthor=E.+Gallieraauthor=F.+O.+Martinezauthor=R.+Di+Bitondoauthor=G.+Troianiauthor=V.+Sabbatiniauthor=G.+D%E2%80%99Anniballeauthor=R.+Anacardioauthor=J.+C.+Cutrinauthor=B.+Cavalieriauthor=F.+Mainieroauthor=R.+Strippoliauthor=P.+Villaauthor=M.+Di+Girolamoauthor=F.+Martinauthor=M.+Gentileauthor=A.+Santoniauthor=D.+Cordaauthor=G.+Poliauthor=A.+Mantovaniauthor=P.+Ghezziauthor=F.+Colotta&title=Noncompetitive+allosteric+inhibitors+of+the+inflammatory+chemokine+receptors+CXCR1+and+CXCR2%3A+Prevention+of+reperfusion+injury"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DTroiani%26aufirst%3DG.%26aulast%3DSabbatini%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Anniballe%26aufirst%3DG.%26aulast%3DAnacardio%26aufirst%3DR.%26aulast%3DCutrin%26aufirst%3DJ.%2BC.%26aulast%3DCavalieri%26aufirst%3DB.%26aulast%3DMainiero%26aufirst%3DF.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DDi%2BGirolamo%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DGentile%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCorda%26aufirst%3DD.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3DNoncompetitive%2520allosteric%2520inhibitors%2520of%2520the%2520inflammatory%2520chemokine%2520receptors%2520CXCR1%2520and%2520CXCR2%253A%2520Prevention%2520of%2520reperfusion%2520injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D11791%26epage%3D11796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">10095</span><span class="NLM_x">–</span> <span class="NLM_lpage">10098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=9553055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span></div><div class="casAuthors">White, John R.; Lee, Judithann M.; Young, Peter R.; Hertzberg, Robert P.; Jurewicz, Anthony J.; Chaikin, Margery A.; Widdowson, Katherine; Foley, James J.; Martin, Lenox D.; Griswold, Don E.; Sarau, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10095-10098</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) and closely related Glu-Leu-Arg (ELR) contg. CXC chemokines, including growth-related oncogene (GRO)α, GROβ, GROγ, and epithelial cell-derived neutrophil-activating peptide-78 (ENA-78), are potent neutrophil chemotactic and activating peptides, which are proposed to be major mediators of inflammation.  IL-8 activates neutrophils by binding to two distinct seven-transmembrane (7-TMR) G-protein coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROα, GROβ, GROγ, and ENA-78 bind to and activate only CXCR2.  A chem. lead, which selectively inhibited CXCR2 was discovered by high throughput screening and chem. optimized.  SB 225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea) is the first reported potent and selective non-peptide inhibitor of a chemokine receptor.  It is an antagonist of 125I-IL-8 binding to CXCR2 with an IC50 = 22 nM.  SB 225002 showed > 150-fold selectivity over CXCR1 and four other 7-TMRs tested.  In vitro, SB 225002 potently inhibited human and rabbit neutrophil chemotaxis induced by both IL-8 and GROα.  In vivo, SB 225002 selectively blocked IL-8-induced neutrophil margination in rabbits.  The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8.  This selective antagonist will be a useful tool compd. to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO6PNyFAVGW7Vg90H21EOLACvtfcHk0lhaaUipVpy-uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D&md5=28b894f2ff3672653a92f3ff5230d1ac</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D10095%26epage%3D10098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Podolin, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognese, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kajikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">6435</span><span class="NLM_x">–</span> <span class="NLM_lpage">6444</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=6435-6444&author=P.+L.+Podolinauthor=B.+J.+Bologneseauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=P.+T.+Buckleyauthor=K.+L.+Widdowsonauthor=Q.+Jinauthor=J.+R.+Whiteauthor=J.+M.+Leeauthor=R.+B.+Goodmanauthor=T.+R.+Hagenauthor=O.+Kajikawaauthor=L.+A.+Marshallauthor=D.+W.+Hayauthor=H.+M.+Sarau&title=A+potent+and+selective+nonpeptide+antagonist+of+CXCR2+inhibits+acute+and+chronic+models+of+arthritis+in+the+rabbit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DGoodman%26aufirst%3DR.%2BB.%26aulast%3DHagen%26aufirst%3DT.%2BR.%26aulast%3DKajikawa%26aufirst%3DO.%26aulast%3DMarshall%26aufirst%3DL.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DA%2520potent%2520and%2520selective%2520nonpeptide%2520antagonist%2520of%2520CXCR2%2520inhibits%2520acute%2520and%2520chronic%2520models%2520of%2520arthritis%2520in%2520the%2520rabbit%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26spage%3D6435%26epage%3D6444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Traves, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1189%2Fjlb.1003495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15155777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=441-450&author=S.+L.+Travesauthor=S.+J.+Smithauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Specific+CXC+but+not+CC+chemokines+cause+elevated+monocyte+migration+in+COPD%3A+A+role+for+CXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span></div><div class="casAuthors">Traves, Suzanne L.; Smith, Susan J.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Leukocyte migration is crit. to maintaining host defense, but uncontrolled cellular infiltration into tissues can lead to chronic inflammation.  In the lung, such diseases include chronic obstructive pulmonary disease (COPD), a debilitating, respiratory condition characterized by progressive and largely irreversible airflow limitation for which cigarette smoking is the major risk factor.  COPD is assocd. with an increased inflammatory cell influx including increased macrophage nos. in the airways and tissue.  Alveolar macrophages develop from immigrating blood monocytes and have the capacity to cause the pathol. changes assocd. with COPD.  This study addressed the hypothesis that increased macrophage nos. in COPD are a result of increased recruitment of monocytes from the circulation.  Chemotaxis assays of peripheral blood mononuclear cells (PBMC)/monocytes from nonsmokers, smokers, and COPD patients demonstrated increased chemotactic responses for cells from COPD patients when compared with controls toward growth-related oncogene (GRO)α and neutrophil-activating peptide (NAP)-2 but not toward monocyte chemoattractant protein, interleukin-8, or epithelial-derived NAP(ENA)-78.  The enhanced chemotactic response toward GROα and NAP-2 was not mediated by differences in expression of their cellular receptors, CXCR1 or CXCR2.  Receptor expression studies using flow cytometry indicated that in COPD, monocyte expression of CXCR2 is regulated differently from nonsmokers and smokers, which may account for the enhanced migration toward GROα and NAP-2.  The results highlight the potential of CXCR2 antagonists as therapy for COPD and demonstrate that an enhanced PBMC/monocyte response to specific CXC chemokines in these patients may contribute to increased recruitment and activation of macrophages in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99e2ZPsnEhrVg90H21EOLACvtfcHk0lgMizBRiEd8qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D&md5=96ff850e7ae1ffaa342c196b785380ac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003495%26sid%3Dliteratum%253Aachs%26aulast%3DTraves%26aufirst%3DS.%2BL.%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DSpecific%2520CXC%2520but%2520not%2520CC%2520chemokines%2520cause%2520elevated%2520monocyte%2520migration%2520in%2520COPD%253A%2520A%2520role%2520for%2520CXCR2%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D76%26spage%3D441%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biju, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Ezel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terminelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozgur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7603</span><span class="NLM_x">–</span> <span class="NLM_lpage">7606</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0609622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7603-7606&author=M.+P.+Dwyerauthor=Y.+Yuauthor=J.+Chaoauthor=C.+Akiauthor=P.+Bijuauthor=V.+Girijavallabhanauthor=D.+Rindgenauthor=R.+Bondauthor=R.+Mayer-Ezelauthor=J.+Jakwayauthor=R.+W.+Hipkinauthor=J.+Fossettaauthor=W.+Gonsiorekauthor=H.+Bianauthor=X.+Fanauthor=C.+Terminelliauthor=J.+Fineauthor=D.+Lundellauthor=J.+R.+Merrittauthor=L.+L.+Rokoszauthor=B.+Kaiserauthor=G.+Liauthor=W.+Wangauthor=T.+Staufferauthor=L.+Ozgurauthor=J.+Baldwinauthor=A.+G.+Taveras&title=Discovery+of+2-hydroxy-N%2CN-dimethyl-3-%7B2-%5B%5B%28R%29-1-%285-methylfuran-2-yl%29propyl%5Damino%5D-3%2C4-dioxocyclobut-1-enylamino%7Dbenzamide+%28SCH+527123%29%3A+A+potent%2C+orally+bioavailable+CXCR2%2FCXCR1+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm0609622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609622%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DBiju%26aufirst%3DP.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DMayer-Ezel%26aufirst%3DR.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DTerminelli%26aufirst%3DC.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DStauffer%26aufirst%3DT.%26aulast%3DOzgur%26aufirst%3DL.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-hydroxy-N%252CN-dimethyl-3-%257B2-%255B%255B%2528R%2529-1-%25285-methylfuran-2-yl%2529propyl%255Damino%255D-3%252C4-dioxocyclobut-1-enylamino%257Dbenzamide%2520%2528SCH%2520527123%2529%253A%2520A%2520potent%252C%2520orally%2520bioavailable%2520CXCR2%252FCXCR1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7603%26epage%3D7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Aul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plumb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span> </span><span class="NLM_article-title">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.intimp.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22561413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-231&author=R.+Aulauthor=S.+Patelauthor=S.+Summerhillauthor=I.+Kiltyauthor=J.+Plumbauthor=D.+Singh&title=LPS+challenge+in+healthy+subjects%3A+An+investigation+of+neutrophil+chemotaxis+mechanisms+involving+CXCR1+and+CXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span></div><div class="casAuthors">Aul, Raminder; Patel, Sheena; Summerhill, Susan; Kilty, Iain; Plumb, Jonathan; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process.14 healthy non-smoking subjects inhaled 30 μg of LPS.  Sputum was induced at baseline, 6 and 24 h post-LPS challenge.  Differential cell counts were detd. and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured.  Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis expts. using sputum supernatant.  To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested.  LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24 h resp.  LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1.  Neutrophil chemotaxis significantly increased (2.7 fold) at 24 h compared to baseline.  Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933.  We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is assocd. with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBzkQc4_KA7Vg90H21EOLACvtfcHk0lgmTeJW39QCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D&md5=c196cbe3264f545d5e2d90b1b95a6c05</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAul%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DLPS%2520challenge%2520in%2520healthy%2520subjects%253A%2520An%2520investigation%2520of%2520neutrophil%2520chemotaxis%2520mechanisms%2520involving%2520CXCR1%2520and%2520CXCR2%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2012%26volume%3D13%26spage%3D225%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexis, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits <i>ex vivo</i> neutrophil activation and ozone-induced airway inflammation in humans</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0lgmTeJW39QCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Moss, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilewski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Investigators, C. F.</span><span> </span><span class="NLM_article-title">Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.jcf.2012.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22995323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2lu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=241-248&author=R.+B.+Mossauthor=S.+J.+Mistryauthor=M.+W.+Konstanauthor=J.+M.+Pilewskiauthor=E.+Keremauthor=R.+Tal-Singerauthor=A.+L.+Lazaarauthor=C.+F.+Investigators&title=Safety+and+early+treatment+effects+of+the+CXCR2+antagonist+SB-656933+in+patients+with+cystic+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis</span></div><div class="casAuthors">Moss, Richard B.; Mistry, Sunil J.; Konstan, Michael W.; Pilewski, Joseph M.; Kerem, Eitan; Tal-Singer, Ruth; Lazaar, Aili L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is hypothesized that a CXCR2 receptor antagonist would inhibit the recruitment and activation of neutrophils and other inflammatory cells into the lung in subjects with cystic fibrosis.  The objective of this study was to evaluate the safety, tolerability and pharmacodynamics of SB-656933, an oral CXCR2 antagonist.146 adult CF patients were randomized to receive either placebo or SB-656933 20 mg or 50 mg once daily for 28 days.  The primary endpoint was safety; secondary endpoints included pharmacokinetics, blood and sputum biomarkers, sputum microbiol., pulmonary function and respiratory symptoms.  SB-656933 was generally well tolerated.  The most frequent adverse event was headache.  Five subjects were withdrawn due to adverse events.  In subjects receiving SB-656933 50 mg, sputum neutrophils and elastase were reduced compared to baseline (probability of a true redn., 0.889 and 0.882 resp.), and free DNA reduced compared to placebo (probability of a true redn., 0.967), while blood levels of fibrinogen, CRP and CXCL8 were increased.  There were no changes in lung function or respiratory symptoms.  Av. plasma concns. of SB-656933 were lower than predicted based on previous studies, only breaching IC50 for ∼ 4 h at the 50 mg dose.  SB-656933 was well-tolerated in adult patients with cystic fibrosis.  Patients receiving a daily dose of 50 mg showed trends for improvement in sputum inflammatory biomarkers despite potential blunting of effects by lower than expected plasma concns.  Although the increase in systemic inflammatory markers requires further evaluation, CXCR2 antagonism may be a useful approach for modulating airway inflammation in patients with cystic fibrosis.  Clin. trial registered with www.clinicaltrials.gov (NCT00903201).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQVyIOt9Ix6LVg90H21EOLACvtfcHk0lgmTeJW39QCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2lu7s%253D&md5=6ac4fe6aea45ac5b1d5b043f24e4f20a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2012.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2012.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DR.%2BB.%26aulast%3DMistry%26aufirst%3DS.%2BJ.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DPilewski%26aufirst%3DJ.%2BM.%26aulast%3DKerem%26aufirst%3DE.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DInvestigators%26aufirst%3DC.%2BF.%26atitle%3DSafety%2520and%2520early%2520treatment%2520effects%2520of%2520the%2520CXCR2%2520antagonist%2520SB-656933%2520in%2520patients%2520with%2520cystic%2520fibrosis%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2013%26volume%3D12%26spage%3D241%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Holz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalilieh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig-Sengpiel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryszak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 × 106 mL-1) compared with prednisolone (0.84 × 106/mL-1; p < 0.001) or placebo (2.98 × 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0lhQ1S2ZLhFRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D564%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. N.</span><span> </span><span class="NLM_article-title">CXCR2 modulators: a patent review (2009–2013)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1517%2F13543776.2014.887682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=24555661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=519-534&author=M.+P.+Dwyerauthor=Y.+N.+Yu&title=CXCR2+modulators%3A+a+patent+review+%282009%E2%80%932013%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 modulators: a patent review (2009 - 2013)</span></div><div class="casAuthors">Dwyer, Michael P.; Yu, Younong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-534</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Small-mol. antagonists of CXC chemokine receptor 2 (CXCR2) have attracted a considerable amt. of attention due to the key central role that this receptor plays in inflammatory conditions.  Recently, several CXCR2 receptor antagonists have demonstrated promising proof of activity in early pulmonary clin. trials, which has stimulated addnl. efforts to identify new CXCR2 receptor antagonists.  Areas covered: During the period 2009 - 2013, there were numerous patent publications from various companies claiming the discovery of novel CXCR2 receptor antagonists.  Herein, an interpretation of these new patent publications combined with emerging disclosures from the peer-reviewed literature during this time frame is given.  This review highlights the preferred or representative compds. from the patent applications along with relevant biol. characterization.  Expert opinion: Many of the new CXCR2 receptor antagonists described in this review represent closely related analogs to previously disclosed clin. candidates.  With the recent discontinuation of several CXCR2 receptor antagonists in the clinic, addnl. clin. trial information for CXCR2 receptor antagonists, both past and present, will det. the long-term therapeutic potential of these compds. for the treatment of a variety of inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLzyTSdxdHbVg90H21EOLACvtfcHk0lhQ1S2ZLhFRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D&md5=c1b5bd8730268cd12851722a3880a118</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.887682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.887682%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%2BN.%26atitle%3DCXCR2%2520modulators%253A%2520a%2520patent%2520review%2520%25282009%25E2%2580%25932013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D519%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Virtala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekman, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardell, L. O.</span><span> </span><span class="NLM_article-title">Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2222.2011.03921.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=22192144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVentbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=590-596&author=R.+Virtalaauthor=A.+K.+Ekmanauthor=L.+Janssonauthor=U.+Westinauthor=L.+O.+Cardell&title=Airway+inflammation+evaluated+in+a+human+nasal+lipopolysaccharide+challenge+model+by+investigating+the+effect+of+a+CXCR2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor</span></div><div class="casAuthors">Virtala, R.; Ekman, A.-K.; Jansson, L.; Westin, U.; Cardell, L. O.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">590-596</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: The existence of a link between inflammation in upper and lower airways is well established.  It may therefore be assumed that the nose could be used to study inflammatory events in the lower airways.  Objective: This study aimed to evaluate a lipopolysaccharide (LPS) nasal challenge model by investigating the effect of the CXCR2 inhibitor AZD8309 on neutrophilic inflammation.  Methods: A total of 18 healthy volunteers were randomized in a placebo-controlled, double-blind, cross-over study.  AZD8309 or placebo was dosed for 3 days.  Subjects were challenged nasally with LPS (50 μg/nostril), and nasal lavage was performed 6 and 24 h later.  Leukocytes, neutrophils and inflammatory mediators were assessed in the lavage fluid.  The outcome was compared with data from analogous expts. performed in a model of inhaled LPS followed by induced sputum.  This trial was registered in the Current Controlled Trials register (ISRCTN trial no.: ISRCTN46666382).  Results: The leukocytes in nasal lavage consisted to 99% of neutrophils on av.  Treatment with AZD8309 reduced the leukocyte count to 48% of placebo 6 h after the LPS challenge.  There was also a redn. in LTB4 levels to 45% of placebo after 6 h and in the neutrophil elastase activity after 24 h.  No major adverse events were seen with either AZD8309 or placebo.  The nasal LPS model induced only minimal local irritation and no signs of systemic inflammation.  Conclusions and Clin. Relevance: LPS-induced neutrophil recruitment was reduced by inhibition of CXCR2.  This outcome mimicked the response previously seen in a lower airway LPS model.  Hence, the nasal model offers a convenient and well-tolerated alternative for pharmacol. evaluation of anti-inflammatory drugs affecting neutrophilic migration and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfyFgE2oSUDbVg90H21EOLACvtfcHk0lhQ1S2ZLhFRtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVentbw%253D&md5=b7829eb66040540a01997baaba10c43b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2011.03921.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2011.03921.x%26sid%3Dliteratum%253Aachs%26aulast%3DVirtala%26aufirst%3DR.%26aulast%3DEkman%26aufirst%3DA.%2BK.%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DWestin%26aufirst%3DU.%26aulast%3DCardell%26aufirst%3DL.%2BO.%26atitle%3DAirway%2520inflammation%2520evaluated%2520in%2520a%2520human%2520nasal%2520lipopolysaccharide%2520challenge%2520model%2520by%2520investigating%2520the%2520effect%2520of%2520a%2520CXCR2%2520inhibitor%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2012%26volume%3D42%26spage%3D590%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Cutshall, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, N. C.</span><span> </span><span class="NLM_article-title">Nicotinanilides as inhibitors of neutrophil chemotaxis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1517-1520&author=N.+S.+Cutshallauthor=K.+A.+Kuceraauthor=R.+Ursinoauthor=J.+Lathamauthor=N.+C.+Ihle&title=Nicotinanilides+as+inhibitors+of+neutrophil+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCutshall%26aufirst%3DN.%2BS.%26aulast%3DKucera%26aufirst%3DK.%2BA.%26aulast%3DUrsino%26aufirst%3DR.%26aulast%3DLatham%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DN.%2BC.%26atitle%3DNicotinanilides%2520as%2520inhibitors%2520of%2520neutrophil%2520chemotaxis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1517%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Maeda, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schepetkin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotina, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zebala, J. A.</span><span> </span><span class="NLM_article-title">Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.109.159020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19779130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2010&pages=145-152&author=D.+Y.+Maedaauthor=M.+T.+Quinnauthor=I.+A.+Schepetkinauthor=L.+N.+Kirpotinaauthor=J.+A.+Zebala&title=Nicotinamide+glycolates+antagonize+CXCR2+activity+through+an+intracellular+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism</span></div><div class="casAuthors">Maeda, Dean Y.; Quinn, Mark T.; Schepetkin, Igor A.; Kirpotina, Liliya N.; Zebala, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease.  Several classes of allosteric small-mol. CXCR1/2 antagonists have been developed.  The data presented here describe the cellular pharmacol. of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8.  Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/CXCR2 binding and CXCL1-stimulated guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange.  Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125I-CXCL8/CXCR2 binding and CXCL1-stimulated [35S]GTPγS exchange.  The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process.  The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior.  Neutrophil efflux of the acid was probenecid-sensitive, consistent with an org. acid transporter.  These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site.  Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI_AT4uMMh7Vg90H21EOLACvtfcHk0lgv8Blk7KaMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yqsw%253D%253D&md5=8b86e6eca136c2884f6267085ebe0779</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.159020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.159020%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DNicotinamide%2520glycolates%2520antagonize%2520CXCR2%2520activity%2520through%2520an%2520intracellular%2520mechanism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D332%26spage%3D145%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Webb, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span> </span><span class="NLM_article-title">A facile oxidation of boronic acids and boronic esters</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">5117</span><span class="NLM_x">–</span> <span class="NLM_lpage">5118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=5117-5118&author=K.+S.+Webbauthor=D.+Levy&title=A+facile+oxidation+of+boronic+acids+and+boronic+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DK.%2BS.%26aulast%3DLevy%26aufirst%3DD.%26atitle%3DA%2520facile%2520oxidation%2520of%2520boronic%2520acids%2520and%2520boronic%2520esters%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D5117%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wittenberger, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donner, B. G.</span><span> </span><span class="NLM_article-title">Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4139</span><span class="NLM_x">–</span> <span class="NLM_lpage">4141</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=4139-4141&author=S.+J.+Wittenbergerauthor=B.+G.+Donner&title=Dialkyltin+oxide+mediated+addition+of+trimethylsilyl+azide+to+nitriles.+A+novel+preparation+of+5-substituted+tetrazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a058%26sid%3Dliteratum%253Aachs%26aulast%3DWittenberger%26aufirst%3DS.%2BJ.%26aulast%3DDonner%26aufirst%3DB.%2BG.%26atitle%3DDialkyltin%2520oxide%2520mediated%2520addition%2520of%2520trimethylsilyl%2520azide%2520to%2520nitriles.%2520A%2520novel%2520preparation%2520of%25205-substituted%2520tetrazoles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D4139%26epage%3D4141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Hunter, P.</span><span> </span><span class="NLM_article-title">Not boring at all Boron is the new carbon in the quest for novel drug candidates</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">U110</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-U110&author=P.+Hunter&title=Not+boring+at+all+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3DU110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Yang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. H.</span><span> </span><span class="NLM_article-title">Boronic acid compounds as potential pharmaceutical agents</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2Fmed.10043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12647314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=346-368&author=W.+Q.+Yangauthor=X.+M.+Gaoauthor=B.+H.+Wang&title=Boronic+acid+compounds+as+potential+pharmaceutical+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic acid compounds as potential pharmaceutical agents</span></div><div class="casAuthors">Yang, Wenqian; Gao, Xingming; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">346-368</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Boronic acid compds. have been used, because of their unique structural features, for the development of potent enzyme inhibitors, boron neutron capture agents for cancer therapy, and as antibody mimics that recognize biol. important saccharides.  Consequently, there has been a surge of interests in boronic acid compds.  This study reviews the recent development in this area during the last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CvJjV10BbVg90H21EOLACvtfcHk0lgv8Blk7KaMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitb8%253D&md5=0b841477e2113218d55991e23133bd60</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fmed.10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10043%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DGao%26aufirst%3DX.%2BM.%26aulast%3DWang%26aufirst%3DB.%2BH.%26atitle%3DBoronic%2520acid%2520compounds%2520as%2520potential%2520pharmaceutical%2520agents%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D346%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hall, D. G.</span> <span class="citation_source-book">Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine</span>; <span class="NLM_publisher-name">WILEY-VCH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1002%2F3527606548" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+G.+Hall&title=Boronic+Acids%3A+Preparation+and+Applications+in+Organic+Synthesis+and+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2F3527606548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527606548%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%2BG.%26btitle%3DBoronic%2520Acids%253A%2520Preparation%2520and%2520Applications%2520in%2520Organic%2520Synthesis%2520and%2520Medicine%26pub%3DWILEY-VCH%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Cutshall, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, N. C.</span><span> </span><span class="NLM_article-title">Nicotinamide N-oxides as CXCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1954</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1951-1954&author=N.+S.+Cutshallauthor=R.+Ursinoauthor=K.+A.+Kuceraauthor=J.+Lathamauthor=N.+C.+Ihle&title=Nicotinamide+N-oxides+as+CXCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCutshall%26aufirst%3DN.%2BS.%26aulast%3DUrsino%26aufirst%3DR.%26aulast%3DKucera%26aufirst%3DK.%2BA.%26aulast%3DLatham%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DN.%2BC.%26atitle%3DNicotinamide%2520N-oxides%2520as%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1951%26epage%3D1954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1038%2Fnrd746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=12120504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFCltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=198-210&author=A.+Christopoulos&title=Allosteric+binding+sites+on+cell-surface+receptors%3A+Novel+targets+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric binding sites on cell-surface receptors: novel targets for drug discovery</span></div><div class="casAuthors">Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-210</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cell-surface receptors are the targets for more than 60% of current drugs.  Traditionally, optimizing the interaction of lead mols. with the binding site for the endogenous agonist (orthosteric site) has been viewed as the best means of achieving selectivity of action.  However, recent developments have highlighted the fact that drugs can interact with binding sites on the receptor mol. that are distinct from the orthosteric site, known as allosteric sites.  Allosteric modulators could offer several advantages over orthosteric ligands, including greater selectivity and saturability of their effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gwh2HPhjn7Vg90H21EOLACvtfcHk0lg7I3pgNMKndQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFCltrc%253D&md5=10f885e2f54f745d9b7dcbf2c6cc583f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd746%26sid%3Dliteratum%253Aachs%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520binding%2520sites%2520on%2520cell-surface%2520receptors%253A%2520Novel%2520targets%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D198%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">de Kruijf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Heteren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Lee, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auld, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkmans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">329</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.108.148387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19190236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=783-790&author=P.+de+Kruijfauthor=J.+van+Heterenauthor=H.+D.+Limauthor=P.+G.+Contiauthor=M.+M.+van+der+Leeauthor=L.+Boschauthor=K.+K.+Hoauthor=D.+Auldauthor=M.+Ohlmeyerauthor=M.+J.+Smitauthor=J.+C.+Wijkmansauthor=G.+J.+Zamanauthor=M.+J.+Smitauthor=R.+Leurs&title=Nonpeptidergic+allosteric+antagonists+differentially+bind+to+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor</span></div><div class="casAuthors">de Kruijf, Petra; van Heteren, Jane; Lim, Herman D.; Conti, Paolo G. M.; van der Lee, Miranda M. C.; Bosch, Leontien; Ho, Koc-Kan; Auld, Douglas; Ohlmeyer, Michael; Smit, Martin J.; Wijkmans, Jac C. H. M.; Zaman, Guido J. R.; Smit, Martine J.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine receptor CXCR2 is involved in different inflammatory diseases, like chronic obstructive pulmonary disease, psoriasis, rheumatoid arthritis, and ulcerative colitis; therefore, it is considered an attractive drug target.  Different classes of small CXCR2 antagonists have been developed.  In this study, seven CXCR2 antagonists were selected from the diarylurea, imidazolylpyrimide, and thiazolopyrimidine class and their mechanisms of action at human CXCR2 were studied.  All compds. are able to displace 125I-CXCL8 and inhibit CXCL8-induced β-arrestin2 recruitment.  Detailed studies with representatives of each class showed that these compds. displace and antagonize CXCL8, most probably via a non-competitive, allosteric mechanism.  In addn., the high-affinity CXCR2 antagonist SB265610 [1-(2-bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]-triazol-7-yl)urea] was radiolabeled and [3H]SB265610 was subjected to a detailed anal.  The binding of this radioligand was saturable and reversible.  Using [3H]SB265610, it was found that compds. of the different chem. classes bind to distinct binding sites.  Hence, the use of a radiolabeled low-mol. wt. CXCR2 antagonist serves as a tool to investigate the different binding sites of CXCR2 antagonists in more detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk1OTdlwM-sLVg90H21EOLACvtfcHk0lg7I3pgNMKndQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1OlsLs%253D&md5=cdb5fcac62aa5c0cc1fff0b66f81557a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.148387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.148387%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKruijf%26aufirst%3DP.%26aulast%3Dvan%2BHeteren%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DConti%26aufirst%3DP.%2BG.%26aulast%3Dvan%2Bder%2BLee%26aufirst%3DM.%2BM.%26aulast%3DBosch%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DK.%2BK.%26aulast%3DAuld%26aufirst%3DD.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3DWijkmans%26aufirst%3DJ.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DNonpeptidergic%2520allosteric%2520antagonists%2520differentially%2520bind%2520to%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mueller, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schraw, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, A.</span><span> </span><span class="NLM_article-title">Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">8207</span><span class="NLM_x">–</span> <span class="NLM_lpage">8214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=8207-8214&author=S.+G.+Muellerauthor=J.+R.+Whiteauthor=W.+P.+Schrawauthor=V.+Lamauthor=A.+Richmond&title=Ligand-induced+desensitization+of+the+human+CXC+chemokine+receptor-2+is+modulated+by+multiple+serine+residues+in+the+carboxyl-terminal+domain+of+the+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DS.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DSchraw%26aufirst%3DW.%2BP.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DRichmond%26aufirst%3DA.%26atitle%3DLigand-induced%2520desensitization%2520of%2520the%2520human%2520CXC%2520chemokine%2520receptor-2%2520is%2520modulated%2520by%2520multiple%2520serine%2520residues%2520in%2520the%2520carboxyl-terminal%2520domain%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D8207%26epage%3D8214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Shyamala, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoja, H.</span><span> </span><span class="NLM_article-title">Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">15918</span><span class="NLM_x">–</span> <span class="NLM_lpage">15924</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi9811415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=15918-15924&author=V.+Shyamalaauthor=H.+Khoja&title=Interleukin-8+receptors+R1+and+R2+activate+mitogen-activated+protein+kinases+and+induce+c-fos%2C+independent+of+Ras+and+Raf-1+in+Chinese+hamster+ovary+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fbi9811415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9811415%26sid%3Dliteratum%253Aachs%26aulast%3DShyamala%26aufirst%3DV.%26aulast%3DKhoja%26aufirst%3DH.%26atitle%3DInterleukin-8%2520receptors%2520R1%2520and%2520R2%2520activate%2520mitogen-activated%2520protein%2520kinases%2520and%2520induce%2520c-fos%252C%2520independent%2520of%2520Ras%2520and%2520Raf-1%2520in%2520Chinese%2520hamster%2520ovary%2520cells%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D15918%26epage%3D15924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Hammond, M. E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedlin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullenbach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekampolson, P.</span><span> </span><span class="NLM_article-title">IL-8 induces neutrophil chemotaxis predominantly via type-I IL-8 receptors</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">1428</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=1428-1433&author=M.+E.+W.+Hammondauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=S.+Hiltauthor=C.+A.+Gallegosauthor=C.+A.+Gordonauthor=M.+A.+Giedlinauthor=G.+Mullenbachauthor=P.+Tekampolson&title=IL-8+induces+neutrophil+chemotaxis+predominantly+via+type-I+IL-8+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DM.%2BE.%2BW.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DHilt%26aufirst%3DS.%26aulast%3DGallegos%26aufirst%3DC.%2BA.%26aulast%3DGordon%26aufirst%3DC.%2BA.%26aulast%3DGiedlin%26aufirst%3DM.%2BA.%26aulast%3DMullenbach%26aufirst%3DG.%26aulast%3DTekampolson%26aufirst%3DP.%26atitle%3DIL-8%2520induces%2520neutrophil%2520chemotaxis%2520predominantly%2520via%2520type-I%2520IL-8%2520receptors%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D1428%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Posadas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terencio, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandiz, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coloma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, M. J.</span><span> </span><span class="NLM_article-title">Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation</span> <span class="citation_source-journal">N-S Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2000&pages=98-106&author=I.+Posadasauthor=M.+C.+Terencioauthor=I.+Guillenauthor=M.+L.+Ferrandizauthor=J.+Colomaauthor=M.+Payaauthor=M.+J.+Alcaraz&title=Co-regulation+between+cyclo-oxygenase-2+and+inducible+nitric+oxide+synthase+expression+in+the+time-course+of+murine+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPosadas%26aufirst%3DI.%26aulast%3DTerencio%26aufirst%3DM.%2BC.%26aulast%3DGuillen%26aufirst%3DI.%26aulast%3DFerrandiz%26aufirst%3DM.%2BL.%26aulast%3DColoma%26aufirst%3DJ.%26aulast%3DPaya%26aufirst%3DM.%26aulast%3DAlcaraz%26aufirst%3DM.%2BJ.%26atitle%3DCo-regulation%2520between%2520cyclo-oxygenase-2%2520and%2520inducible%2520nitric%2520oxide%2520synthase%2520expression%2520in%2520the%2520time-course%2520of%2520murine%2520inflammation%26jtitle%3DN-S%2520Arch.%2520Pharmacol.%26date%3D2000%26volume%3D361%26spage%3D98%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Moriconi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervellera, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coniglio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colagioia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beccari, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavicchia, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Benedetto, P.</span><span> </span><span class="NLM_article-title">Vigilante, P.; Bertini, R.; Allegretti, M. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3984</span><span class="NLM_x">–</span> <span class="NLM_lpage">4002</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061469t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3984-4002&author=A.+Moriconiauthor=M.+C.+Cestaauthor=M.+N.+Cervelleraauthor=A.+Araminiauthor=S.+Coniglioauthor=S.+Colagioiaauthor=A.+R.+Beccariauthor=C.+Bizzarriauthor=M.+R.+Cavicchiaauthor=M.+Locatiauthor=E.+Gallieraauthor=P.+Di+Benedetto&title=Vigilante%2C+P.%3B+Bertini%2C+R.%3B+Allegretti%2C+M.+Design+of+noncompetitive+interleukin-8+inhibitors+acting+on+CXCR1+and+CXCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm061469t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061469t%26sid%3Dliteratum%253Aachs%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3DAramini%26aufirst%3DA.%26aulast%3DConiglio%26aufirst%3DS.%26aulast%3DColagioia%26aufirst%3DS.%26aulast%3DBeccari%26aufirst%3DA.%2BR.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DCavicchia%26aufirst%3DM.%2BR.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DDi%2BBenedetto%26aufirst%3DP.%26atitle%3DVigilante%252C%2520P.%253B%2520Bertini%252C%2520R.%253B%2520Allegretti%252C%2520M.%2520Design%2520of%2520noncompetitive%2520interleukin-8%2520inhibitors%2520acting%2520on%2520CXCR1%2520and%2520CXCR2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3984%26epage%3D4002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0lhfPwY34P7ecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span> </span><span class="NLM_article-title">Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">6682</span><span class="NLM_x">–</span> <span class="NLM_lpage">6686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=6682-6686&author=S.+A.+Jonesauthor=M.+Wolfauthor=S.+Qinauthor=C.+R.+Mackayauthor=M.+Baggiolini&title=Different+functions+for+the+interleukin+8+receptors+%28IL-8R%29+of+human+neutrophil+leukocytes%3A+NADPH+oxidase+and+phospholipase+D+are+activated+through+IL-8R1+but+not+IL-8R2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DBaggiolini%26aufirst%3DM.%26atitle%3DDifferent%2520functions%2520for%2520the%2520interleukin%25208%2520receptors%2520%2528IL-8R%2529%2520of%2520human%2520neutrophil%2520leukocytes%253A%2520NADPH%2520oxidase%2520and%2520phospholipase%2520D%2520are%2520activated%2520through%2520IL-8R1%2520but%2520not%2520IL-8R2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D6682%26epage%3D6686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Geiser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewald, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrengruber, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarklewis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span> </span><span class="NLM_article-title">The interleukin-8-related chemotactic cytokines GRO-alpha, GRO-beta, and GRO-gamma activate human neutrophil and basophil leukocytes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">15419</span><span class="NLM_x">–</span> <span class="NLM_lpage">15424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=15419-15424&author=T.+Geiserauthor=B.+Dewaldauthor=M.+U.+Ehrengruberauthor=I.+Clarklewisauthor=M.+Baggiolini&title=The+interleukin-8-related+chemotactic+cytokines+GRO-alpha%2C+GRO-beta%2C+and+GRO-gamma+activate+human+neutrophil+and+basophil+leukocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeiser%26aufirst%3DT.%26aulast%3DDewald%26aufirst%3DB.%26aulast%3DEhrengruber%26aufirst%3DM.%2BU.%26aulast%3DClarklewis%26aufirst%3DI.%26aulast%3DBaggiolini%26aufirst%3DM.%26atitle%3DThe%2520interleukin-8-related%2520chemotactic%2520cytokines%2520GRO-alpha%252C%2520GRO-beta%252C%2520and%2520GRO-gamma%2520activate%2520human%2520neutrophil%2520and%2520basophil%2520leukocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D15419%26epage%3D15424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Kaur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span> </span><span class="NLM_article-title">Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: The role of CXCL8 and the receptors CXCR1/CXCR2</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1124%2Fjpet.112.201855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=23912333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=173-180&author=M.+Kaurauthor=D.+Singh&title=Neutrophil+chemotaxis+caused+by+chronic+obstructive+pulmonary+disease+alveolar+macrophages%3A+The+role+of+CXCL8+and+the+receptors+CXCR1%2FCXCR2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2</span></div><div class="casAuthors">Kaur, Manminder; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-180</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Alveolar macrophages produce neutrophil chemoattractants; this cellular cross-talk contributes to neutrophilic airway inflammation in chronic obstructive pulmonary disease (COPD).  We have investigated the chemotaxis cross-talk mechanisms between these cells using COPD alveolar macrophages.  Using conditioned media from stimulated COPD alveolar macrophages, we investigated the relative contributions of growth-related oncogene (CXCL1), interleukin-8 (CXCL8), and regulated on activation normal T cell expressed and secreted (CCL5) to neutrophil chemotaxis and evaluated the effect of blocking the chemokine receptors CXCR1 and CXCR2 on chemotaxis caused by macrophage-conditioned media.  Furthermore, we evaluated whether corticosteroid treatment of stimulated alveolar macrophages inhibited the chemotaxis ability of conditioned media.  Alveolar macrophages isolated from COPD (n = 8) and smoker (S) (n = 8) lungs were treated with ultra-pure lipopolysaccharide in the presence and absence of dexamethasone (1 μM).  Supernatants were used for neutrophil chemotaxis assays.  SB656933 (2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}-benzamide) (CXCR2 antagonist) and Sch527123 [1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea, 3-(2-chloro-3-fluoro-phenyl)-1-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonyl-phenyl)urea] (dual CXCR1 and CXCR2 antagonist) and blocking antibodies for CXCL8, CXCL1, and CCL5 were assessed.  Conditioned media caused neutrophil chemotaxis in COPD and smokers (60.5 and 79.9% of total cells, resp.).  Dexamethasone did not significantly reduce neutrophil chemotaxis in COPD or S. SB656933 and Sch527123 inhibited chemotaxis in a concn.-dependent manner, with the dual antagonist Sch527123 causing greater inhibition of chemotaxis.  CXCL8 antibody inhibited neutrophil chemotaxis to basal levels, although there was no significant effect of blocking either CXCL1 or CCL5 (P > 0.05).  CXCL8 plays a major role in neutrophil chemotaxis caused by alveolar macrophage-derived conditioned media, and this is most effectively inhibited by dual antagonism of CXCR1 and CXCR2.  Corticosteroids do not inhibit chemotaxis caused by macrophage-derived chemokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsoYyZrJgEbrVg90H21EOLACvtfcHk0lhfPwY34P7ecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2ks7vL&md5=4f381dffd65c9a5e87e4c02877c7d96e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201855%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DNeutrophil%2520chemotaxis%2520caused%2520by%2520chronic%2520obstructive%2520pulmonary%2520disease%2520alveolar%2520macrophages%253A%2520The%2520role%2520of%2520CXCL8%2520and%2520the%2520receptors%2520CXCR1%252FCXCR2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D173%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">May, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avlani, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors</span> <span class="citation_source-journal">Curr. Pharm. Design</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.2174%2F1381612043384303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=15279541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=2003-2013&author=L.+T.+Mayauthor=V.+A.+Avlaniauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+modulation+of+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors</span></div><div class="casAuthors">May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2003-2013</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) constitute the largest receptor superfamily in the human genome and represent the most common targets of drug action.  Classic agonist and antagonist ligands that act at GPCRs tend to bind to the receptor's orthosteric site, i.e., the site recognized by the endogenous agonist for that receptor.  However, it is now evident that GPCRs possess addnl., extracellular, allosteric binding sites that can be recognized by a variety of small mol. modulator ligands.  Allosteric modulators offer many advantages over classic orthosteric ligands as therapeutic agents, including the potential for greater GPCR-subtype selectivity and safety.  However, the manifestations of allosterism at GPCRs are many and varied and, in the past, traditional screening methods have generally failed to detect many allosteric modulators.  More recently, there have been a no. of major advances in high throughput screening, including the advent of cell-based functional assays, which have led to the discovery of more allosteric modulator ligands than previously appreciated.  In addn., a no. of powerful anal. techniques have also been developed exclusively for detecting and quantifying allosteric effects, based on an increased awareness of various mechanisms underlying allosteric modulator actions at GPCRs.  Together, these advances promise to change the current paucity of GPCR allosteric modulators in the clin. setting and yield novel therapeutic entities for the treatment of numerous disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiEpajFz3ILVg90H21EOLACvtfcHk0lgaAU7i3iF3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFCntbs%253D&md5=c4448105f37b36763b935b215383f2bb</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1381612043384303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043384303%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DL.%2BT.%26aulast%3DAvlani%26aufirst%3DV.%2BA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DCurr.%2520Pharm.%2520Design%26date%3D2004%26volume%3D10%26spage%3D2003%26epage%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1476-5381.2009.00182.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=19422399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=328-338&author=M.+E.+Bradleyauthor=M.+E.+Bondauthor=J.+Maniniauthor=Z.+Brownauthor=S.+J.+Charlton&title=SB265610+is+an+allosteric%2C+inverse+agonist+at+the+human+CXCR2+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor</span></div><div class="casAuthors">Bradley, M. E.; Bond, M. E.; Manini, J.; Brown, Z.; Charlton, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">328-338</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and purpose: In several previous studies, the C-X-C chemokine receptor (CXCR)2 antagonist 1-(2-bromophenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea (SB265610) has been described as binding competitively with the endogenous agonist.  This is in contrast to many other chemokine receptor antagonists, where the mechanism of antagonism has been described as allosteric.  Exptl. approach: To det. whether it displays a unique mechanism among the chemokine receptor antagonists, the mode of action of SB265610 was investigated at the CXCR2 receptor using radioligand and [35S]-GTPγS binding approaches in addn. to chemotaxis of human neutrophils.  Key results: In equil. satn. binding studies, SB265610 depressed the maximal binding of [125I]-interleukin-8 ([125I]-IL-8) without affecting the Kd.  In contrast, IL-8 was unable to prevent binding of [3H]-SB265610.  Kinetic binding expts. demonstrated that this was not an artifact of irreversible or slowly reversible binding.  In functional expts., SB265610 caused a rightward shift of the concn.-response curves to IL-8 and growth-related oncogene α, but also a redn. in maximal response elicited by each agonist.  Fitting these data to an operational allosteric ternary complex model suggested that, once bound, SB265610 completely blocks receptor activation.  SB265610 also inhibited basal [35S]-GTPγS binding in this prepn.  Conclusions and implications: Taken together, these data suggest that SB265610 behaves as an allosteric inverse agonist at the CXCR2 receptor, binding at a region distinct from the agonist binding site to prevent receptor activation, possibly by interfering with G protein coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquo8b-CAGzn7Vg90H21EOLACvtfcHk0lgaAU7i3iF3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsrzF&md5=33b692e981e8ea5ef3f8527843451748</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00182.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00182.x%26sid%3Dliteratum%253Aachs%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBond%26aufirst%3DM.%2BE.%26aulast%3DManini%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DZ.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DSB265610%2520is%2520an%2520allosteric%252C%2520inverse%2520agonist%2520at%2520the%2520human%2520CXCR2%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D328%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Nicholls, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomkinson, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brammall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grahames, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meghani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallinder, P. R.</span><span> </span><span class="NLM_article-title">Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1193-1202&author=D.+J.+Nichollsauthor=N.+P.+Tomkinsonauthor=K.+E.+Wileyauthor=A.+Brammallauthor=L.+Bowersauthor=C.+Grahamesauthor=A.+Gawauthor=P.+Meghaniauthor=P.+Sheltonauthor=T.+J.+Wrightauthor=P.+R.+Mallinder&title=Identification+of+a+putative+intracellular+allosteric+antagonist+binding-site+in+the+CXC+chemokine+receptors+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DTomkinson%26aufirst%3DN.%2BP.%26aulast%3DWiley%26aufirst%3DK.%2BE.%26aulast%3DBrammall%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DL.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DMeghani%26aufirst%3DP.%26aulast%3DShelton%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DT.%2BJ.%26aulast%3DMallinder%26aufirst%3DP.%2BR.%26atitle%3DIdentification%2520of%2520a%2520putative%2520intracellular%2520allosteric%2520antagonist%2520binding-site%2520in%2520the%2520CXC%2520chemokine%2520receptors%25201%2520and%25202%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1193%26epage%3D1202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">de Kruijf, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renjaan, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auld, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkmans, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Identification of a novel allosteric binding site in the CXCR2 chemokine receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=1108-1118&author=P.+de+Kruijfauthor=H.+D.+Limauthor=L.+Roumenauthor=V.+A.+Renjaanauthor=J.+Zhaoauthor=M.+L.+Webbauthor=D.+S.+Auldauthor=J.+C.+Wijkmansauthor=G.+J.+Zamanauthor=M.+J.+Smitauthor=C.+de+Graafauthor=R.+Leurs&title=Identification+of+a+novel+allosteric+binding+site+in+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKruijf%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DRoumen%26aufirst%3DL.%26aulast%3DRenjaan%26aufirst%3DV.%2BA.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DWijkmans%26aufirst%3DJ.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DSmit%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520a%2520novel%2520allosteric%2520binding%2520site%2520in%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D1108%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Onuffer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokines, chemokine receptors and small-molecule antagonists: Recent developments</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=459-467&author=J.+J.+Onufferauthor=R.+Horuk&title=Chemokines%2C+chemokine+receptors+and+small-molecule+antagonists%3A+Recent+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOnuffer%26aufirst%3DJ.%2BJ.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokines%252C%2520chemokine%2520receptors%2520and%2520small-molecule%2520antagonists%253A%2520Recent%2520developments%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D459%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Groll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkers, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovaa, H.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+Structure+of+the+Boronic+Acid-Based+Proteasome+Inhibitor+Bortezomib+in+Complex+with+the+Yeast+20S+Proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lhXfnWXzQqTIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Boronic%2520Acid-Based%2520Proteasome%2520Inhibitor%2520Bortezomib%2520in%2520Complex%2520with%2520the%2520Yeast%252020S%2520Proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Hu, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. L.</span><span> </span><span class="NLM_article-title">Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate</span> <span class="citation_source-journal">Mol. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1111%2Fj.1365-2958.2005.05036.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=16468986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Shsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1417-1428&author=G.+Q.+Huauthor=G.+Linauthor=M.+Wangauthor=L.+Dickauthor=R.+M.+Xuauthor=C.+Nathanauthor=H.+L.+Li&title=Structure+of+the+Mycobacterium+tuberculosis+proteasome+and+mechanism+of+inhibition+by+a+peptidyl+boronate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate</span></div><div class="casAuthors">Hu, Guiqing; Lin, Gang; Wang, Ming; Dick, Lawrence; Xu, Rui-Ming; Nathan, Carl; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1417-1428</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) has the remarkable ability to resist killing by human macrophages.  The 750 kDa proteasome, not available in most eubacteria except Actinomycetes, appears to contribute to Mtb's resistance.  The crystal structure of the Mtb proteasome at 3.0 Å resoln. reveals a substrate-binding pocket with composite features of the distinct β1, β2 and β5 substrate binding sites of eukaryotic proteasomes, accounting for the broad specificity of the Mtb proteasome towards oligopeptides described in the companion article.  The substrate entrance at the end of the cylindrical proteasome appears open in the crystal structure due to partial disorder of the α-subunit N-terminal residues.  However, cryo-electron microscopy of the core particle reveals a closed end, compatible with the d. obsd. in neg.-staining electron microscopy that depended on the presence of the N-terminal octapetides of the α-subunits in the companion article, suggesting that the Mtb proteasome has a gated structure.  We det. for the first time the proteasomal inhibition mechanism of the dipeptidyl boronate N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid (MLN-273), an analog of the antimyeloma drug bortezomib.  The structure improves prospects for designing Mtb-specific proteasomal inhibitors as a novel approach to chemotherapy of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosRye2y6oNzLVg90H21EOLACvtfcHk0lhXfnWXzQqTIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Shsb0%253D&md5=25d9f52eb39604629dc5e86f9527c0b5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2005.05036.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2005.05036.x%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DG.%2BQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DR.%2BM.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%2BL.%26atitle%3DStructure%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520proteasome%2520and%2520mechanism%2520of%2520inhibition%2520by%2520a%2520peptidyl%2520boronate%26jtitle%3DMol.%2520Microbiol.%26date%3D2006%26volume%3D59%26spage%3D1417%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Tsilikounas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">B-11 NMR-spectroscopy of peptide boronic acid inhibitor complexes of alpha-lytic protease: Direct evidence for tetrahedral boron in both boron histidine and boron serine adduct complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">12651</span><span class="NLM_x">–</span> <span class="NLM_lpage">12655</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00210a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=12651-12655&author=E.+Tsilikounasauthor=C.+A.+Kettnerauthor=W.+W.+Bachovchin&title=B-11+NMR-spectroscopy+of+peptide+boronic+acid+inhibitor+complexes+of+alpha-lytic+protease%3A+Direct+evidence+for+tetrahedral+boron+in+both+boron+histidine+and+boron+serine+adduct+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fbi00210a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00210a013%26sid%3Dliteratum%253Aachs%26aulast%3DTsilikounas%26aufirst%3DE.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DB-11%2520NMR-spectroscopy%2520of%2520peptide%2520boronic%2520acid%2520inhibitor%2520complexes%2520of%2520alpha-lytic%2520protease%253A%2520Direct%2520evidence%2520for%2520tetrahedral%2520boron%2520in%2520both%2520boron%2520histidine%2520and%2520boron%2520serine%2520adduct%2520complexes%26jtitle%3DBiochemistry%26date%3D1993%26volume%3D32%26spage%3D12651%26epage%3D12655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Farrjones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span> </span><span class="NLM_article-title">Crystal versus solution structure of enzymes: NMR-spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">6922</span><span class="NLM_x">–</span> <span class="NLM_lpage">6924</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=6922-6924&author=S.+Farrjonesauthor=S.+O.+Smithauthor=C.+A.+Kettnerauthor=R.+G.+Griffinauthor=W.+W.+Bachovchin&title=Crystal+versus+solution+structure+of+enzymes%3A+NMR-spectroscopy+of+a+peptide+boronic+acid-serine+protease+complex+in+the+crystalline+state"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarrjones%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BO.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DGriffin%26aufirst%3DR.%2BG.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DCrystal%2520versus%2520solution%2520structure%2520of%2520enzymes%253A%2520NMR-spectroscopy%2520of%2520a%2520peptide%2520boronic%2520acid-serine%2520protease%2520complex%2520in%2520the%2520crystalline%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D6922%26epage%3D6924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Bachovchin, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrjones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenvi, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span> </span><span class="NLM_article-title">N-15 NMR-spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">7689</span><span class="NLM_x">–</span> <span class="NLM_lpage">7697</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00420a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=7689-7697&author=W.+W.+Bachovchinauthor=W.+Y.+L.+Wongauthor=S.+Farrjonesauthor=A.+B.+Shenviauthor=C.+A.+Kettner&title=N-15+NMR-spectroscopy+of+the+catalytic-triad+histidine+of+a+serine+protease+in+peptide+boronic+acid+inhibitor+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fbi00420a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00420a018%26sid%3Dliteratum%253Aachs%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DWong%26aufirst%3DW.%2BY.%2BL.%26aulast%3DFarrjones%26aufirst%3DS.%26aulast%3DShenvi%26aufirst%3DA.%2BB.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26atitle%3DN-15%2520NMR-spectroscopy%2520of%2520the%2520catalytic-triad%2520histidine%2520of%2520a%2520serine%2520protease%2520in%2520peptide%2520boronic%2520acid%2520inhibitor%2520complexes%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D7689%26epage%3D7697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Bone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenvi, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettner, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agard, D. A.</span><span> </span><span class="NLM_article-title">Serine protease mechanism: Structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">7609</span><span class="NLM_x">–</span> <span class="NLM_lpage">7614</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00398a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=7609-7614&author=R.+Boneauthor=A.+B.+Shenviauthor=C.+A.+Kettnerauthor=D.+A.+Agard&title=Serine+protease+mechanism%3A+Structure+of+an+inhibitory+complex+of+alpha-lytic+protease+and+a+tightly+bound+peptide+boronic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fbi00398a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00398a012%26sid%3Dliteratum%253Aachs%26aulast%3DBone%26aufirst%3DR.%26aulast%3DShenvi%26aufirst%3DA.%2BB.%26aulast%3DKettner%26aufirst%3DC.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26atitle%3DSerine%2520protease%2520mechanism%253A%2520Structure%2520of%2520an%2520inhibitory%2520complex%2520of%2520alpha-lytic%2520protease%2520and%2520a%2520tightly%2520bound%2520peptide%2520boronic%2520acid%26jtitle%3DBiochemistry%26date%3D1987%26volume%3D26%26spage%3D7609%26epage%3D7614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Siemsen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schepetkin, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotina, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. T.</span><span> </span><span class="NLM_article-title">Neutrophil isolation from nonhuman species</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1007%2F978-1-59745-467-4_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=18453103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A280%3ADC%252BD1c3pt1OjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2007&pages=21-34&author=D.+W.+Siemsenauthor=I.+A.+Schepetkinauthor=L.+N.+Kirpotinaauthor=B.+Leiauthor=M.+T.+Quinn&title=Neutrophil+isolation+from+nonhuman+species"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil isolation from nonhuman species</span></div><div class="casAuthors">Siemsen Daniel W; Schepetkin Igor A; Kirpotina Liliya N; Lei Benfang; Quinn Mark T</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-34</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">Advances in the understanding of neutrophil biochemistry require the development of effective procedures for isolating purified neutrophil populations.  Although methods for human neutrophil isolation are now standard, similar procedures for isolating neutrophils from many of the nonhuman species used to model human diseases are not as well developed.  Because neutrophils are reactive cells, the method of isolation is extremely important to avoid isolation technique-induced alterations in cell function.  We present methods here for reproducibly isolating highly-purified neutrophils from large (cow, horse, sheep) and small (mouse, rabbit) animal models and describe optimized details for obtaining the highest cell purity, yield, and viability.  We also describe methods to verify phagocytic capacity in the purified cell populations using a flow cytometry-based phagocytosis assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREXeD7T5ENZcve_zCu79I8fW6udTcc2eaE1ma-oq7oE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3pt1OjsQ%253D%253D&md5=d5df703ae008bb8fe6185c08ee67f7ab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-467-4_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-467-4_3%26sid%3Dliteratum%253Aachs%26aulast%3DSiemsen%26aufirst%3DD.%2BW.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DLei%26aufirst%3DB.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26atitle%3DNeutrophil%2520isolation%2520from%2520nonhuman%2520species%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2007%26volume%3D412%26spage%3D21%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Hall, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, H.</span><span> </span><span class="NLM_article-title">Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: A comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm500827t&amp;key=10.1038%2Fsj.bjp.0702329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm500827t&amp;key=10188995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm500827t&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=810-818&author=D.+A.+Hallauthor=I.+J.+Beresfordauthor=C.+Browningauthor=H.+Giles&title=Signalling+by+CXC-chemokine+receptors+1+and+2+expressed+in+CHO+cells%3A+A+comparison+of+calcium+mobilization%2C+inhibition+of+adenylyl+cyclase+and+stimulation+of+GTPgammaS+binding+induced+by+IL-8+and+GROalpha"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL-8 and GROα</span></div><div class="casAuthors">Hall, David A.; Beresford, Isabel J. M.; Browning, Christopher; Giles, Heather</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-818</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The effect of interleukin-8 (IL-8) and growth-related oncogene α (GROα) on [35S]-guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPγS) binding, forskolin-stimulated cAMP accumulation and cytosolic calcium concn. were detd. in recombinant CHO cells expressing HA-tagged CXC-chemokine receptors 1 and 2 (CXCR1 and CXCR2).  Radioligand binding assays confirmed that the binding profiles of the recombinant receptors were similar to those of the native proteins.  IL-8 displaced [125I]-IL-8 binding to CXCR1 and CXCR2 with pKi values of 8.89±0.05 and 9.27±0.03, resp.  GROα, a selective CXCR2 ligand, had a pKi value of 9.66±0.39 at CXCR2 but a pKi>8 at CXCR1.  Calcium mobilization expts. were also consistent with previous reports on native receptors.  Activation of both receptors resulted in stimulation of [35S]GTPγS binding and inhibition of adenylyl cyclase.  A comparison of the functional data at CXCR1 showed that a similar potency order (IL-8> >GROα) was obtained in all three assays.  However, at CXCR2 while the potency orders for calcium mobilization and inhibition of adenylyl cyclase were similar (IL-8≥GROα), the order was reversed for stimulation of [35S]GTPγS binding (GROα>IL-8).  All of the functional responses at both receptors were inhibited by pertussis toxin (PTX), suggesting coupling to a Gi/Go protein.  However, the calcium mobilization induced by IL-8 at CXCR1 was not fully inhibited by PTX, suggesting an interaction with a G-protein of the Gq family.  Our results with pertussis toxin also suggested that, in the [35S]GTPγS binding assay, CXCR1 displays some constitutive activity.  Thus, we have characterized the binding and several functional responses at HA-tagged CXCRs 1 and 2 and have shown that their pharmacol. agrees well with that of the native receptors.  We also have preliminary evidence that CXCR1 displays constitutive activity in our cell line and that CXCR2 may traffic between different PTX sensitive G-proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CdsolstFrrVg90H21EOLACvtfcHk0ljQXZcC99Jatw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWitLc%253D&md5=76e8dca183c59752a227a35616766d31</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702329%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DBeresford%26aufirst%3DI.%2BJ.%26aulast%3DBrowning%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DH.%26atitle%3DSignalling%2520by%2520CXC-chemokine%2520receptors%25201%2520and%25202%2520expressed%2520in%2520CHO%2520cells%253A%2520A%2520comparison%2520of%2520calcium%2520mobilization%252C%2520inhibition%2520of%2520adenylyl%2520cyclase%2520and%2520stimulation%2520of%2520GTPgammaS%2520binding%2520induced%2520by%2520IL-8%2520and%2520GROalpha%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D810%26epage%3D818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500827t&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm500827t%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500827t" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bdfd6ce6d187","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
